
<html lang="en"     class="pb-page"  data-request-id="ae3cfc61-9865-4b4e-85f6-3179c6d61848"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b00891;issue:issue:10.1021/jmcmar.2019.62.issue-15;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design" /></meta><meta name="dc.Creator" content="Xiaowu  Dong" /></meta><meta name="dc.Creator" content="Wenhu  Zhan" /></meta><meta name="dc.Creator" content="Mengting  Zhao" /></meta><meta name="dc.Creator" content="Jinxin  Che" /></meta><meta name="dc.Creator" content="Xiaoyang  Dai" /></meta><meta name="dc.Creator" content="Yizhe  Wu" /></meta><meta name="dc.Creator" content="Lei  Xu" /></meta><meta name="dc.Creator" content="Yubo  Zhou" /></meta><meta name="dc.Creator" content="Yanmei  Zhao" /></meta><meta name="dc.Creator" content="Tian  Tian" /></meta><meta name="dc.Creator" content="Gang  Cheng" /></meta><meta name="dc.Creator" content="Zegao  Jin" /></meta><meta name="dc.Creator" content="Jia  Li" /></meta><meta name="dc.Creator" content="Yanfei  Shao" /></meta><meta name="dc.Creator" content="Qiaojun  He" /></meta><meta name="dc.Creator" content="Bo  Yang" /></meta><meta name="dc.Creator" content="Qinjie  Weng" /></meta><meta name="dc.Creator" content="Yongzhou  Hu" /></meta><meta name="dc.Description" content="A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor effi..." /></meta><meta name="Description" content="A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor effi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 12, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00891" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00891" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00891" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00891" /></link>
        
    
    

<title>Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00891" /></meta><meta property="og:title" content="Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0022.jpeg" /></meta><meta property="og:description" content="A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure–activity relationship of compound A12, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative E22. E22 showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound E22 also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound E22 could significantly inhibit the phosphorylation of proteins downstream of Akt kinase in cells and tumor tissue from the xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00891"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00891">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00891&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00891&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00891&amp;href=/doi/10.1021/acs.jmedchem.9b00891" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 7264-7288</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00795" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00932" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiaowu Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaowu Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaowu++Dong">Xiaowu Dong</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2178-4372" title="Orcid link">http://orcid.org/0000-0002-2178-4372</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenhu Zhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenhu Zhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenhu++Zhan">Wenhu Zhan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mengting Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mengting Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mengting++Zhao">Mengting Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinxin Che</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinxin Che</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinxin++Che">Jinxin Che</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoyang Dai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoyang Dai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyang++Dai">Xiaoyang Dai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yizhe Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yizhe Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yizhe++Wu">Yizhe Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Xu">Lei Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yubo Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yubo Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yubo++Zhou">Yubo Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanmei Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanmei Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanmei++Zhao">Yanmei Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tian Tian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tian Tian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tian++Tian">Tian Tian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311402, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Cheng">Gang Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zegao Jin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zegao Jin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zegao++Jin">Zegao Jin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jia Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jia Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Li">Jia Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yanfei Shao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanfei Shao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, Zhejiang Provincial People’s Hospital, Hangzhou 310014, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanfei++Shao">Yanfei Shao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qiaojun He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qiaojun He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qiaojun++He">Qiaojun He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bo Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bo Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bo++Yang">Bo Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qinjie Weng</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qinjie Weng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Pharmacology & Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#4136242f2630282f2b2824013b2b346f2425346f222f"><span class="__cf_email__" data-cfemail="86f1e3e8e1f7efe8ecefe3c6fcecf3a8e3e2f3a8e5e8">[email protected]</span></a> (Q.W.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qinjie++Weng">Qinjie Weng</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yongzhou Hu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongzhou Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">ZJU-ENS Joint Laboratory of Medicinal Chemistry, Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#600815191a201a0a154e0504154e030e"><span class="__cf_email__" data-cfemail="3a524f43407a40504f145f5e4f145954">[email protected]</span></a> (Y.H.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongzhou++Hu">Yongzhou Hu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7349-4062" title="Orcid link">http://orcid.org/0000-0001-7349-4062</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00891&amp;href=/doi/10.1021%2Facs.jmedchem.9b00891" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 7264–7288</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 12, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 June 2019</li><li><span class="item_label"><b>Published</b> online</span>12 July 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 August 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00891" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00891</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7264%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiaowu%2BDong%252C%2BWenhu%2BZhan%252C%2BMengting%2BZhao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D15%26contentID%3Dacs.jmedchem.9b00891%26title%3DDiscovery%2Bof%2B3%252C4%252C6-Trisubstituted%2BPiperidine%2BDerivatives%2Bas%2BOrally%2BActive%252C%2BLow%2BhERG%2BBlocking%2BAkt%2BInhibitors%2Bvia%2BConformational%2BRestriction%2Band%2BStructure-Based%2BDesign%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7288%26publicationDate%3DAugust%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00891"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2558</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00891" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiaowu&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Wenhu&quot;,&quot;last_name&quot;:&quot;Zhan&quot;},{&quot;first_name&quot;:&quot;Mengting&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Jinxin&quot;,&quot;last_name&quot;:&quot;Che&quot;},{&quot;first_name&quot;:&quot;Xiaoyang&quot;,&quot;last_name&quot;:&quot;Dai&quot;},{&quot;first_name&quot;:&quot;Yizhe&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Yubo&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yanmei&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Tian&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Zegao&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yanfei&quot;,&quot;last_name&quot;:&quot;Shao&quot;},{&quot;first_name&quot;:&quot;Qiaojun&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Bo&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Qinjie&quot;,&quot;last_name&quot;:&quot;Weng&quot;},{&quot;first_name&quot;:&quot;Yongzhou&quot;,&quot;last_name&quot;:&quot;Hu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;7264-7288&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00891&quot;},&quot;abstract&quot;:&quot;A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure–activity relationship of compound A12, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative E22. E22 showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound E22 also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound E22 could significantly inhibit the phosphorylation of proteins d&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00891&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00891" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00891&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00891" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00891&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00891" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00891&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00891&amp;href=/doi/10.1021/acs.jmedchem.9b00891" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00891" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00891" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00891%26sid%3Dliteratum%253Aachs%26pmid%3D31298542%26genre%3Darticle%26aulast%3DDong%26date%3D2019%26atitle%3DDiscovery%2Bof%2B3%252C4%252C6-Trisubstituted%2BPiperidine%2BDerivatives%2Bas%2BOrally%2BActive%252C%2BLow%2BhERG%2BBlocking%2BAkt%2BInhibitors%2Bvia%2BConformational%2BRestriction%2Band%2BStructure-Based%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D15%26spage%3D7264%26epage%3D7288%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291870" title="Piperidines">Piperidines</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/jmcmar.2019.62.issue-15/20190808/jmcmar.2019.62.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, <b>A12</b>, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure–activity relationship of compound <b>A12</b>, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative <b>E22</b>. <b>E22</b> showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound <b>E22</b> also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound <b>E22</b> could significantly inhibit the phosphorylation of proteins downstream of Akt kinase in cells and tumor tissue from the xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Akt, also known as protein kinase B, is a serine/threonine kinase that belongs to the AGC family of kinases, sharing high homology with protein kinase A (PKA) and protein kinase C (PKC). Akt can be classified into three different isozymes, including Akt1, Akt2, and Akt3; all three share a high degree of overall homology and similar downstream targets.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> It is very common that the PI3K/Akt signaling pathway is overactivated in various cancer cells,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and tumor growth can be effectively decreased via the inhibition of Akt alone or in combination with other chemotherapeutics.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8 ref9">(4−9)</a> Currently, the efficacy of a number of Akt inhibitors is evaluated in clinical trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Akt inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In particular, a phase II clinical trial of <b>GDC0068</b> was completed<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and a phase III clinical trial is currently investigating the effectiveness of <b>GDC0068</b> in the treatment of triple-negative breast cancer (TNBC) (NCT03337724) and metastatic prostate cancer (NCT03072238). In addition, the results of clinical studies on the use of <b>AZD5363</b> in combination with paclitaxel for the treatment of TNBC have also been disclosed, indicating that this therapy resulted in a positive outcome of significantly longer progression-free survival and overall survival,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> thus fully demonstrating the promising prospect of Akt as an anticancer target.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18">(12−18)</a> Additionally, <b>GSK2141795</b> (also known as <b>GSK-795</b> or <b>Uprosertib</b>) is another adenosine 5′-triphosphate (ATP)-competitive Akt inhibitor developed by GlaxoSmithKline, which is currently in early clinical trials for evaluation of its therapeutic effect against different types of cancer, such as multiple myeloma (NCT01989598), breast cancer (NCT01964924), and others. In the discovery stage of <b>AZD5363</b> and <b>GDC0068</b>,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> the druggability involving in vitro and in vivo anticancer efficacy, safety issues [human ether-a-go-go-related gene (hERG)], pharmacokinetic (PK) profiles, and kinase selectivity was primarily explored and optimized. In comparison to the preclinical data, some of their advantages are clear, such as low hERG blockage of <b>AZD5363</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> high selectivity profiles of <b>GDC0068</b>,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> low effective dose, and excellent PK profiles of <b>GSK-795</b>,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> the data pertaining to which have also provided a criterion for searching novel Akt inhibitors.</div><div class="NLM_p last">Conformational restriction is one of the most effective methodologies for drug design, since it can help improve the PK profiles of compounds and stabilize a favorable binding pattern to improve the binding affinities or kinase isoform selectivity.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> This strategy has been widely applied in drug discovery.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> In fact, some Food and Drug Administration-approved drugs were discovered and developed by using conformational restriction, such as Dolutegravir.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In our previous study, the discovery of a series of 4,4-disubstituted piperidine derivatives featuring more restricted conformations in contrast to <b>GSK-795</b> were successfully achieved,<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29">(25−29)</a> which proved that conformational restriction strategy could be used for discovery of new Akt inhibitors with novel skeletons. As a continuation of this earlier work, herein, the structural modifications of 3,4-disubstituted piperidine derivatives were reported, which exhibit excellent potency and good PK profiles. Further structure-based drug design was used to introduce a side chain, leading to the discovery of a series of novel and highly potent 3,4,6-trisubstituted derivatives of <b>E22</b> with good PK profiles, lower hERG blockage, and improved safety profiles. Furthermore, the molecular mechanisms of <b>E22</b> were studied, confirming the blockage of the PI3K–Akt pathway in cancer cells and tumor tissue.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Discovery of 3,4-Disubstituted Piperidine Derivatives as Akt Inhibitors</h3><div class="NLM_p">On the basis of multiple previous research projects,<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32">(27−32)</a> most of the ATP-competitive Akt inhibitors were found to share common pharmacophore characteristics, including a hinge-binding group, a basic center, and a hydrophobic group. These three pharmacophores generate a “Y” shape through a linkage. Although the cocrystal structure of <b>GSK-795</b> with Akt1 has not been reported, the docking results (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S1</a>) disclosed that the amino and pyrazole groups were hydrogen-bonded to the amino acid residues of Glu278 and Ala230. The 3,4-difluorophenyl group inserted into the hydrophobic pocket, and π–π interacted with Phe161. Therefore, we hypothesized that cyclization of the amino group with the methylene moiety of the benzyl group based on the conformational restriction strategy may facilitate conformational stability of the phenyl group and basic center, and therefore would improve the Akt inhibitory potency (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design rationale based on the structures of <b>GSK-795</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the present study, the racemic 3,4-disubstituted piperidine or pyrrolidine derivatives were synthesized for further exploration. The linkage and hinge groups selected were the privileged furan moiety and <i>N</i>-methyl pyrazole, respectively, according to the structure of <b>GSK-795</b>. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, when R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> substituents were all hydrogens, compound <b>A1</b> resulted in an 50% inhibitory concentration (IC<sub>50</sub>) value of 709.6 nM. After introducing a halogen to <b>A1</b>, the Akt1 inhibitory potency was reinforced, as shown in compounds <b>A2</b>–<b>A4</b>, demonstrating the importance of halogens in maintaining the compound activity. Notably, when R<sub>3</sub> was 4-CF<sub>3</sub> or 3,4-difluoro, compounds <b>A5</b> and <b>A6</b> both exhibited comparable Akt1 inhibitory potency to that of <b>GSK-795</b>. However, after the replacement of piperidine with pyrrolidine, the activities of compounds <b>A7</b>–<b>A9</b> were dramatically reduced. Therefore, highly potent 3,4-disubstituted compounds <b>A5</b> and <b>A6</b> were selected for further chiral resolution to determine the optimal configuration.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Akt1 Inhibitory Activities of Compounds <b>A1</b>–<b>A9</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">Akt1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A1</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">709.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A2</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3,4-difluoro</td><td class="colsep0 rowsep0" align="left">191.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A3</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">17.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A4</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">17.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A5</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A6</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">3,4-difluoro</td><td class="colsep0 rowsep0" align="left">6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A7</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">3,4-difluoro</td><td class="colsep0 rowsep0" align="left">1566</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A8</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Br</td><td class="colsep0 rowsep0" align="left">3,4-difluoro</td><td class="colsep0 rowsep0" align="left">3646</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>A9</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">538</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>GSK-795</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.7</td></tr></tbody></table></div></div><div class="NLM_p">According to the asymmetric synthetic method for constructing 3,4-disubstituted piperidine derivatives,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> the trans-conformations (3S,4S or 3R,4R) of 3,4-disubstituted piperidine were the main products resulting from using (<i>S</i>)- or (<i>R</i>)-Jorgensen–Hayashi reagent catalysts, respectively. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the activity of the (3S,4S) enantiomer (compounds <b>A10</b> and <b>A12</b>) was significantly better than that of the (3R,4R) enantiomer (compounds <b>A11</b> and <b>A13</b>), including their Akt1 inhibitory activities and antiproliferative activities against different cancer cell lines, such as OVCAR-8 and HCT116. In addition, one of the cis-conformation products, the (3R,4S)-enantiomer, was further separated during the asymmetric synthesis and afforded the compound (3<i>R</i>,4<i>S</i>)-<b>A6</b>, exhibiting a good IC<sub>50</sub> value of 2.5 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S2</a>). Considering that the product yield of the cis-conformation of 3,4-disubstituted piperidine was minimal and difficult to obtain, we only focused on the (3S,4S)-enantiomer of 3,4-disubstituted piperidine derivatives in the following studies.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Akt1 Enzymatic and Cancer Cell Line Activities for Compounds <b>A10</b>–<b>A13</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0015.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd.</th><th class="colsep0 rowsep0" align="center" char=".">Akt1 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">OVCAR-8 (μM)</th><th class="colsep0 rowsep0" align="center" char=".">HCT116 (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(3<i>S</i>,4<i>S</i>)-<b>A5</b> (<b>A10</b>)</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(3<i>R</i>,4<i>R</i>)-<b>A5</b> (<b>A11)</b></td><td class="colsep0 rowsep0" align="char" char=".">127.4</td><td class="colsep0 rowsep0" align="char" char=".">0.90</td><td class="colsep0 rowsep0" align="char" char=".">1.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(3<i>S</i>,4<i>S</i>)-<b>A6</b> (<b>A12</b>)</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(3<i>R</i>,4<i>R</i>)-<b>A6</b> (<b>A13</b>)</td><td class="colsep0 rowsep0" align="char" char=".">51.2</td><td class="colsep0 rowsep0" align="char" char=".">0.49</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>GSK-795</b></td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">0.24</td><td class="colsep0 rowsep0" align="char" char=".">0.72</td></tr></tbody></table></div></div><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>A12</b> exhibited good pharmacokinetics and long <i>t</i><sub>1/2</sub> (10.7 h) and excellent bioavailability (<i>F</i> = 97.9%) in mice. This compound was slightly unstable in the liver microsomes of monkeys (39.9% remaining after incubating for 1.5 h) and had a high hERG inhibition rate (62.1% inhibition at 3 μM). Next, the safety profile of <b>A12</b> in mice was assessed. After 7 days of intragastric administration of <b>A12</b> (10, 20, and 40 mg/kg), toxic effects can be obviously observed in moderate- and high-dose groups (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S3 and Table S1</a>): three of five and two of five mice died at the dosages of 40 and 20 mg/kg, respectively. Some of the serum hematological and biochemical parameters such as red blood cell (RBC), hemoglobin, RBC-specific volume, and creatinine were obviously downregulated at the high dose (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S3B,C</a>). Thus, we reasoned that 10 mg/kg may be a tolerated dose for an in vivo study. The effect of <b>A12</b> in vivo was first characterized by measuring its antitumor activity in an MM1S multiple myeloma xenograft model. Following single oral doses of 10 mg/kg, the impact on tumor growth was assessed over 22 days. In total, 87.5% inhibition of tumor growth was observed, indicating that the in vivo efficacy of <b>A12</b> was strong (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S4A,B</a>). However, significant body weight loss (up to 25%) was observed in the mice (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S4C</a>), and one of the four mice died during the experiment (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S4D</a>); the death may be attributed to lower tolerance to the dose in nude mouse. It is demonstrated that the maximum tolerated dose (MTD) of <b>A12</b> was lower than 10 mg/kg, and dose escalation of <b>A12</b> was highly limited, suggesting that potential safety issues must be further resolved.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Profiles of in vitro and in vivo biological activities and safety issues of compound <b>A12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  Discovery of Akt Inhibitors with Improved Safety Profiles</h3><div class="NLM_p">After careful evaluation of the safety profile, we found that obvious deficiencies of compound <b>A12</b> existed: (1) the MTD dose of <b>A12</b> was quite low; (2) some toxicity was indicated by serum hematological and biochemical parameters; (3) heavy gastrointestinal hemorrhage caused the death of mice in autopsy analysis; and (4) high hERG inhibition of <b>A12</b> was observed (62.1% inhibition at 3 μM). To address these issues, subsequent investigation primarily focused on structure optimization, including the hinge-linkage moiety and phenyl substituents. In particular, on the basis of the docking results of compound <b>A12</b> to the ATP-bound pocket of Akt1 kinase, it was found that the 5- or 6-position of the piperidine ring may be oriented to the solvent area, providing us with a suitable point for exploration (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Strategies for further optimization of compound <b>A12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.2.1.  Modification of the Hinge-Linkage Moiety and Phenyl Substituents</h4><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compounds <b>B1</b> and <b>B2</b>, but not compound <b>B3</b>, showed IC<sub>50</sub> values below 10 nM when the phenyl group was substituted with different halogens. Furthermore, different hinge binders and linkages were evaluated. The 4-position of the <i>N</i>-methyl pyrazole hinge binder linked to the 2- or 3-position of the furan linkage (compounds <b>C1</b> and <b>C3</b>) leads to a dramatic loss of enzyme activity. Removal of the methyl group of <b>C1</b> to yield compound <b>C2</b> resulted in an increase in potency. Other hinge binders and linkages were also tested, such as 3-amino-pyrimidine (compound <b>C4</b>) and cyclopentane-pyrimidine (compound <b>C5</b>), and the activities of both of these compounds were dramatically reduced. Furthermore, the antiproliferation potencies of compounds against OVCAR-8 and HCT116 cells were determined in accordance with the Akt IC<sub>50</sub> values. Compounds <b>A12</b>, <b>B1</b>, and <b>B2</b> exhibited good Akt IC<sub>50</sub> values of <10 nM and good antiproliferation activities superior to that of <b>GSK-795</b>. Although compounds <b>A12</b> and <b>B1</b> showed good Akt1 activity, they also exhibited disappointingly high hERG inhibitory potencies at the concentration of 3 μM (62 and 87%, respectively), even higher than that of <b>GSK-795</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Akt1 Enzymatic and Cancer Cell Line Activities for Compounds <b>B1</b>–<b>B3</b> and <b>C1</b>–<b>C5</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0017.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Inhibition% or IC<sub>50</sub> values are an average of three independent determinations.</p></div></div><div></div></div><div class="NLM_p">Since we cannot identify better hinge-linkage fragments, <i>N</i>-methyl pyrazole was chosen as hinge binder and the linkage was further investigated. Different five-membered ring linkages were first evaluated, including furan, thiophene, and <i>N</i>-methyl pyrrole (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In the case of the furan linkage, removal of the chloro group on <i>N</i>-methyl pyrazole yielded the unsubstituted compound <b>D1</b> or <b>D2</b>, which resulted in a slight reduction in potency (<b>D1</b> vs <b>B3</b>; <b>D2</b> vs <b>A12</b>). In addition, introducing a bromo group to the pyrazole did not favor activity improvement (<b>D3</b> vs <b>D1</b>). After changing from the 2,4-disubstituted to 2,5-substituted furan linkage, the activities of the obtained compounds were reduced (compounds <b>D4</b>–<b>D9</b>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Akt1 Enzymatic and Cancer Cell Line Activities for Compounds <b>D1</b>–<b>D28</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0018.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0019.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Inhibition% or IC<sub>50</sub> values are an average of three independent determinations.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">N.T. = not tested.</p></div></div><div></div></div><div class="NLM_p">When the linkage was between thiophene and <i>N</i>-methyl pyrrole, the IC<sub>50</sub> values of the resulting compounds (<b>D10</b>–<b>D18</b>) were over 100 nM. In contrast to the structure–activity relationship (SAR), when the linkage included furan, introduction of a chloro group to the 5-position of the thiophene linkage was unfavorable to the compound activity, which even suffered a significant loss of potency (<b>D10</b> vs <b>D11</b>). After introducing a chloro or bromo group to the <i>N</i>-methyl pyrrole, the inhibitory potency of compounds improved (<b>D15</b> vs <b>D17</b>; <b>D16</b> vs <b>D18</b>).</div><div class="NLM_p">The six-membered ring linkage was also evaluated, including substituted phenyl and pyridyl. Although the activities of compounds with six-membered-ring linkages were not better than those of compounds with furan linkages, some of the IC<sub>50</sub> values were still lower than 100 nM. Compound <b>D19</b> showed the most potent IC<sub>50</sub> value of 21.6 nM. The activities of compounds with pyridine linkages were inferior to those of compounds with phenyl linkages (<b>D19</b> vs <b>D23</b>; <b>D20</b> vs <b>D24;</b><b>D21</b> vs <b>D25</b>; and <b>D22</b> vs <b>D27</b>).</div><div class="NLM_p last">The cellular potencies of the compounds against OVCAR-8 and HCT-116 cells were relatively insensitive, with most of the compounds exhibiting IC<sub>50</sub> values greater than 1 μM. Compound <b>D2</b>, exhibiting an Akt1 IC<sub>50</sub> value of 5.1 nM, only showed approximately 1 μM antiproliferative activity, which is comparable to that of <b>GSK-795</b>. Compound <b>D16</b>, with lower Akt1 inhibitory activity, also exhibited high hERG inhibition, demonstrating no relationship between Akt1 and hERG inhibition. Despite the low hERG inhibition observed for compounds <b>D19</b> and <b>D22</b>, in which each linkage consisted of phenyl groups, the Akt1 inhibitory potency was unsatisfactory.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">2.2.2.  3,4,6-Trisubstituted Piperidine Derivatives</h4><div class="NLM_p">Following the previous SAR studies of 3,4-disubstituted piperidine derivatives, we found that the Akt and hERG inhibitory activities cannot be well balanced. Since the 5- or 6-position of the piperidine may be oriented to the solvent area, this may offer an overall balance, particularly with respect to Akt inhibitory potency. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, a range of introduced side chains could be well tolerated in both synthesized (3S,4S,6S)-trisubstituted piperidine derivatives. Additionally, the length of the side chains showed minor influence on the Akt1 inhibitory activity of compounds, and the IC<sub>50</sub> values of most compounds were below 10 nM. Compounds with hydrophilic side chains performed better in terms of Akt1 inhibitory potency compared to those with hydrophobic side chains (compounds <b>E1</b> and <b>E2</b>) and the positive control compounds <b>GSK-795</b> and <b>AZD5363</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Akt1 Enzymatic and Cancer Cell Line Activities for Compounds <b>E1</b>–<b>E25</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0020.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0021.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values or inhibition% are an average of three independent determinations.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">N.T. = not tested.</p></div></div><div></div></div><div class="NLM_p">As for cellular potency, most of the compounds showed good antiproliferation activity against LNCaP, OVCAR-8, and HCT116 cells. Comparing these cell lines, LNCaP cells were more sensitive to the inhibitors than the OVCAR-8 or HCT116 cells. The IC<sub>50</sub> values of several compounds against LNCaP cells were below 0.1 μM (compounds <b>A12</b>, <b>B1</b>, <b>E5</b>, <b>E12</b>, <b>E15</b>, <b>E17</b>, <b>E18</b>, <b>E20</b>, <b>E22</b>, and <b>E23</b>).</div><div class="NLM_p">The hERG inhibition of compounds with lipophilic side chains still exhibited high potency: for example, compound <b>E1</b>. Introduction of a hydroxyl group to increase the hydrophilicity of the side chain (compound <b>E3</b>) led to a decrease in hERG inhibition. Furthermore, the removal of one carbon to obtain a shortened side chain (compound <b>E4</b>) resulted in lower hERG activity. Introduction of two hydroxyls to continue increasing the hydrophilicity of the side chain (compound <b>E5</b>) resulted in significantly reduced hERG activity.</div><div class="NLM_p">Further exploration of the SAR around the basic group analogues, including <i>N</i>,<i>N</i>-dimethyl (<b>E7</b>), piperidine (<b>E9</b>), and morpholine (<b>E10</b>), led to compounds with increased hERG affinity. By contrast, introducing a hydroxyl group to the piperidine analogue side chain (compound <b>E11</b>) led to an obvious reduction in hERG inhibition. When the side chains were analogues with carboxyl (compound <b>E13</b>) and carbamoyl (compound <b>E14</b>) substitution, hERG inhibition was significantly lowered, exhibiting only 9.0 and 15.7% of the activity, respectively.</div><div class="NLM_p">When the phenyl group on piperidine was 3,4-difluoro-substituted, the hERG affinity values of compounds were lower than those of 3,4-dichloro-substituted compounds (<b>E20</b> vs <b>E4</b>; <b>E21</b> vs <b>E5</b>; and <b>E22</b> vs <b>E15</b>). The hERG inhibition rates of compounds <b>E20</b>–<b>E24</b> were all below 10%, which was comparable to the value for <b>AZD5363</b> but much lower than the values of <b>GSK-795</b> and <b>A12</b>.</div><div class="NLM_p">Following the exploration of the compounds’ reduced hERG inhibition, other ion channels were also evaluated to exclude potential off-target effects. The inhibition rates of compound <b>E22</b> against 16 different ion channels, including chloride (CFTR), sodium (Nav1.7), and potassium ion channels (Kir1.1, 2.1; Kv1.2–1.8; HCN 1–4), were quite low at a concentration of 3 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Table S2</a>); these results suggest a safer ion-channel profile and significant advancement over the disubstituted piperidine lead compound, <b>A12</b>.</div><div class="NLM_p">For preliminary assessment of the selectivity profiles of compounds, the IC<sub>50</sub> values or inhibition rates of compounds <b>A12</b>, <b>E20</b>, and <b>E22</b> were assayed against a panel of representative kinases (20), including AGC kinase family and tyrosine kinases (TK), among others (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Both compounds exhibited IC<sub>50</sub> values of <10 nM against Akt1-3. In addition, the tested compounds also exhibited good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK, while no significant inhibition was observed against other non-AGC family kinases.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Results of Preliminary Assessment of Compounds’ Kinase Selectivity Profiles</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">IC<sub>50</sub> (nM)/inhibition (%, 0.5 μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">kinases</th><th class="colsep0 rowsep0" align="center"><b>A12</b></th><th class="colsep0 rowsep0" align="center"><b>E20</b></th><th class="colsep0 rowsep0" align="center"><b>E22</b></th><th class="colsep0 rowsep0" align="center"><b>GSK-795</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="12" align="left">AGC kinase family</td><td class="colsep0 rowsep0" align="left">Akt1</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">0.98</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">9.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Akt2</td><td class="colsep0 rowsep0" align="left"><0.64</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Akt3</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKC</td><td class="colsep0 rowsep0" align="left">156</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">753</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROCK1</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RSK1</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">131</td><td class="colsep0 rowsep0" align="left">339</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P70S6K</td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SGK</td><td class="colsep0 rowsep0" align="left">59</td><td class="colsep0 rowsep0" align="left">102</td><td class="colsep0 rowsep0" align="left">145</td><td class="colsep0 rowsep0" align="left">211</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MSK1</td><td class="colsep0 rowsep0" align="left">88.8%</td><td class="colsep0 rowsep0" align="left">4.2%</td><td class="colsep0 rowsep0" align="left">–1.0%</td><td class="colsep0 rowsep0" align="left">87.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDK1</td><td class="colsep0 rowsep0" align="left">3.7%</td><td class="colsep0 rowsep0" align="left">4.0%</td><td class="colsep0 rowsep0" align="left">12.9%</td><td class="colsep0 rowsep0" align="left">–6.1%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TSSK1</td><td class="colsep0 rowsep0" align="left">–3.9%</td><td class="colsep0 rowsep0" align="left">–1.8%</td><td class="colsep0 rowsep0" align="left">–10.4%</td><td class="colsep0 rowsep0" align="left">6.2%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">TK</td><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="left">–3.0%</td><td class="colsep0 rowsep0" align="left">6.1%</td><td class="colsep0 rowsep0" align="left">–0.8%</td><td class="colsep0 rowsep0" align="left">2.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TKL</td><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="left">20.8%</td><td class="colsep0 rowsep0" align="left">13.8%</td><td class="colsep0 rowsep0" align="left">8.5%</td><td class="colsep0 rowsep0" align="left">5.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">CMGC</td><td class="colsep0 rowsep0" align="left">JNK2</td><td class="colsep0 rowsep0" align="left">12.7%</td><td class="colsep0 rowsep0" align="left">6.3%</td><td class="colsep0 rowsep0" align="left">4.3%</td><td class="colsep0 rowsep0" align="left">8.4%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">N.I.<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAMK</td><td class="colsep0 rowsep0" align="left">CHK1</td><td class="colsep0 rowsep0" align="left">1.3%</td><td class="colsep0 rowsep0" align="left">–2.0%</td><td class="colsep0 rowsep0" align="left">–26.8%</td><td class="colsep0 rowsep0" align="left">–7.9%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">atypical</td><td class="colsep0 rowsep0" align="left">PI3Ka</td><td class="colsep0 rowsep0" align="left">2.2%</td><td class="colsep0 rowsep0" align="left">6.3%</td><td class="colsep0 rowsep0" align="left">5.9%</td><td class="colsep0 rowsep0" align="left">0.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="left">–9.6%</td><td class="colsep0 rowsep0" align="left">–5.7%</td><td class="colsep0 rowsep0" align="left">–15.7%</td><td class="colsep0 rowsep0" align="left">N.T.<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values or inhibition% are an average of three independent determinations.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">N.I. = no inhibition.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">N.T. = not tested.</p></div></div></div><div class="NLM_p last">To fully understand the selectivity profile of compound <b>E22</b>, inhibition was further assessed using the KINOMEscan methodology against a full panel of kinases (nonmutant, mutant, lipid, atypical, and pathogen kinases; total number: 468) at a single dose concentration of 1 μM. The KINOMEscan selectivity score of <i>S</i><sub>1</sub> was 0.032 (13/468; <i>S</i><sub>1</sub> = (number of nonmutant kinases with %Ctrl < 1)/(number of nonmutant kinases tested), %Ctrl = (test compound signal – positive control signal)/(negative control signal – positive control signal) × 100; for full screening results, refer <a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Table S3</a>). Additionally, the interaction of compound <b>E22</b> with PRKD, PRKG, HASPIN, CSNK1E, etc., was detected, showing a comparable selectivity profile to <b>GSK-795</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S5</a>).</div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">2.3.  Compound <b>E22</b> Exhibited a Good PK Profile</h3><div class="NLM_p">Based on the results of SAR studies, compounds <b>E20</b> and <b>E22</b> were chosen for further testing of their PK profiles. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, after 40 mg/kg oral dosing of <b>E22</b> in mice and rats (compounds were dissolved in saline), we found that the absorption of <b>E22</b> in mice was better than in rats, but the compound was more easily cleared in mice. Furthermore, <b>E22</b> showed a good bioavailability value of 48.4% in mice. The high plasma protein binding (PPB) rate (93%) may indicate a long residence time for <b>E22</b>. The dosage of compound <b>E20</b> was 25 mg/kg, which indicated good absorption in rats, and a good clearance rate was observed. In addition, the in vitro stability of <b>E20</b> and <b>E22</b> was also evaluated in liver microsomes and plasma. The stability of these two compounds was good in the plasma, whereas compound <b>E20</b> was less stable than <b>E22</b> in rat and monkey microsomes.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Profiles of Compounds <b>E20</b> and <b>E22</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><b>E22</b></th><th class="rowsep1 colsep0" align="center"><b>E20</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameters</th><th class="colsep0 rowsep0" align="center">mouse (40 mg/kg, i.g.)</th><th class="colsep0 rowsep0" align="center">rat (40 mg/kg, i.g.)</th><th class="colsep0 rowsep0" align="center">rat (25 mg/kg, i.g.)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" align="left">12.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μg/L)</td><td class="colsep0 rowsep0" align="left">3620.0</td><td class="colsep0 rowsep0" align="left">407.4</td><td class="colsep0 rowsep0" align="left">145.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/(h kg))</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">14.2</td><td class="colsep0 rowsep0" align="left">26.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (μg/(L h))</td><td class="colsep0 rowsep0" align="left">21 091.9</td><td class="colsep0 rowsep0" align="left">2442.2</td><td class="colsep0 rowsep0" align="left">1014.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–∞</sub> (μg/(L h))</td><td class="colsep0 rowsep0" align="left">21 221.5</td><td class="colsep0 rowsep0" align="left">3092.2</td><td class="colsep0 rowsep0" align="left">1657.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0–<i>t</i></sub> (h)</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">5.8</td><td class="colsep0 rowsep0" align="left">5.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>0–∞</sub> (h)</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="left">12.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">147.2</td><td class="colsep0 rowsep0" align="left">300.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">48.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma protein binding rate (%, 300 ng/mL) [mouse]</td><td class="colsep0 rowsep0" colspan="2" align="left">93</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">liver microsome stability (%, remaining percent @ 1.5 h) [mouse, rat, dog, monkey]</td><td class="colsep0 rowsep0" colspan="2" align="left">>99, 89, 96, 84</td><td class="colsep0 rowsep0" align="left">>99, 69, 96, 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma stability (%, remaining percent @ 1 h) [mouse, human]</td><td class="colsep0 rowsep0" colspan="2" align="left">>99, >99</td><td class="colsep0 rowsep0" align="left">>99, >99</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">2.4.  Compound <b>E22</b> Induces Apoptosis and Inhibits Metastasis of Cancer Cells</h3><div class="NLM_p">Compound <b>E22</b> was very effective at inhibiting the phosphorylation of downstream Akt substrates in the LNCaP cell line, and it exhibited potent inhibition against phosphorylated PRAS40, which is a direct marker of Akt cell activity, with an observed IC<sub>50</sub> value of 44 nM. To examine the influence of compound <b>E22</b> on ovarian cancer cell survival prior to conducting an in vivo study, SKOV3, A2780, and OVCAR8 cells were incubated with different concentrations of <b>E22</b> for 72 h. A concentration-dependent inhibitory effect of compound <b>E22</b> was observed on the growth of ovarian cancer cells, which was similar to that of the positive control <b>GSK-795</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). In addition, Western blot analysis was further performed to test the Akt inhibitory ability of compound <b>E22</b> in tumor cells. The results demonstrated that upon treatment with the inhibitor <b>E22</b> in vitro, a dose-dependent significant reduction in the phosphorylation of GSK3β, PRAS40, and FOX3a was observed in SKOV3 cells. Consistent with previously reported studies,<a onclick="showRef(event, 'ref20 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref20 ref34 ref35">(20,34,35)</a><b>E22</b> showed a concentration-dependent feedback increase in Akt phosphorylation, similar to other ATP-competitive Akt kinase inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). To determine whether the antiproliferative activity of <b>E22</b> against ovarian cancer cell proliferation was accompanied by enhanced cancer cell apoptosis, annexin V–propidium iodide (PI) staining plus fluorescence activated cell sorting (FACS) analysis was carried out, and the percentages of apoptotic cells were tested by conducting a flow cytometry assay. The results indicated that <b>E22</b> had an apoptosis-inducing effect in a dose-dependent manner, with 79.9% of cells presenting as apoptotic at the concentration of 10 μM (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>E22</b> inhibits cell growth and induces apoptosis in vitro. (A) Cells (SKOV3, OVCAR8, and A2780) were exposed to <b>E22</b> and <b>GSK-795</b> for 72 h, and cell viability was then determined by sulforhodamine B (SRB) assay. (B) Western blot analysis of total AKT, p-AKT, PRAS40, p-PRAS40, and p-FOX3a was conducted in the ovarian cancer cell line SKOV3. (C) Apoptosis was assessed upon treatment with the indicated concentrations (0.4–10 μM) by flow cytometry using the FL1-H channel (Annexin-V) and FL2-H channel (PI) of a Becton Dickinson FACSCalibur. Representative dot plots are shown, and the results are summarized in (D). The results are presented as the mean ± standard deviation (SD) from three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, the effect of <b>E22</b> on the metastasis of ovarian cancer cells was investigated in the present study through transwell and scratch assays. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B, the motility of the cells in the <b>E22</b>-treated group was significantly lower than that of the cells in the control group, indicating that compound <b>E22</b> may inhibit the migratory capacity of ovarian cells. Similarly, the transwell migration assays showed that <b>E22</b>-exposed cells traversed less efficiently into the lower portion of the transwell chamber compared to the control cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D). As a consequence, it is evident that compound <b>E22</b> can inhibit the metastasis of ovarian cells.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>E22</b> suppresses the migratory capacity of ovarian cancer cells. (A) Human umbilical vein endothelial cells (HUVECs) were treated with <b>E22</b> (0–2.5 μM) for 36 h. Afterward, images were captured, and cell migration was determined using image analysis software; these results are summarized in (B). (C) HUVECs were placed in the upper Matrigel-coated invasion chamber, with <b>E22</b> (0–2.5 μM) in the bottom chamber for 36 h. Invaded cells were stained with crystal violet and quantified by measuring the absorbance of dissolved crystals in 0.1% sodium dodecyl sulfate (SDS) at 540 nm; these results are summarized in (D). The results are presented as the mean ± SD from three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control. The scale bars represent 200 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">2.5.  Compound <b>E22</b> Exhibited Improved Safety and Good in Vivo Efficacy</h3><div class="NLM_p">The safety profile of <b>E22</b> was evaluated before in vivo efficacy study. After 7 days of intragastric administration of <b>E22</b> (80 and 160 mg/kg), minimal body weight loss was observed (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S3A</a>). With lower hERG inhibition, we found that the MTD of <b>E22</b> was increased to ≥80 mg/kg (two of five mice in the 160 mg/kg group died), and the serum hematological and biochemical parameters remained normal (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S3B,C</a>). Although the organ-to-body/brain weight ratio of thymus in <b>E22</b>-treated mice decreased (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Table S1</a>) and intestinal hemorrhage in mice could also be observed, the therapeutic safety window was obviously improved in comparison to compound <b>A12</b>.</div><div class="NLM_p">The in vivo effect of compound <b>E22</b> was characterized by measuring its antitumor activity in the SKOV3 ovarian cancer xenograft model in nude mice. After 21 days of treatment with three doses of <b>E22</b> (60 and 80 mg/kg, 40 mg/kg bid), remarkable tumor growth inhibition was observed. The <b>E22</b> dose of 40 mg/kg twice per day appeared to be less effective than the dose of 80 mg/kg once per day (82.5 vs 90% inhibition for 40 and 80 mg/kg, respectively), whereas it was comparable to the dose of 60 mg/kg once per day (82.5 vs 79.2% for doses of 40 and 60 mg/kg, respectively); notably, the effect of all of these doses of <b>E22</b> was better than that of <b>GSK-795</b> at 60 mg/kg (63.3% inhibition; <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). In addition, the body weights of mice were not affected, and no mice died during treatment with the different doses (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), demonstrating the improved safety profile of this compound in comparison to that of compound <b>A12</b>, which had an MTD of only approximately 10 mg/kg. After dosing at 50 mg/(kg day) for 7 consecutive days, 560 ng/mL of <b>E22</b> could be detected in the tumor, suggesting that <b>E22</b> can effectively penetrate into the tumor tissue. After the completion of in vivo testing, Western blot analysis of the tumor tissues indicated that <b>E22</b> showed a dose-dependent inhibition of the levels of Akt substrate phosphorylation, including Fox3a and PRAS40 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C,D).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>E22</b> develops an antitumor effect through inhibiting the kinase activity of Akt. (A–C) The mice transplanted with SKOV3 human xenografts were randomly divided into five groups (<i>N</i> = 5 mice/group) and were administered injections of <b>E22</b> at different doses (60, 40 + 40, or 80 mg/kg, i.g.), <b>GSK-795</b> (60 mg/kg, i.g.) or vehicle daily for a period of 21 days. The relative tumor volume, tumor weight, tumor growth inhibition, and T/C values were measured after the mice were sacrificed. Data represent the mean ± SD. (D) Western blot analysis of total AKT, p-AKT, PRAS40, p-PRAS40, and p-FOX3a in tumor tissues. The results are presented as the mean ± SD of three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.6.  Docking Study and Dynamic Simulation</h3><div class="NLM_p">To explore the possible binding mode of compound <b>E22</b> with Akt protein, computational docking and molecular dynamics (MD) were performed. First, the complex of Akt1 protein (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> with <b>E22</b> was simulated for 4000 ps. The root-mean-square deviation (RMSD) value of the protein backbone was calculated in a trajectory from 0 to 4000 ps. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, after approximately 200 ps of simulation, the RMSD became stable, indicating that dynamic equilibrium was attained. The distances between <b>E22</b> and Glu234 or Glu278 indicated that the system reached equilibrium conditions (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B,C). Based on the relatively stable conformation, <b>E22</b> was hydrogen-bonded with the carboxyl group of Akt residue Glu 278. In addition, the 6-position side chain on the piperidine extended to the solvent area, while the 4-phenyl group was hydrophobic and interacted with the Gly159, Thr160, Phe161, and Val164 residues (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. MD simulations and analysis of the interaction of compound <b>E22</b> with Akt1 protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>). (A) RMSD of Akt backbone during the 4000 ps simulation time; (B) distance plot of Glu234 and Glu278 with <b>E22</b>; (C) plot of the inhibitor–residue interaction spectrum; and (D) three-dimensional plot of the binding pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">2.7.  Chemistry</h3><div class="NLM_p">Inhibitors of Akt described in this study were generally synthesized from readily available starting materials. Target compounds can be obtained by the condensation of the hinge-linkage acid fragments with the amine fragments. The synthetic route of acid fragments <b>1a</b>–<b>q</b> is similar to the conditions in the literature (patent: WO2008098104), using coupling reactions to yield biaryl esters (compounds <b>4</b>, <b>6</b>, <b>9</b>, <b>11</b>, <b>14</b>, <b>18</b>, <b>20</b>, <b>22</b>, and <b>24</b>) or aldehyde (<b>16</b>), and further introducing halogen substituents with <i>N</i>-bromosuccinimide or <i>N</i>-chlorosuccinimide and subsequent hydrolysis or oxidation afforded the acid intermediates (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S6</a>, Supporting Information).</div><div class="NLM_p">The synthetic routes of amines are outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. The Knoevenagel condensation reaction was performed to convert the aryl aldehydes <b>25a</b>–<b>d</b> to cinnamic acids <b>26a</b>–<b>d</b>, with subsequent esterification providing the methyl cinnamates <b>27a</b>–<b>d</b>. Further additive reaction with nitromethane yielded the compounds <b>28a</b>–<b>d</b>. Next, cyclization (<b>29a</b>–<b>d</b>) and reduction afforded the benzyl-protected 3,4-disubstituted piperidine derivatives <b>30a</b>–<b>d</b>, followed by Zn/AcOH-mediated reduction to obtain the corresponding amines <b>2a</b>–<b>d</b>. Compounds <b>31a</b>,<b>b</b> were prepared by condensation of substituted benzaldehyde with nitromethane, followed by cyclization to obtain <b>32a</b>,<b>b</b>. Subsequent reduction with stannous chloride afforded amines <b>2e</b>,<b>f</b>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Malonic acid, piperidine, pyridine; (b) dimethyl sulfate, K<sub>2</sub>CO<sub>3</sub>, acetone; (c) nitromethane, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), MeCN; (d) paraformaldehyde, benzylamine, EtOH; (e) borane–methyl sulfide complex in tetrahydrofuran (THF); (f) Zn, AcOH, EtOH; (g) nitromethane, ammonium acetate, AcOH; (h) CF<sub>3</sub>COOH, <i>N</i>-(methoxymethyl)-<i>N</i>-(trimethylsilylmethyl)benzylamine, dichloromethane (DCM); (i) SnCl<sub>2</sub>, EtOAc.</p></p></figure><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (<i>S</i>) or (<i>R</i>)-2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, dichloromethane; ii. trifluoracetic acid (TFA), dichloromethane; (b) i. Et<sub>3</sub>SiH, TFA; ii. Boc<sub>2</sub>O, triethylamine, dichloromethane; (c) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O; (d) i. (<i>S</i>)-2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, DCM; ii. allyltrimethylsilane, boron trifluoride etherate, DCM; (e) borane–methyl sulfide complex, NaOH, H<sub>2</sub>O<sub>2</sub>.</p></p></figure><div class="NLM_p">According to a previously reported method,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> compounds <b>33a</b>–<b>f</b> were subjected to (<i>R</i>) or (<i>S</i>)-Jorgensen–Hayashi reagent-catalyzed cyclization with compound <b>34</b> to provide the (3S,4S) compounds <b>37a</b>–<b>f</b> and (3R,4R) compounds <b>35a</b>,<b>b</b>. Subsequent treatment of compounds <b>35a</b>,<b>b</b> and <b>37a</b>–<b>f</b> with Et<sub>3</sub>SiH, followed by reduction with Fe/NH<sub>4</sub>Cl, provided the amines <b>2g</b>–<b>o</b>. As reported,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> BF<sub>3</sub>·OEt<sub>2</sub>-mediated allylation with Et<sub>3</sub>SiH can deliver 3,4,6-trisubstituted piperidine derivatives <b>39a</b> or <b>39b</b> as a single product (2R,4S,5S). Further, the configuration of compound <b>39b</b> was confirmed by NMR (NMR spectra, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Supporting Information</a>). The intermediate with the other configuration (2S,4S,5S) was impure and difficult to purify (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Figure S7</a>). Compound <b>39a</b> was oxidized with borane–methyl sulfide complex/H<sub>2</sub>O<sub>2</sub> to afford compound <b>40a</b>. The desired amines <b>2p</b>–<b>r</b> were finally acquired by reduction with the Fe/NH<sub>4</sub>Cl system.</div><div class="NLM_p">The synthesis of 3,4-disubstituted piperidine Akt inhibitors (<b>A1</b>–<b>A13</b>, <b>B1</b>–<b>B3</b>, <b>C1</b>–<b>C5</b>, <b>D1</b>–<b>D28</b>) described in this study is outlined in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Different acid fragments <b>1a</b>–<b>q</b> and amines <b>2a</b>–<b>o</b> were condensed to obtain the <i>tert</i>-butyloxycarbonyl (Boc)- or Bn-protected intermediates, which were subsequently deprotected to yield the target compounds. In addition, some oily liquid target compounds were treated with <span class="smallcaps smallerCapital">l</span>-tartaric acid to generate solid compounds.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 1-Ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBT), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DCM; (b) chloroethyl chloroformate, 1,2-dichloroethane; (c) <span class="smallcaps smallerCapital">l</span>-tartrate; (d) HCl/ethyl acetate (EA).</p></p></figure><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) EDCI, HOBT, DIPEA, DCM; (b) <span class="smallcaps smallerCapital">l</span>-tartrate; (c) HCl/EA.</p></p></figure><div class="NLM_p">The synthesis of 3,4,6-trisubstituted piperidine Akt inhibitors described in this study is outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Pyrazole–furan acid <b>1b</b> was condensed with the amines <b>2p</b>–<b>q</b> to yield the key allyl building blocks <b>41a</b>,<b>b</b>, which were subsequently oxidized to afford compounds <b>42a</b>,<b>b</b> and <b>43a</b>,<b>b</b>. The aldehydes <b>43a</b>,<b>b</b> were further reduced to alcohols <b>44a</b>,<b>b</b>, which then served as useful precursors to the amine <b>46a</b> or were oxidized to acids <b>44c</b>,<b>d</b>.</div><figure id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) EDCI, HOBT, DIPEA, DCM; (b) OsO<sub>4</sub>, <i>N</i>-methylmorpholine <i>N</i>-oxide, THF/H<sub>2</sub>O; (c) NaIO<sub>4</sub>, THF/H<sub>2</sub>O; (d) NaClO<sub>2</sub>, KH<sub>2</sub>PO<sub>4</sub>, 2-methylbut-2-ene; (e) NaBH<sub>4</sub>, THF/MeOH; (f) MsCl, DIPEA, DCM; (g) NaN<sub>3</sub>, DCM; (h) Pd/C, H<sub>2</sub>, EtOAc; (i) HCl/EA; (j) amines or CH<sub>3</sub>ONa; (k) MsCl or AcCl, DIPEA.</p></p></figure><div class="NLM_p last">Reduction of the allyl <b>41a</b> and deprotection produced inhibitor <b>E1</b>. Similarly, removing the protecting groups of compounds <b>41b</b>, <b>42a</b>,<b>b</b>, and <b>44a</b>–<b>c</b> yielded the inhibitors <b>E2</b>, <b>E4</b>, <b>E5</b>, <b>E13</b>, <b>E20</b>, and <b>E21</b>. Reduction of compound <b>2r</b> produced an amine, which was then condensed with acid <b>1b</b> and deprotected to afford inhibitor <b>E3</b>. Nucleophilic reaction of compound <b>45a</b> with different bases provided inhibitors <b>E6</b>–<b>E12</b> after removal of the protecting groups. Furthermore, condensation of compounds <b>44c</b>–<b>d</b> with various substituted amines afforded the inhibitors <b>E14</b>–<b>E19</b> and <b>E22</b> after deprotection. As before, capping <b>46a</b> or <b>44b</b> with mesyl or acetyl groups, followed by deprotection, yielded the inhibitors <b>E23</b>–<b>E25</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">3.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26413" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26413" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>A12</b>, designed based on the conformational restriction strategy, served as a promising lead Akt inhibitor with an acceptable pharmacokinetic profile and in vivo antitumor efficacy. Nevertheless, it exhibited unfavorable safety profile characteristics such as low MTD, high hERG inhibition, and gastrointestinal hemorrhage. Further optimization of this compound was ultimately explored with a range of diverse hinge or linkage groups, as well as by introducing side chains suggested by the docking results of this compound bound to Akt1, leading to compound <b>E22</b>. This compound inhibited all Akt isoforms with a potency of <2 nM, with good selectivity against other kinases, especially non-AGC family kinases. It also exhibited low hERG ion-channel inhibition, outstanding pharmacokinetic properties, and effective xenograft tumor inhibitory activity. The 3,4,6-trisubstituted piperidine derivative <b>E22</b> is better tolerated than <b>A12</b>, with improved safety properties, demonstrating that <b>E22</b> is a promising drug candidate for further preclinical study.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">4.  Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54257" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54257" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">4.1.  Chemistry</h3><div class="NLM_p"><sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded at 500 MHz using a Bruker AVANCE III spectrometer in CDCl<sub>3</sub>, or dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub> solution, with tetramethylsilane serving as internal standard. Chemical shift values (δ) were reported in ppm. Multiplicities are recorded by the following abbreviations: s, singlet; d, double; t, triplet; q, quartet; m, multiplet; <i>J</i>, coupling constant (Hz). High-resolution mass spectra (HRMS) were obtained from Agilent Technologies 6224 time-of-flight LC/MS. The purities of compounds for biological testing were assessed by NMR and high-performance liquid chromatography (HPLC), and the purities were ≥95%. Analytical HPLC was performed on an Agilent 1260 Infinity II (LC03) machine and a C18 reversed-phase column (Agilent Eclipse XDB-C18, 4.6 × 250 mm<sup>2</sup>, 5 μm), with a flow rate of 1.0 mL/min, the detection by UV absorbance at a wavelength of 254 nm, the column temperature was 25 °C, eluting with water (0.1% trifluoroacetic acid) as A phase and methanol as B phase (0 min, A phase: 90%, B phase: 10%; 8 min, A phase: 10%, B phase: 90%; 13 min, A phase: 10%, B phase: 90%; 15 min, A phase: 90%, B phase: 10%; 20 min, A phase: 90%, B phase: 10%). Unless otherwise noted, reagents and solvents were obtained from commercial suppliers and without further purification.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">4.1.1.  General Procedure I</h4><div class="NLM_p last">To a suspension of the acid (0.2 mmol), EDCI (69 mg, 0.36 mmol), HOBT (49 mg, 0.36 mmol), and DIPEA (87 μL, 0.5 mmol) in dichloromethane was added the amine (0.2 mmol); then, the mixture was reacted for 5 h at room temperature (RT) with mechanical stirring. After it was fully reacted, the mixture was concentrated under vacuum. The residue was dissolved in ethyl acetate (50 mL), washed by 1 N HCl (20 mL × 2) and saturated brine (20 mL × 2), and dried over anhydrous sodium sulfate. After solvent removal, the residue was purified by column chromatography to afford the product.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29">4.1.2.  General Procedure II</h4><div class="NLM_p last">To the solution of disubstituted piperidine compound in 1,2-dichloroethane was added 1-chloroethyl chloroformate (0.3 mmol) dropwise. The resulting mixture was heated to reflux for 4 h. After it was fully reacted, the mixture was concentrated under vacuum. The residue dissolved in MeOH (5 mL) was heated to reflux for another 2 h. After solvent removal, the residue was added with saturated sodium bicarbonate and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford the product. To a solution of the above-resulted product in MeOH was added <span class="smallcaps smallerCapital">l</span>-tartaric acid and stirred at room temperature for 2 h. After the solvent removal, the residue was washed with diethyl ether and dried in vacuum to afford <span class="smallcaps smallerCapital">l</span>-tartrate.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">4.1.3.  General Procedure III</h4><div class="NLM_p last">To a solution of the Boc-protected target compound in ethyl acetate was added HCl-saturated ethyl acetate and stirred overnight at room temperature. Then, the reaction was added with saturated sodium bicarbonate and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and dried in vacuum to afford a white solid.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31">4.1.4.  General Procedure IV</h4><div class="NLM_p last">To a solution of the Boc-protected target compound in ethyl acetate was added HCl-saturated ethyl acetate and stirred at room temperature for 6 h. A white solid was precipitated, filtered, washed with diethyl ether, and dried in vacuum to afford target product as white powder</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">4.1.5.  General Procedure V</h4><div class="NLM_p last">To a solution of substituted piperidine compound in ethyl acetate (0.5 mL) was added HCl-saturated ethyl acetate (2 mL) and stirred overnight at room temperature. Then, the reaction was added with saturated sodium bicarbonate (5 mL) and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated, and dried in vacuum to afford the product. Then, a solution of above-resulted product in MeOH (2 mL) was added with <span class="smallcaps smallerCapital">l</span>-tartaric acid and stirred at room temperature for 2 h. After the solvent removal, the residue was washed with diethyl ether and dried in vacuum to afford the <span class="smallcaps smallerCapital">l</span>-tartrate.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">4.1.6.  General Procedure VI</h4><div class="NLM_p last">To the solution of compound <b>45a</b> (71 mg, 0.1 mmol) in anhydrous DMF (5 mL) was added amines (1.0 mmol) dropwise under N<sub>2</sub> protection. The reaction was heated to 80 °C and stirred for 6 h. After completion of reaction, the mixture was poured into H<sub>2</sub>O (10 mL) and extracted with DCM (5 mL × 3). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid. Then, a solution of the above white solid in ethyl acetate (0.3 mL) was added with HCl-saturated ethyl acetate (4 mL) in ice bath and stirred overnight at room temperature. A white solid was precipitated, filtered, washed with diethyl ether, and dried in vacuum to afford target product as white powder.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">4.1.7.  General Procedure VII</h4><div class="NLM_p last">To the solution of trisubstituted piperidine (<b>44c</b> or <b>44d</b>, 0.1 mmol) and DIPEA (37 mg, 0.3 mmol) in anhydrous DMF (5 mL) was added HBTU (76 mg, 0.2 mmol). After stirred at RT for 30 min, the mixture was added with amines and stirred overnight. Then, the mixture was poured into H<sub>2</sub>O (10 mL) and extracted with ethyl acetate (5 mL × 3). The combined organic extracts were washed with brine (5 mL × 2), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid. Then, a solution of the above white solid in ethyl acetate (0.3 mL) was added HCl-saturated ethyl acetate (4 mL) in ice bath and stirred overnight at room temperature. The white solid was precipitated, filtered, washed with diethyl ether, and dried in vacuum to afford target product as white powder.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35">4.1.8.  General Procedure VIII</h4><div class="NLM_p">To the solution of compound <b>46a</b> (0.05 mmol) and DIPEA (26 μL, 0.15 mmol) in THF (5 mL) was added MsCl (10 μL, 0.10 mmol) in ice bath. The resulting mixture was stirred at RT for 4 h. After completion of reaction, the reaction mixture was poured into saturated NaHCO<sub>3</sub> (5 mL) and extracted with ethyl acetate (5 mL × 3). The combined organic extracts were washed with brine (5 mL × 2), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid. Then, a solution of the above white solid in ethyl acetate (0.1 mL) was added to HCl-saturated ethyl acetate (1 mL) in ice bath and stirred overnight at room temperature. The white solid was precipitated, filtered, washed with diethyl ether, and dried in vacuum to afford target product as white powder.</div><div class="NLM_p">After the synthesis, 74 compounds were obtained in total, and the compound information of the target compounds and the intermediates can be found in the following part and the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">Supporting Information</a>, respectively.</div><div id="sec4_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36">4.1.8.1.  4-(1-Methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-phenylpiperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A1</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 21.5%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.51–8.54 (d, <i>J</i> = 11.4 Hz, 1H), 8.17 (s, 1H), 7.40 (s, 1H), 7.17–7.33 (m, 6H), 6.45 (s, 1H), 4.55 (m, 1H), 4.21 (s, 2H), 3.87 (s, 3H), 3.38 (m, 2H), 2.93–3.07 (m, 3H), 1.96 (m, 2H). <sup>13</sup>C NMR (500 MHz, DMSO) δ 173.46 (×2), 156.66, 147.67, 141.89, 141.67, 137.86, 133.44, 128.34 (×2), 127.29 (×2), 126.71, 117.06, 113.58, 105.64, 71.94 (×2), 41.64, 46.60, 44.59, 43.36, 37.83, 30.22. HRMS: calcd (M + H) 351.1552, found 351.1808.</div></div><div id="sec4_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37">4.1.8.2.  <i>N</i>-(4-(3,4-Difluorophenyl)piperidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A2</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 22.5%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.61 (d, <i>J</i> = 10.75 Hz, 1H), 8.20 (s, 1H), 7.92 (d, <i>J</i> = 15.75 Hz, 1H), 7.21–7.41 (m, 3H), 7.11 (m, 1H), 6.48 (s, 1H), 4.49 (m, 1H), 4.18 (s, 2H), 3.88 (s, 3H), 3.35 (m, 2H), 3.08 (m, 1H), 2.94 (m, 1H), 2.85 (m, 1H), 1.97 (m, 2H). <sup>13</sup>C NMR (500 MHz, DMSO) δ 173.61 (×2), 168.81, 156.72, 147.57, 141.98, 137.86, 133.44, 124.13, 117.36, 117.19, 117.08, 116.39, 116.23, 113.67, 105.65, 71.93 (×2), 46.73, 46.53, 44.09, 43.18, 37.84, 29.69. HRMS: calcd (M + H) 387.1633, found 387.1642.</div></div><div id="sec4_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38">4.1.8.3.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-phenylpiperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A3</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 21.2%; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i>) δ 8.77–8.79 (d, <i>J</i> = 11.15 Hz, 1H), 7.71 (s, 1H), 7.46 (s, 1H), 7.24–7.33 (m, 5H), 4.59 (m, 1H), 4.26 (s, 2H), 3.77 (s, 3H), 3.42 (m, 2H), 3.12 (m, 1H), 3.00 (m, 2H), 2.01 (m, 2H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i>) δ 173.80 (×2), 155.63, 146.75, 141.62, 137.22, 136.58, 128.87, 128.37 (×2), 127.31 (×2), 126.78, 116.83, 110.06, 109.26, 72.04 (×2), 46.72, 46.32, 44.50, 43.24, 38.13, 30.02. HRMS: calcd (M + H) 419.1042, found 419.0971.</div></div><div id="sec4_1_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39">4.1.8.4.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A4</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 21.6%; <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i>) δ 8.75–8.77 (d, <i>J</i> = 10.9 Hz, 1H), 7.68 (s, 1H), 7.46 (s, 1H), 7.35–7.37 (d, <i>J</i> = 10.3 Hz, 2H), 7.28–7.30 (d, <i>J</i> = 10.25 Hz, 2H), 4.54 (m, 1H), 4.22 (s, 2H), 3.74 (s, 3H), 3.39 (m, 2H), 3.08 (m, 2H), 2.96 (m, 1H), 1.96 (m, 2H). <sup>13</sup>C NMR (500 MHz, DMSO) δ 173.69 (×2), 155.62, 146.74, 140.69, 137.20, 136.58, 131.27, 129.24 (×2), 128.87, 128.35 (×2), 116.96, 110.12, 109.24, 72.04 (×2), 46.73, 46.31, 43.98, 43.16, 38.17, 29.93. HRMS: calcd (M + H) 453.0651, found 453.0479.</div></div><div id="sec4_1_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40">4.1.8.5.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A5</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 20.1%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.79–8.81 (d, <i>J</i> = 10.9 Hz, 1H), 7.68 (s, 1H), 7.49 (s, 1H), 7.13–7.38 (m, 4H), 4.49 (m, 1H), 4.21 (s, 4H), 3.74 (s, 3H), 3.36 (m, 2H), 3.10 (m, 1H), 2.95 (m, 2H), 1.98 (m, 2H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i>) δ 173.79 (×2), 155.67, 146.72, 139.48, 137.23, 136.58, 128.87, 124.17, 117.41, 117.14, 116.99, 116.41, 116.24, 110.12, 109.24, 72.04 (×2), 46.81, 46.29, 43.89, 43.11, 38.15, 29.76. MS: calcd (M + H) 487.09, found 487.09.</div></div><div id="sec4_1_8_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41">4.1.8.6.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-(3,4-difluorophenyl)piperidin -3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A6</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 25.9%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.63–8.65 (d, <i>J</i> = 9.05 Hz, 1H), 8.23 (s, 1H), 7.62 (s, 1H), 7.36 (s, 1H), 7.10–7.34 (m, 3H), 4.46 (m, 1H), 4.21 (s, 2H), 3.82 (s, 3H), 3.36 (m, 3H), 2.90 (m, 2H), 2.85 (m, 1H), 1.98 (m, 1H), 1.91 (m, 1H). HRMS: calcd (M + H) 455.0854, found 455.0840.</div></div><div id="sec4_1_8_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42">4.1.8.7.  5-Chloro-<i>N</i>-(4-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide (<b>A7</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 42.5%; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.75 (s, 1H), 7.57–7.59 (d, <i>J</i> = 7.65 Hz, 1H), 7.43 (s, 1H), 7.39 (s, 1H), 7.07–7.20 (m, 3H), 4.69 (m, 1H), 3.86 (s, 3H), 3.68 (m, 1H), 3.59 (m, 1H),3.50 (m, 1H), 3.26 (s, 1H) 3.20 (m, 1H). Electrospray ionization mass spectrometry (ESI-MS): <i>m</i>/<i>z</i> = 407.68 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43">4.1.8.8.  5-Bromo-<i>N</i>-(4-(3,4-difluorophenyl)pyrrolidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide (<b>A8</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 40.0%; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.78 (s, 1H), 7.73–7.74 (d, <i>J</i> = 6.75 Hz, 1H), 7.48 (s, 1H), 7.41 (s, 1H), 7.10–7.24 (m, 3H), 4.72 (m, 1H), 3.88 (s, 3H), 3.72 (m, 1H), 3.58 (m, 2H), 3.26–3.30 (m, 2H). ESI-MS: <i>m</i>/<i>z</i> = 453 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44">4.1.8.9.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-(4-(4-(trifluoromethyl)phenyl)pyrrolidin-3-yl)furan-2-carboxamide (<b>A9</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure II, yield: 40.5%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.03 (d, <i>J</i> = 8.1 Hz, 1H), 7.71–7.72 (d, <i>J</i> = 8.1 Hz, 2H), 7.69 (s, 1H), 7.61–7.63 (d, <i>J</i> = 8.1 Hz, 2H), 7.53 (s, 1H), 4.71 (m, 1H), 3.74 (s, 3H), 3.65 (m, 2H), 3.52 (m, 1H), 3.19 (m, 1H), 3.09 (m, 1H). ESI-MS: <i>m</i>/<i>z</i> = 473 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45">4.1.8.10.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-(trifluoromethyl)phenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A10</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 49%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.81 (d, <i>J</i> = 8.9 Hz, 1H), 7.70–7.60 (m, 3H), 7.49 (d, <i>J</i> = 7.9 Hz, 2H), 7.43 (s, 1H), 4.66–4.53 (m, 1H), 4.20 (s, 2H), 3.71 (s, 3H), 3.45–3.34 (m, 2H), 3.25–3.17 (m, 1H), 3.05–2.92 (m, 2H), 2.05–1.93 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 173.96, 155.78, 146.76, 146.65, 137.30, 136.65, 128.94, 128.36, 127.50 (q, <i>J</i> = 32.5 Hz), 125.35, 124.30 (q, <i>J</i> = 270.0 Hz), 117.10, 110.21, 109.31, 72.15, 46.68, 46.36, 44.53, 43.17, 38.23, 30.02. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>20</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 487.0910, found 487.0923.</div></div><div id="sec4_1_8_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46">4.1.8.11.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>R</i>,4<i>R</i>)-4-(4-(trifluoromethyl)phenyl) piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A11</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 71%; retention time: 10.014 min, purity: 98.57%; ESI-MS: <i>m</i>/<i>z</i> = 487 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47">4.1.8.12.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>A12</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 56%; retention time: 10.214 min, purity: 98.49%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.91–8.79 (m, 1H), 7.65 (s, 1H), 7.46 (d, <i>J</i> = 17.4 Hz, 1H), 7.36–7.27 (m, 2H), 7.12 (s, 1H), 4.50 (d, <i>J</i> = 6.8 Hz, 1H), 4.15 (s, 2H), 3.72 (s, 3H), 3.35 (d, <i>J</i> = 7.1 Hz, 2H), 3.07 (d, <i>J</i> = 24.7 Hz, 1H), 3.16–2.88 (m, 3H), 2.96 (d, <i>J</i> = 9.1 Hz, 2H), 1.97 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 174.70, 155.76, 150.17, 150.08, 149.26, 149.16, 148.22, 148.11, 147.31, 147.22, 146.86, 139.68, 137.25, 136.62, 128.95, 124.27, 117.32, 117.19, 116.90, 116.48, 116.35, 110.14, 109.31, 72.26, 47.17, 46.45, 44.10, 43.15, 38.17, 29.95. ESI-MS: <i>m</i>/<i>z</i> = 455 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48">4.1.8.13.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>R</i>,4<i>R</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate(<b>A13</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 62%; retention time: 10.014 min, purity: 98.57%; ESI-MS: <i>m</i>/<i>z</i> = 455 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49">4.1.8.14.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-dichlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>B1</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 63%; retention time: 10.746 min, purity: 97.38%; HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>19</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 489.0227, found 489.0235.</div></div><div id="sec4_1_8_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50">4.1.8.15.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-(trifluoromethyl)phenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>B2</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 53%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.81 (d, <i>J</i> = 9.0 Hz, 1H), 7.66 (s, 1H), 7.64–7.51 (m, 4H), 7.43 (s, 1H), 4.59–4.49 (m, 1H), 4.16 (s, 2H), 3.71 (s, 3H), 3.44–3.34 (m, 2H), 3.25–3.16 (m, 1H), 2.96 (t, <i>J</i> = 11.4 Hz, 2H), 2.11–1.96 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.20, 155.72, 146.79, 143.05, 137.29, 136.66, 131.25, 129.55, 128.95, 128.92 (q, <i>J</i> = 30.0 Hz), 124.60 (q, <i>J</i> = 3.8 Hz), 124.19 (q, <i>J</i> = 271.3 Hz), 123.63 (q, <i>J</i> = 3.8 Hz), 116.97, 110.14, 109.32, 72.14, 47.05, 46.47, 44.51, 43.21, 38.15, 29.47. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>20</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 487.0910, found 487.0933.</div></div><div id="sec4_1_8_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51">4.1.8.16.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>B3</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 43%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (d, <i>J</i> = 8.7 Hz, 1H), 7.67 (s, 1H), 7.44 (s, 1H), 7.35 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 4.59–4.44 (m, 1H), 4.21 (s, 2H), 3.72 (s, 3H), 3.40–3.33 (m, 2H), 3.15–2.89 (m, 3H), 2.01–1.88 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.76, 155.69, 146.81, 140.76, 137.27, 136.65, 131.34, 129.31, 128.94, 128.42, 117.03, 110.19, 109.31, 72.11, 46.80, 46.38, 44.05, 43.23, 38.24, 30.00. ESI-MS: <i>m</i>/<i>z</i> = 453 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 453.0646, found 453.0679.</div></div><div id="sec4_1_8_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52">4.1.8.17.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)furan-2-carboxamide Hydrochloride (<b>C1</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 61%; retention time: 8.803 min, purity: 95.23%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.62 (s, 1H), 9.53 (s, 1H), 8.60 (d, <i>J</i> = 6.1 Hz, 1H), 8.16 (s, 1H), 7.84 (s, 1H), 7.35–7.26 (m, 4H), 7.12–7.08 (m, 1H), 6.55 (d, <i>J</i> = 3.3 Hz, 1H), 4.58–4.47 (m, 1H), 3.85 (s, 3H), 3.32 (t, <i>J</i> = 12.7 Hz, 2H), 3.22 (s, 1H), 2.99 (t, <i>J</i> = 15.7 Hz, 1H), 2.94–2.89 (m, 1H), 2.10–1.90 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 157.08, 149.91, 144.74, 140.99, 136.09, 131.29, 129.46, 128.41, 128.34, 115.95, 112.70, 105.35, 46.55, 46.43, 44.03, 43.29, 38.81, 29.50. ESI-MS: <i>m</i>/<i>z</i> = 385 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426, found 385.1425.</div></div><div id="sec4_1_8_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53">4.1.8.18.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-5-(1<i>H</i>-pyrazol-4-yl)furan-2-carboxamide (<b>C2</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure III, yield: 53%; retention time: 8.771 min, purity: 95.54%; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.79 (s, 2H), 7.27–7.18 (m, 4H), 7.01 (d, <i>J</i> = 3.5 Hz, 1H), 6.36 (d, <i>J</i> = 3.5 Hz, 1H), 6.07 (d, <i>J</i> = 8.3 Hz, 1H), 4.29–4.22 (m, 1H), 3.57–3.44 (m, 2H), 3.17 (d, <i>J</i> = 12.5 Hz, 1H), 2.79–2.69 (m, 2H), 1.96–1.88 (m, 1H), 1.75–1.62 (m, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 158.12, 149.98, 145.61, 141.04, 132.61, 131.31, 129.01, 128.87, 116.47, 112.99, 106.43, 52.10, 51.11, 48.50, 46.44, 36.16. ESI-MS: <i>m</i>/<i>z</i> = 371 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>19</sub>H<sub>20</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 371.1269, found 371.1292.</div></div><div id="sec4_1_8_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54">4.1.8.19.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)furan-2-carboxamide Hydrochloride (<b>C3</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 73%; retention time: 8.966 min, purity: 95.13%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.62 (d, <i>J</i> = 9.4 Hz, 1H), 9.52 (d, <i>J</i> = 10.4 Hz, 1H), 8.56 (d, <i>J</i> = 9.1 Hz, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.65 (s, 1H), 7.32–7.26 (m, 3H), 7.24 (d, <i>J</i> = 8.5 Hz, 2H), 4.56–4.48 (m, 1H), 3.80 (s, 3H), 3.29 (t, <i>J</i> = 9.6 Hz, 2H), 3.14–3.06 (m, 1H), 2.94–2.83 (m, 2H), 2.08–1.96 (m, 1H), 1.95–1.89 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 156.93, 147.51, 140.86, 139.59, 136.34, 131.27, 129.38, 128.33, 128.05, 119.56, 112.99, 112.22, 46.46, 46.29, 44.06, 43.20, 38.63, 29.50. ESI-MS: <i>m</i>/<i>z</i> = 385 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426, found 385.1403.</div></div><div id="sec4_1_8_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55">4.1.8.20.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-5-(6-(methylamino)pyrimidin-4-yl)furan-2-carboxamide (<b>C4</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 41%; retention time: 8.522 min, purity: 96.15%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.71 (d, <i>J</i> = 9.1 Hz, 1H), 9.58–9.35 (m, 3H), 8.72–8.60 (m, 1H), 7.91–7.62 (m, 1H), 7.52–7.28 (m, 5H), 7.28–7.10 (m, 1H), 4.56 (s, 1H), 3.42–3.20 (m, 3H), 3.13–2.85 (m, 5H), 2.12–2.00 (m, 1H), 1.97 (d, <i>J</i> = 9.4 Hz, 1H). ESI-MS: <i>m</i>/<i>z</i> = 412 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>ClN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 412.1535, found 412.1539.</div></div><div id="sec4_1_8_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56">4.1.8.21.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-5-(7-hydroxy-6,7-dihydro-5<i>H</i>-cyclopenta[<i>d</i>] pyrimidin-4-yl)thiophene-2-carboxamide (<b>C5</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure III, yield: 32%; retention time: 8.838 min, purity: 95.08%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.92 (s, 1H), 7.67 (dd, <i>J</i> = 4.1, 2.4 Hz, 1H), 7.54 (dd, <i>J</i> = 4.1, 1.0 Hz, 1H), 7.32–7.27 (m, 2H), 7.27–7.23 (m, 2H), 5.10 (dd, <i>J</i> = 7.6, 6.4 Hz, 1H), 4.27 (td, <i>J</i> = 11.1, 4.5 Hz, 1H), 3.29–3.22 (m, 2H), 3.12 (d, <i>J</i> = 12.8 Hz, 1H), 3.08–3.01 (m, 4.3 Hz, 1H), 2.88 (dd, <i>J</i> = 11.7, 3.8 Hz, 1H), 2.79–2.71 (m, 1H), 2.68–2.62 (m, 1H), 2.62–2.54 (m, 1H), 2.03–1.96 (m, 1H), 1.95–1.88 (m, 1H), 1.82–1.73 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 173.10, 160.28, 155.06, 152.90, 144.09, 140.55, 139.95, 130.41, 128.30, 127.34, 127.25, 127.25, 126.54, 72.20, 49.64, 48.68, 45.57, 43.74, 32.57, 30.67, 25.70. ESI-MS: <i>m</i>/<i>z</i> = 455 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57">4.1.8.22.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>D1</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 76%; retention time: 9.050 min, purity: 95.02%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.54 (d, <i>J</i> = 9.9 Hz, 1H), 9.42 (d, <i>J</i> = 10.3 Hz, 1H), 8.73 (d, <i>J</i> = 9.1 Hz, 1H), 8.19 (d, <i>J</i> = 0.8 Hz, 1H), 7.46 (d, <i>J</i> = 0.8 Hz, 1H), 7.42 (d, <i>J</i> = 1.9 Hz, 1H), 7.33 (d, <i>J</i> = 8.5 Hz, 2H), 7.27 (d, <i>J</i> = 8.6 Hz, 2H), 6.46 (d, <i>J</i> = 1.9 Hz, 1H), 4.57–4.50 (m, 1H), 3.88 (s, 3H), 3.37–3.30 (m, 2H), 3.15–3.10 (m, 1H), 2.97–2.88 (m, 2H), 2.08–1.99 (m, 1H), 1.98–1.92 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 156.66, 147.64, 142.08, 140.74, 137.83, 133.61, 131.26, 129.33, 128.30, 116.99, 113.68, 105.68, 46.56, 46.26, 43.99, 43.19, 37.89, 29.47. ESI-MS: <i>m</i>/<i>z</i> = 385 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426, found 385.1399.</div></div><div id="sec4_1_8_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58">4.1.8.23.  4-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>D2</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 71%; retention time: 9.531 min, purity: 96.56%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.04 (s, 1H), 7.50 (s, 1H), 7.37 (s, 1H), 7.29–7.16 (m, 3H), 4.61–4.53 (m, 1H), 3.86 (s, 3H), 3.61–3.49 (m, 2H), 3.16–3.04 (m, 3H), 2.19 (d, <i>J</i> = 14.4 Hz, 1H), 2.07–1.99 (m, 1H). ESI-MS: <i>m</i>/<i>z</i> = 421 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59">4.1.8.24.  4-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D3</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 55%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.65 (d, <i>J</i> = 8.9 Hz, 1H), 8.22 (s, 1H), 7.61 (s, 1H), 7.38 (s, 1H), 7.34 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 4.58–4.46 (m, 1H), 4.21 (s, 2H), 3.83 (s, 3H), 3.43–3.29 (m, 2H), 3.14–3.04 (m, 1H), 3.02–2.87 (m, 2H), 2.03–1.89 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.80, 156.67, 147.71, 144.30, 140.81, 138.64, 132.04, 131.32, 129.32, 129.32, 128.39, 128.25, 114.54, 113.88, 92.90, 72.11, 46.78, 46.45, 44.10, 43.24, 38.64, 29.93. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>21</sub>BrClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 463.0531, found 463.0509.</div></div><div id="sec4_1_8_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60">4.1.8.25.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-5-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>D4</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 61%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.47 (d, <i>J</i> = 10.0 Hz, 1H), 9.36 (d, <i>J</i> = 10.0 Hz, 1H), 8.61 (d, <i>J</i> = 9.0 Hz, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 7.35–7.26 (m, 4H), 7.21 (d, <i>J</i> = 3.6 Hz, 1H), 6.90 (d, <i>J</i> = 3.6 Hz, 1H), 6.71 (d, <i>J</i> = 2.0 Hz, 1H), 4.54–4.46 (m, 1H), 3.97 (s, 3H), 3.37–3.31 (m, 2H), 3.18 (td, <i>J</i> = 11.8, 3.9 Hz, 1H), 3.02–2.88 (m, 2H), 2.08–1.98 (m, 2H).<sup>13</sup>C NMR (125 MHz, DMSO) δ 156.78, 146.52, 145.61, 140.74, 138.05, 132.48, 131.29, 129.34, 128.31, 115.62, 110.16, 106.06, 46.83, 46.31, 43.91, 43.24, 38.54, 29.32. ESI-MS: <i>m</i>/<i>z</i> = 385 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 385.1426, found 385.1431.</div></div><div id="sec4_1_8_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61">4.1.8.26.  5-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>D5</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 69%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.50 (d, <i>J</i> = 10.1 Hz, 1H), 9.40 (d, <i>J</i> = 10.1 Hz, 1H), 8.64 (d, <i>J</i> = 9.0 Hz, 1H), 7.68 (s, 1H), 7.35–7.26 (m, 5H), 6.99 (d, <i>J</i> = 3.6 Hz, 1H), 4.53–4.44 (m, 1H), 3.97 (s, 3H), 3.37–3.32 (m, 2H), 3.17 (td, <i>J</i> = 11.9, 3.8 Hz, 1H), 3.01–2.88 (m, 2H), 2.12–1.93 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 156.61, 147.35, 142.44, 140.67, 136.87, 131.29, 129.32, 128.97, 128.28, 115.22, 112.73, 108.41, 47.04, 46.24, 43.83, 43.20, 39.74, 29.14. ESI-MS: <i>m</i>/<i>z</i> = 419 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 419.1036, found 419.1060.</div></div><div id="sec4_1_8_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62">4.1.8.27.  5-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>D6</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 74%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.49 (d, <i>J</i> = 9.6 Hz, 1H), 9.39 (d, <i>J</i> = 10.3 Hz, 1H), 8.63 (d, <i>J</i> = 9.0 Hz, 1H), 7.73–7.61 (m, 1H), 7.36–7.26 (m, 5H), 7.01 (d, <i>J</i> = 3.6 Hz, 1H), 4.53–4.45 (m, 1H), 3.96 (s, 3H), 3.37 (dd, <i>J</i> = 14.0, 7.0 Hz, 2H), 3.17 (td, <i>J</i> = 11.9, 3.8 Hz, 1H), 2.99–2.88 (m, 2H), 2.11–1.93 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 156.62, 147.42, 142.80, 140.67, 139.11, 131.31, 130.57, 129.34, 128.29, 115.17, 113.05, 93.50, 47.04, 46.25, 43.84, 43.21, 39.65, 29.15. ESI-MS: <i>m</i>/<i>z</i> = 463 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63">4.1.8.28.  4-Bromo-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)-5-(1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D7</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 52%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.59 (d, <i>J</i> = 8.5 Hz, 1H), 7.56 (d, <i>J</i> = 1.8 Hz, 1H), 7.34 (d, <i>J</i> = 7.7 Hz, 2H), 7.31–7.23 (m,3H), 6.76 (d, <i>J</i> = 1.8 Hz, 1H), 4.41 (d, <i>J</i> = 7.4 Hz, 1H), 4.12 (s, 2H), 3.92 (s, 3H), 3.40–3.32 (m, 2H), 3.10–2.86 (m, 3H), 2.03–1.90 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.01, 156.01, 146.88, 142.44, 140.69, 138.31, 131.35, 129.80, 129.33, 128.37, 117.88, 108.06, 100.35, 71.96, 47.39, 46.59, 44.19, 43.30, 38.58, 29.75. ESI-MS: <i>m</i>/<i>z</i> = 465 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>21</sub>BrClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 465.0510, found 465.0526.</div></div><div id="sec4_1_8_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64">4.1.8.29.  4-Bromo-5-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D8</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 69%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (s, 1H), 7.41 (s, 1H), 7.36–7.22 (m, 4H), 4.42–4.33 (m, 1H), 4.10 (s, 2H), 3.76 (s, 3H), 3.40–3.28 (m, 2H), 3.12–2.89 (m, 3H), 2.12–1.89 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.26, 155.76, 148.93, 140.71, 139.22, 137.08, 131.32, 129.34, 128.31, 127.48, 117.57, 111.56, 104.51, 71.98, 47.42, 46.59, 44.20, 43.28, 38.68, 29.74. ESI-MS: <i>m</i>/<i>z</i> = 497 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>20</sub>BrCl<sub>2</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 499.0121, found 499.0127.</div></div><div id="sec4_1_8_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65">4.1.8.30.  4-Bromo-5-(4-bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)furan-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D9</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 52%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.69 (d, <i>J</i> = 8.7 Hz, 1H), 7.77 (s, 1H), 7.40 (s, 1H), 7.36–7.21 (m, 4H), 4.44–4.34 (m, 1H), 4.09 (s, 2H), 3.76 (s, 3H), 3.40–3.27 (m, 2H), 3.08–2.97 (m, 1H), 2.97–2.81 (m, 2H), 2.03–1.87 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.08, 155.74, 148.86, 140.68, 139.74, 139.26, 131.30, 129.32, 129.29, 128.31, 117.51, 104.56, 96.82, 71.87, 47.42, 46.67, 44.20, 43.34, 38.60, 29.76. ESI-MS: <i>m</i>/<i>z</i> = 543 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>20</sub>Br<sub>2</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 542.9616, found 542.9629.</div></div><div id="sec4_1_8_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66">4.1.8.31.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-Chlorophenyl)piperidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)thiophene-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D10</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 39%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.95 (s, 1H), 7.89 (s, 1H), 7.43 (s, 1H), 7.38–7.25 (m, 4H), 6.41 (s, 1H), 4.57–4.39 (m, 1H), 4.25 (s, 2H), 3.89 (s, 3H), 3.60–3.49 (m, 1H), 3.44–3.34 (m, 1H), 3.11–3.02 (m, 2H), 3.01–2.86 (m, 1H), 2.06–1.90 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.37, 160.17, 140.66, 139.63, 137.79, 137.24, 131.29, 130.63, 129.29, 128.42, 128.34, 113.88, 105.65, 72.07, 47.45, 46.58, 44.15, 43.29, 37.88, 29.67. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>22</sub>ClN<sub>4</sub>OS [M + H]<sup>+</sup> 401.1197, found 401.1179.</div></div><div id="sec4_1_8_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67">4.1.8.32.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)thiophene-2-carboxamide Hydrochloride (<b>D11</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 74%; retention time: 10.372 min, purity: 97.31%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.36 (s, 1H), 9.29 (s, 1H), 9.06 (d, <i>J</i> = 8.9 Hz, 1H), 8.11 (s, 1H), 8.09 (s, 1H), 7.36–7.27 (m, 4H), 4.52–4.44 (m, 1H), 3.82 (s, 3H), 3.42–3.36 (m, 2H), 3.21–3.15 (m, 1H), 2.96 (d, <i>J</i> = 9.1 Hz, 2H), 2.08–1.93 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 159.89, 140.65, 140.24, 136.14, 134.71, 132.38, 131.24, 129.31, 128.40, 128.26, 126.52, 105.18, 47.44, 46.37, 43.84, 43.22, 39.02, 29.24. ESI-MS: <i>m</i>/<i>z</i> = 471 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>N<sub>4</sub>OS [M + H]<sup>+</sup> 471.0388, found 471.0412.</div></div><div id="sec4_1_8_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68">4.1.8.33.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-fluorophenyl)piperidin-3-yl)thiophene-2-carboxamide Hydrochloride (<b>D12</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 68%; retention time: 10.007 min, purity: 99.27%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.93 (d, <i>J</i> = 1.2 Hz, 1H), 7.79 (s, 1H), 7.30 (td, <i>J</i> = 7.9, 6.2 Hz, 1H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 7.11 (dd, <i>J</i> = 10.1, 2.0 Hz, 1H), 6.93 (td, <i>J</i> = 8.5, 2.3 Hz, 1H), 4.58 (td, <i>J</i> = 11.6, 4.3 Hz, 1H), 3.80 (s, 3H), 3.65–3.59 (m, 1H), 3.54 (d, <i>J</i> = 12.8 Hz, 1H), 3.25–3.10 (m, 3H), 2.23–2.15 (m, 1H), 2.14–2.04 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 164.31 (d, <i>J</i> = 243.8 Hz), 162.95, 144.73 (d, <i>J</i> = 6.3 Hz), 140.70, 137.65, 137.28, 133.52, 131.47 (d, <i>J</i> = 7.5 Hz), 129.83, 128.68, 124.60 (d, <i>J</i> = 2.5 Hz), 115.44 (d, <i>J</i> = 22.5 Hz), 115.13 (d, <i>J</i> = 21.3 Hz), 107.68, 49.49, 48.04, 46.39, 45.14, 39.20, 31.18. ESI-MS: <i>m</i>/<i>z</i> = 453 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69">4.1.8.34.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)thiophene-2-carboxamide Hydrochloride (<b>D13</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 57%; retention time: 9.432 min, purity: 98.90%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.18 (s, 2H), 9.01 (d, <i>J</i> = 8.9 Hz, 1H), 8.13 (d, <i>J</i> = 1.3 Hz, 1H), 8.08 (s, 1H), 7.37–7.29 (m, 2H), 7.15–7.10 (m, 1H), 4.49–4.43 (m, 1H), 3.82 (s, 3H), 3.42–3.35 (m, 2H), 3.21–3.13 (m, 1H), 3.00–2.90 (m, 2H), 2.08–1.97 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 159.97, 149.12 (dd, <i>J</i> = 242.5, 12.5 Hz), 148.32 (dd, <i>J</i> = 242.5, 12.5 Hz), 140.12, 139.41, 136.14, 134.73, 132.47, 128.41, 126.55, 124.16, 117.32 (d, <i>J</i> = 17.5 Hz), 116.50 (d, <i>J</i> = 17.5 Hz), 105.17, 47.51, 46.38, 43.73, 43.19, 38.97, 29.07. ESI-MS: <i>m</i>/<i>z</i> = 471 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70">4.1.8.35.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chloro-3-(trifluoromethyl)phenyl)piperidin-3-yl)thiophene-2-carboxamide Hydrochloride (<b>D14</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 71%; retention time: 10.942 min, purity: 96.05%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.31 (s, 1H), 9.18 (s, 1H), 9.12 (d, <i>J</i> = 9.0 Hz, 1H), 8.12 (d, <i>J</i> = 1.2 Hz, 1H), 8.10 (s, 1H), 7.79 (d, <i>J</i> = 1.6 Hz, 1H), 7.66 (d, <i>J</i> = 8.3 Hz, 1H), 7.58 (dd, <i>J</i> = 8.3, 1.5 Hz, 1H), 4.52–4.44 (m, 1H), 3.82 (s, 3H), 3.35–3.25 (m, 3H), 2.97 (q, <i>J</i> = 11.1 Hz, 2H), 2.13–2.01 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 160.00, 141.59, 140.01, 136.15, 134.74, 132.75, 132.53, 131.69, 128.93, 128.44, 127.48 (q, <i>J</i> = 5.3 Hz), 126.54, 126.23 (q, <i>J</i> = 30.1 Hz), 122.78 (q, <i>J</i> = 271.1 Hz), 105.20, 56.01, 47.44, 46.37, 43.78, 43.17, 28.54. ESI-MS: <i>m</i>/<i>z</i> = 537 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71">4.1.8.36.  4-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)-1-methyl-1<i>H</i>-pyrrole-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D15</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 40%; retention time: 10.058 min, purity: 95.54%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.15 (d, <i>J</i> = 7.0 Hz, 1H), 7.52 (s, 1H), 7.38–7.24 (m, 5H), 6.86 (s, 1H), 4.40 −4.31 (m, 1H), 4.00 (s, 2H), 3.78 (s, 3H), 3.76 (s, 3H), 3.42–3.28 (m, 2H), 3.01–2.83 (m, 3H), 2.02 −1.87 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.53, 160.16, 141.13, 136.23, 133.88, 131.15, 129.43, 128.23, 127.46, 125.89, 111.82, 107.78, 105.94, 71.85, 47.25, 47.09, 44.66, 43.38, 38.60, 36.23, 30.07. ESI-MS: <i>m</i>/<i>z</i> = 432 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 432.1352, found 432.1363.</div></div><div id="sec4_1_8_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72">4.1.8.37.  4-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)-1-methyl-1<i>H</i>-pyrrole-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D16</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 65%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.15 (d, <i>J</i> = 8.8 Hz, 1H), 7.53 (s, 1H), 7.38–7.23 (m, 5H), 6.85 (d, <i>J</i> = 1.4 Hz, 1H), 4.45–4.33 (m, 1H), 4.11 (s, 2H), 3.80 (s, 3H), 3.74 (s, 3H), 3.39–3.30 (m, 2H), 3.01–2.86 (m, 3H), 2.01–1.90 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.19, 160.16, 140.96, 138.38, 135.45, 131.19, 129.40, 128.25, 127.70, 125.77, 112.23, 108.18, 91.28, 71.98, 47.01, 46.80, 44.45, 43.23, 38.49, 36.20, 29.71. ESI-MS: <i>m</i>/<i>z</i> = 478 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>24</sub>BrClN<sub>5</sub>O [M + H]<sup>+</sup> 478.0853, found 478.0847.</div></div><div id="sec4_1_8_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73">4.1.8.38.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)-1-methyl-1<i>H</i>-pyrrole-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D17</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 39%; retention time: 10.367 min, purity: 95.05%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.29 (d, <i>J</i> = 7.9 Hz, 1H), 7.61 (s, 1H), 7.34 (d, <i>J</i> = 7.8 Hz, 2H), 7.28 (d, <i>J</i> = 7.8 Hz, 2H), 6.76 (s, 1H), 4.47–4.35 (m, 1H), 4.18 (s, 2H), 3.73 (s, 3H), 3.65 (s, 3H), 3.41–3.30 (m, 2H), 3.06–2.80 (m, 3H), 2.01–1.90 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 173.82, 159.54, 140.82, 136.39, 132.29, 131.27, 129.42, 128.29, 125.92, 121.39, 112.98, 108.68, 105.71, 72.06, 47.07, 46.66, 44.44, 43.20, 37.88, 32.90, 29.60. ESI-MS: <i>m</i>/<i>z</i> = 466 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>21</sub>H<sub>23</sub>Cl<sub>3</sub>N<sub>5</sub>O [M + H]<sup>+</sup> 466.0963, found 466.0987.</div></div><div id="sec4_1_8_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74">4.1.8.39.  5-Bromo-4-(4-bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(4-chlorophenyl)piperidin-3-yl)-1-methyl-1<i>H</i>-pyrrole-2-carboxamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D18</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 43%; retention time: 9.742 min, purity: 95.19%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.27 (d, <i>J</i> = 8.1 Hz, 1H), 7.61 (s, 1H), 7.34 (d, <i>J</i> = 8.1 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 6.74 (s, 1H), 4.39 (d, <i>J</i> = 8.4 Hz, 1H), 4.09 (s, 2H), 3.75 (s, 3H), 3.64 (s, 3H), 3.40–3.31 (m, 2H), 3.02–2.80 (m, 3H), 2.07–1.89 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 174.29, 159.56, 140.90, 138.43, 134.88, 131.23, 129.42, 128.28, 127.57, 113.87, 111.15, 109.60, 94.22, 71.97, 47.20, 46.76, 44.53, 43.21, 37.92, 34.59, 29.74. ESI-MS: <i>m</i>/<i>z</i> = 556 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75">4.1.8.40.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-Difluorophenyl)piperidin-3-yl)-4-(1-methyl-1<i>H</i>-pyrazol-5-yl)benzamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D19</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 51%; retention time: 9.318 min, purity: 95.52%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.60 (d, <i>J</i> = 8.8 Hz, 1H), 7.75 (d, <i>J</i> = 8.3 Hz, 2H), 7.58 (d, <i>J</i> = 8.3 Hz, 2H), 7.47 (d, <i>J</i> = 1.9 Hz, 1H), 7.37–7.27 (m, 2H), 7.14 (s, 1H), 6.44 (d, <i>J</i> = 1.9 Hz, 1H), 4.56–4.46 (m, 1H), 4.14 (s, 2H), 3.84 (s, 3H), 3.42–3.36 (m, 2H), 3.14–3.04 (m, 1H), 3.03–2.86 (m, 2H), 2.01–1.95 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 173.92, 165.36, 149.13 (dd, <i>J</i> = 244.0, 12.0 Hz), 148.38 (dd, <i>J</i> = 244.0, 12.0 Hz), 141.78, 139.70, 138.00, 133.39, 132.94, 128.20, 127.54, 124.27, 117.25 (d, <i>J</i> = 16.0 Hz), 116.41 (d, <i>J</i> = 16.0 Hz), 106.31, 71.94, 47.62, 46.63, 44.23, 43.24, 37.66, 29.73. ESI-MS: <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76">4.1.8.41.  4-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl) benzamide Hydrochloride (<b>D20</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 70%; retention time: 9.842 min, purity: 98.26%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.65 (d, <i>J</i> = 8.3 Hz, 1H), 7.80 (d, <i>J</i> = 8.0 Hz, 2H), 7.67 (s, 1H), 7.57 (d, <i>J</i> = 8.0 Hz, 2H), 7.39–7.27 (m, 2H), 7.14 (s, 1H), 4.53–4.42 (m, 1H), 4.10 (s, 2H), 3.76 (s, 3H), 3.43–3.27 (m, 2H), 3.12–3.02 (m, 1H), 2.97–2.83 (m, 2H), 2.02–1.89 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 174.07, 165.35, 149.07 (dd, <i>J</i> = 234.0, 11.0 Hz), 148.17(dd, <i>J</i> = 234.0, 11.0 Hz), 139.75, 138.03, 136.48, 134.44, 130.07, 129.50, 127.54, 124.30, 117.27 (d, <i>J</i> = 17.0 Hz), 116.39 (d, <i>J</i> = 18.0 Hz), 107.51, 71.88, 47.69, 46.71, 44.29, 43.29, 38.35, 29.90. ESI-MS: <i>m</i>/<i>z</i> = 431 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77">4.1.8.42.  4-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)benzamide (2<i>R</i>,3<i>R</i>)-2,3-Dihydroxysuccinate (<b>D21</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure V, yield: 73%; retention time: 9.980 min, purity: 95.07%; <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.64 (d, <i>J</i> = 8.3 Hz, 1H), 7.78 (d, <i>J</i> = 7.8 Hz, 2H), 7.66 (s, 1H), 7.55 (d, <i>J</i> = 7.9 Hz, 2H), 7.41–7.27 (m, 2H), 7.14 (s, 1H), 4.51–4.42 (m, 1H), 4.07 (s, 2H), 3.75 (s, 3H), 3.43–3.28 (m, 2H), 3.13–3.02 (m, 1H), 3.00–2.82 (m, 2H), 2.08–1.89 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 174.22, 165.36, 149.15 (dd, <i>J</i> = 243.0, 11.0 Hz), 148.58 (dd, <i>J</i> = 243.0, 11.0 Hz), 139.82, 139.64, 138.58, 134.48, 130.65, 129.67, 127.47, 124.29, 117.25 (d, <i>J</i> = 16.0 Hz), 116.39 (d, <i>J</i> = 17.0 Hz), 92.68, 71.84, 47.81, 46.84, 44.37, 43.34, 38.35, 30.07. ESI-MS: <i>m</i>/<i>z</i> = 475 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78">4.1.8.43.  4-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-fluorophenyl)piperidin-3-yl)benzamide Hydrochloride (<b>D22</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 81%; retention time: 9.661 min, purity: 99.19%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.75 (d, <i>J</i> = 8.4 Hz, 2H), 7.56 (s, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.36–7.30 (m, 1H), 7.19 (d, <i>J</i> = 7.8 Hz, 1H), 7.15–7.11 (m, 1H), 6.99–6.94 (m, 1H), 4.70–4.62 (m, 1H), 3.77 (s, 3H), 3.66–3.62 (m, 1H), 3.55 (d, <i>J</i> = 12.8 Hz, 1H), 3.26–3.17 (m, 2H), 3.14 (t, <i>J</i> = 12.0 Hz, 1H), 2.21 (dd, <i>J</i> = 14.5, 2.3 Hz, 1H), 2.15–2.05 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 169.03, 164.34 (d, <i>J</i> = 243.4 Hz), 144.86 (d, <i>J</i> = 7.1 Hz), 140.19, 137.93, 135.72, 132.23, 131.49 (d, <i>J</i> = 8.3 Hz), 130.96, 128.74, 124.68 (d, <i>J</i> = 2.6 Hz), 115.42 (d, <i>J</i> = 21.8 Hz), 115.17 (d, <i>J</i> = 22.4 Hz), 110.15, 49.47, 48.01, 46.51, 45.16, 38.61, 31.28. ESI-MS: <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79">4.1.8.44.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-Difluorophenyl)piperidin-3-yl)-6-(1-methyl-1<i>H</i>-pyrazol-5-yl)nicotinamide Hydrochloride (<b>D23</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 47%; retention time: 9.166 min, purity: 98.84%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.74–9.58 (m, 2H), 9.25 (d, <i>J</i> = 8.9 Hz, 1H), 8.97 (d, <i>J</i> = 1.9 Hz, 1H), 8.24 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.85 (d, <i>J</i> = 8.3 Hz, 1H), 7.51 (d, <i>J</i> = 1.9 Hz, 1H), 7.35–7.29 (m, 2H), 7.14 (d, <i>J</i> = 4.5 Hz, 1H), 6.87 (d, <i>J</i> = 1.9 Hz, 1H), 4.63–4.55 (m, 1H), 4.10 (s, 3H), 3.41–3.33 (m, 2H), 3.32–3.25 (m, 1H), 3.06–2.89 (m, 2H), 2.18–2.09 (m, 1H), 2.03–1.96 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 163.76, 150.86, 149.16 (dd, <i>J</i> = 243.8, 12.5 Hz), 148.31 (dd, <i>J</i> = 242.5, 12.5 Hz), 147.89, 139.75, 139.70, 137.90, 136.57, 127.71, 124.46, 122.39, 117.33 (d, <i>J</i> = 16.3 Hz), 116.69 (d, <i>J</i> = 16.3 Hz), 107.93, 47.64, 46.33, 43.89, 43.25, 39.65, 29.00. ESI-MS: <i>m</i>/<i>z</i> = 398 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80">4.1.8.45.  6-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)nicotinamide Hydrochloride (<b>D24</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 54%; retention time: 9.801 min, purity: 98.68%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.62–9.49 (m, 2H), 9.23 (d, <i>J</i> = 8.9 Hz, 1H), 9.03 (d, <i>J</i> = 1.8 Hz, 1H), 8.30 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.78 (d, <i>J</i> = 8.2 Hz, 1H), 7.69 (s, 1H), 7.36–7.29 (m, 2H), 7.15 (d, <i>J</i> = 4.7 Hz, 1H), 4.65–4.57 (m, 1H), 3.92 (s, 3H), 3.43–3.34 (m, 2H), 3.27–3.21 (m, 1H), 3.04–2.91 (m, 2H), 2.16–2.07 (m, 1H), 2.00 (d, <i>J</i> = 12.6 Hz, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 163.78, 149.16 (dd, <i>J</i> = 243.8, 12.5 Hz), 148.78, 148.59, 148.30 (dd, <i>J</i> = 243.8, 12.5 Hz), 139.62, 136.73, 136.47, 136.19, 128.64, 124.42, 124.17, 117.34 (d, <i>J</i> = 16.3 Hz), 116.51 (d, <i>J</i> = 16.3 Hz), 108.59, 47.56, 46.27, 43.88, 43.19, 39.19, 29.08. ESI-MS: <i>m</i>/<i>z</i> = 432 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81">4.1.8.46.  6-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3,4-difluorophenyl)piperidin-3-yl)nicotinamide (<b>D25</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure III, yield: 54%; retention time: 9.831 min, purity: 98.46%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.68–9.53 (m, 2H), 9.27 (d, <i>J</i> = 8.9 Hz, 1H), 9.03 (d, <i>J</i> = 1.7 Hz, 1H), 8.31 (dd, <i>J</i> = 8.2, 2.2 Hz, 1H), 7.78 (d, <i>J</i> = 8.2 Hz, 1H), 7.68 (s, 1H), 7.37–7.30 (m, 2H), 7.15 (d, <i>J</i> = 4.5 Hz, 1H), 4.66–4.58 (m, 1H), 3.90 (s, 3H), 3.42–3.34 (m, 2H), 3.28–3.22 (m, 1H), 3.05–2.91 (m, 2H), 2.18–2.06 (m, 1H), 2.04–1.97 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 163.77, 149.16 (dd, <i>J</i> = 243.8, 12.5 Hz), 149.23, 148.60, 148.30 (dd, <i>J</i> = 243.8, 12.5 Hz), 139.65, 138.89, 138.12, 136.12, 128.72, 124.55, 124.43, 117.34 (d, <i>J</i> = 17.5 Hz), 116.52 (d, <i>J</i> = 17.5 Hz), 93.53, 47.57, 46.27, 43.87, 43.20, 39.19, 29.09. ESI-MS: <i>m</i>/<i>z</i> = 476 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82">4.1.8.47.  <i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-Fluorophenyl)piperidin-3-yl)-5-(1-methyl-1<i>H</i>-pyrazol-5-yl)picolinamide Hydrochloride (<b>D26</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 74%; retention time: 8.960 min, purity: 97.65%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.71 (s, 1H), 9.58 (s, 1H), 8.98 (d, <i>J</i> = 9.5 Hz, 1H), 8.74 (d, <i>J</i> = 1.7 Hz, 1H), 8.12 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 7.99 (d, <i>J</i> = 8.1 Hz, 1H), 7.53 (d, <i>J</i> = 1.9 Hz, 1H), 7.28 (dd, <i>J</i> = 14.3, 7.9 Hz, 1H), 7.09 (d, <i>J</i> = 7.8 Hz, 1H), 7.06 (d, <i>J</i> = 10.2 Hz, 1H), 6.97 (td, <i>J</i> = 8.6, 2.3 Hz, 1H), 6.60 (d, <i>J</i> = 1.9 Hz, 1H), 4.72–4.63 (m, 1H), 3.87 (s, 3H), 3.35–3.22 (m, 3H), 3.04 (q, <i>J</i> = 11.1 Hz, 1H), 2.88 (dd, <i>J</i> = 23.6, 11.9 Hz, 1H), 2.14–1.97 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 162.97, 162.03 (d, <i>J</i> = 246.0 Hz), 148.51, 147.52, 144.87 (d, <i>J</i> = 7.0 Hz), 138.82, 138.20, 137.19, 130.27 (d, <i>J</i> = 8.0 Hz), 128.78, 123.63 (d, <i>J</i> = 2.1 Hz), 122.08, 114.13 (d, <i>J</i> = 21.0 Hz), 113.57 (d, <i>J</i> = 20.8 Hz), 107.22, 46.77, 46.05, 44.27, 43.19, 37.74, 29.66. ESI-MS: <i>m</i>/<i>z</i> = 380 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83">4.1.8.48.  5-(4-Chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-fluorophenyl)piperidin-3-yl)picolinamide Hydrochloride (<b>D27</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 74%; retention time: 9.675 min, purity: 97.71%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.61 (d, <i>J</i> = 9.7 Hz, 1H), 9.48 (d, <i>J</i> = 10.3 Hz, 1H), 9.04 (d, <i>J</i> = 9.5 Hz, 1H), 8.73 (d, <i>J</i> = 1.5 Hz, 1H), 8.13 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 8.06 (d, <i>J</i> = 8.0 Hz, 1H), 7.73 (s, 1H), 7.33–7.26 (m, 1H), 7.10 (d, <i>J</i> = 7.8 Hz, 1H), 7.07 (d, <i>J</i> = 10.2 Hz, 1H), 6.98 (td, <i>J</i> = 8.5, 2.2 Hz, 1H), 4.72–4.65 (m, 1H), 3.79 (s, 3H), 3.38–3.23 (m, 3H), 3.04 (q, <i>J</i> = 11.2 Hz, 1H), 2.93–2.83 (m, 1H), 2.10–1.99 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 162.88, 162.00 (d, <i>J</i> = 241.5 Hz), 149.34, 148.55, 144.83 (d, <i>J</i> = 7.0 Hz), 138.79, 136.65, 135.31, 130.27 (d, <i>J</i> = 8.0 Hz), 126.23, 123.59, 122.15, 114.11(d, <i>J</i> = 21.1 Hz), 113.58 (d, <i>J</i> = 20.5 Hz), 108.37, 46.74, 46.04, 44.24, 43.20, 38.50, 29.73. ESI-MS: <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84">4.1.8.49.  5-(4-Bromo-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>)-4-(3-fluorophenyl)piperidin-3-yl)picolinamide Hydrochloride (<b>D28</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure IV, yield: 80%; retention time: 9.598 min, purity: 97.58%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.64 (d, <i>J</i> = 9.7 Hz, 1H), 9.52 (d, <i>J</i> = 10.1 Hz, 1H), 9.04 (d, <i>J</i> = 9.5 Hz, 1H), 8.72 (d, <i>J</i> = 1.5 Hz, 1H), 8.12 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.0 Hz, 1H), 7.73 (s, 1H), 7.30 (dd, <i>J</i> = 14.3, 7.8 Hz, 1H), 7.09 (dd, <i>J</i> = 18.3, 9.0 Hz, 2H), 6.98 (td, <i>J</i> = 8.6, 2.2 Hz, 1H), 4.71–4.64 (m, 1H), 3.80 (s, 3H), 3.40–3.23 (m, 3H), 3.04 (q, <i>J</i> = 11.3 Hz, 1H), 2.89 (dd, <i>J</i> = 22.6, 11.3 Hz, 1H), 2.10–1.97 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 162.87, 162.00 (d, <i>J</i> = 241.4 Hz), 149.35, 148.74, 144.84 (d, <i>J</i> = 7.0 Hz), 138.96, 138.76, 136.92, 130.27 (d, <i>J</i> = 8.3 Hz), 126.80, 123.59, 122.08, 114.11 (d, <i>J</i> = 20.9 Hz), 113.58 (d, <i>J</i> = 20.8 Hz), 93.58, 46.72, 46.03, 44.23, 43.18, 38.51, 29.73. ESI-MS: <i>m</i>/<i>z</i> = 458 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85">4.1.8.50.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>R</i>)-4-(3,4-dichlorophenyl)-6-propylpiperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E1</b>)</h5><div class="NLM_p last">General Procedure IV, yield: 67%; retention time: 10.865 min, purity: 96.10%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.58–7.51 (m, 2H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.33–7.25 (m, 2H), 4.58–4.51 (m, 1H), 3.81–3.66 (m, 4H), 3.45–3.33 (m, 2H), 2.23–2.08 (m, 2H), 2.07–1.96 (m, 1H), 1.89–1.80 (m, 1H), 1.58–1.44 (m, 2H), 1.07 (t, <i>J</i> = 7.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 158.39, 147.83, 142.48, 140.20, 138.12, 133.54, 132.34, 131.86, 131.05, 130.78, 128.62, 118.78, 112.07, 112.00, 53.66, 48.36, 42.35, 40.55, 38.55, 33.60, 30.89, 20.19, 14.03. ESI-MS: <i>m</i>/<i>z</i> = 531 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 531.0697, found 531.0709.</div></div><div id="sec4_1_8_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86">4.1.8.51.  <i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>R</i>)-6-allyl-4-(3,4-dichlorophenyl)piperidin-3-yl)-5-chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>E2</b>)</h5><div class="NLM_p last">General Procedure IV, yield: 82%; retention time: 10.981 min, purity: 97.54%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.53 (s, 1H), 7.51 (d, <i>J</i> = 2.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.30 (s, 1H), 7.27 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 5.90–5.81 (m, 1H), 5.41 (dd, <i>J</i> = 17.0, 1.1 Hz, 1H), 5.30 (d, <i>J</i> = 10.3 Hz, 1H), 4.61–4.55 (m, 1H), 3.83–3.77 (m, 1H), 3.75 (s, 3H), 3.44–3.32 (m, 3H), 2.82–2.69 (m, 2H), 2.21–2.09 (m, 2H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.33, 147.80, 142.43, 140.19, 138.11, 133.53, 133.24, 132.34, 131.88, 130.99, 130.77, 128.61, 120.78, 118.80, 112.06, 111.99, 52.88, 48.77, 42.18, 40.37, 38.57, 33.41, 33.33. ESI-MS: <i>m</i>/<i>z</i> = 529 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>23</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 529.0540, found 529.0550</div></div><div id="sec4_1_8_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87">4.1.8.52.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>R</i>)-4-(3,4-dichlorophenyl)-6-(3-hydroxypropyl)piperidin-3-yl)furan-2-carboxamide (<b>E3</b>)</h5><div class="NLM_p last">General Procedure I and General Procedure III, yield: 47%; retention time: 9.621 min, purity: 96.32%; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.54–7.46 (m, 2H), 7.44 (s, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.25–7.18 (m, 2H), 4.49–4.44 (m, 1H), 3.81–3.70 (m, 4H), 3.68–3.59 (m, 1H), 3.31–3.12 (m, 4H), 2.18–2.09 (m, 1H), 2.04–1.94 (m, 2H), 1.89–1.66 (m, 3H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 156.78, 146.88, 141.55, 138.42, 137.51, 132.98, 131.26, 130.97, 129.83, 129.34, 127.06, 117.60, 111.23, 111.13, 62.50, 52.35, 49.74, 43.81, 40.80, 38.52, 34.62, 30.37, 29.95. ESI-MS: <i>m</i>/<i>z</i> = 547 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 547.0646, found 546.9982.</div></div><div id="sec4_1_8_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88">4.1.8.53.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-hydroxyethyl)piperidin-3-yl)furan-2-carboxamide (<b>E4</b>)</h5><div class="NLM_p last">General Procedure III, yield: 77%; retention time: 10.753 min, purity: 95.41%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.53 (s, 1H), 7.48 (dd, <i>J</i> = 12.9, 1.9 Hz, 1H), 7.41 (t, <i>J</i> = 7.0 Hz, 1H), 7.28–7.22 (m, 1H), 7.21 (d, <i>J</i> = 6.2 Hz, 1H), 4.37–4.31 (m, 1H), 3.79–3.71 (m, 5H), 3.47–3.40 (m, 1H), 3.23–3.15 (m, 1H), 3.13–2.99 (m, 2H), 2.16–2.10 (m, 1H), 2.09–1.99 (m, 1H), 1.97–1.91 (m, 1H), 1.89–1.77 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.39, 148.31, 144.73, 139.81, 138.11, 133.21, 131.57, 131.51, 131.06, 130.91, 128.59, 118.16, 111.95, 111.92, 61.16, 51.82, 50.91, 44.75, 42.61, 38.54, 37.95, 33.01. ESI-MS: <i>m</i>/<i>z</i> = 533 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>23</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 533.0489, found 532.8913.</div></div><div id="sec4_1_8_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89">4.1.8.54.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2,3-dihydroxypropyl)piperidin-3-yl)furan-2-carboxamide (<b>E5</b>)</h5><div class="NLM_p last">General Procedure III, yield: 72%; retention time: 10.722 min, purity: 95.31%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.53 (s, 1H), 7.52 (d, <i>J</i> = 2.0 Hz, 1H), 7.46 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 7.27 (dd, <i>J</i> = 5.9, 2.6 Hz, 2H), 4.59–4.52 (m, 1H), 4.03–3.94 (m, 1H), 3.94–3.84 (m, 1H), 3.75 (s, 3H), 3.64–3.55 (m, 2H), 3.45–3.34 (m, 3H), 2.37–2.09 (m, 3H), 2.05–1.90 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD, 1:1 ratio due to epimers) δ 158.41 and 158.38, 147.81, 142.58 and 142.50, 140.21, 138.12, 133.52 and 133.51, 132.32 and 132.27, 131.86 and 131.84, 131.07 and 131.06, 130.79, 128.55, 118.79, 112.07, 112.00, 72.00 and 70.39, 67.17 and 66.62, 53.17, 51.87, 42.40 and 42.19, 40.90 and 40.78, 38.56, 35.65 and 35.28, 32.20 and 31.36. ESI-MS: <i>m</i>/<i>z</i> = 563 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90">4.1.8.55.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-methoxyethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E6</b>)</h5><div class="NLM_p">To the solution of compound <b>45a</b> (71 mg, 0.1 mmol) in methanol (5 mL) was added sodium methylate (11 mg, 0.2 mmol) under N<sub>2</sub> atmosphere. The reaction was stirred at 45 °C overnight. After completion of reaction, it was poured into H<sub>2</sub>O and extracted with ethyl ecetate (5 mL × 3). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid.</div><div class="NLM_p last">To a solution of the above white solid in ethyl acetate (0.3 mL) was added HCl-saturated ethyl acetate in ice bath and stirred overnight at room temperature. Then, the reaction was added with saturated sodium bicarbonate and extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid (18 mg, 0.033 mmol). Yield: 33%; retention time: 10.791 min, purity: 95.16%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.54 (s, 1H), 7.51 (s, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 7.29–7.24 (m, 2H), 4.57–4.48 (m, 1H), 3.92–3.83 (m, 1H), 3.75 (s, 3H), 3.68–3.62 (m, 2H), 3.45–3.32 (m, 6H), 2.40–2.31 (m, 1H), 2.23–2.10 (m, 2H), 2.11–2.03 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.40, 147.84, 142.47, 140.21, 138.14, 133.56, 132.35, 131.88, 131.04, 130.78, 128.53, 118.82, 112.12, 112.02, 71.09, 59.34, 53.36, 47.95, 42.39, 40.84, 38.55, 34.95, 28.84. ESI-MS: <i>m</i>/<i>z</i> = 547 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>25</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 547.0646, found 547.0654.</div></div><div id="sec4_1_8_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91">4.1.8.56.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-(dimethylamino)ethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E7</b>)</h5><div class="NLM_p">To the solution of compound <b>45a</b> (71 mg, 0.1 mmol) and DIPEA (260 μL, 1.5 mmol) in anhydrous DMF (5 mL) was added dimethylamine hydrochloride (80 mg, 1.0 mmol) dropwise. The reaction was heated to 80 °C and stirred for 6 h. After completion of reaction, the mixture was poured into H<sub>2</sub>O (10 mL) and extracted with DCM (5 mL × 3). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid.</div><div class="NLM_p last">To a solution of the above white solid in ethyl acetate (0.3 mL) was added HCl-saturated ethyl acetate (4 mL) in ice bath and stirred overnight at room temperature. The white solid was precipitated, filtered, washed with diethyl ether, and dried in vacuum to afford the target product as white powder (33 mg, 0.052 mmol). Yield: 52%; retention time: 10.101 min, purity: 95.62%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.86 (s, 1H), 9.99 (s, 1H), 9.58 (d, <i>J</i> = 9.7 Hz, 1H), 9.03 (d, <i>J</i> = 9.2 Hz, 1H), 7.69 (s, 1H), 7.63 (s, 1H), 7.61–7.57 (m, 2H), 7.31 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 4.62–4.51 (m, 1H), 3.81–3.71 (m, 4H), 3.51–3.44 (m, 1H), 3.30–3.17 (m, 4H), 2.81 (d, <i>J</i> = 4.1 Hz, 3H), 2.78 (d, <i>J</i> = 4.1 Hz, 3H), 2.37–2.27 (m, 2H), 2.21–2.14 (m, 1H), 1.99–1.92 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 155.51, 146.72, 142.64, 137.40, 136.68, 130.78, 130.60, 130.16, 129.40, 128.93, 127.79, 117.14, 110.13, 109.32, 52.73, 48.46, 46.20, 42.07, 41.76, 40.61, 38.35, 38.26, 31.59, 22.22. ESI-MS: <i>m</i>/<i>z</i> = 560 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>28</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 560.0962, found 559.9503.</div></div><div id="sec4_1_8_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92">4.1.8.57.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-(pyrrolidin-1-yl)ethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E8</b>)</h5><div class="NLM_p last">General Procedure VI, yield: 67%; retention time: 10.162 min, purity: 95.00%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.10 (s, 1H), 9.93 (s, 1H), 9.53 (d, <i>J</i> = 10.4 Hz, 1H), 8.99 (d, <i>J</i> = 9.2 Hz, 1H), 7.68 (s, 1H), 7.62–7.56 (m, 3H), 7.31 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 4.60–4.50 (m, 1H), 3.84–3.77 (m, 1H), 3.74 (s, 3H), 3.48–3.26 (m, 4H), 3.25–3.12 (m, 2H), 3.06–2.99 (m, 2H), 2.35–2.28 (m, 2H), 2.20–2.13 (m, 1H), 2.07–1.87 (m, 6H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 155.50, 146.70, 142.54, 137.35, 136.63, 130.76, 130.56, 130.10, 129.38, 128.89, 127.76, 117.11, 110.12, 109.29, 55.99, 52.91, 52.68, 50.07, 48.51, 46.25, 40.64, 38.33, 38.21, 31.54, 23.55, 22.68. ESI-MS: <i>m</i>/<i>z</i> = 586 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>30</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 586.1119, found 586.1138.</div></div><div id="sec4_1_8_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93">4.1.8.58.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-(piperidin-1-yl)ethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E9</b>)</h5><div class="NLM_p last">General Procedure VI, yield: 46%; retention time: 10.226 min, purity: 95.03%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 10.75 (s, 1H), 9.94 (s, 1H), 9.55 (s, 1H), 8.97 (d, <i>J</i> = 5.5 Hz, 1H), 7.68 (s, 1H), 7.61 (d, <i>J</i> = 2.0 Hz, 2H), 7.58 (d, <i>J</i> = 8.3 Hz, 1H), 7.32 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 4.61–4.51 (m, 1H), 3.79–3.71 (m, 4H), 3.58–3.47 (m, 3H), 3.30–3.13 (m, 4H), 2.95–2.84 (m, 2H), 2.41 −2.31 (m, 2H), 2.16 (t, <i>J</i> = 12.6 Hz, 1H), 1.97 (d, <i>J</i> = 11.9 Hz, 1H), 1.90–1.77 (m, 4H), 1.77–1.68 (m, 1H), 1.49–1.34 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 155.50, 146.70, 142.61, 137.34, 136.63, 130.76, 130.55, 130.11, 129.36, 128.89, 127.75, 117.10, 110.12, 109.29, 52.00, 51.82, 48.63, 46.15, 40.61, 38.34, 38.21, 31.73, 22.17, 21.74, 21.41. ESI-MS: <i>m</i>/<i>z</i> = 600 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>32</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup> 600.1275, found 600.1285.</div></div><div id="sec4_1_8_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94">4.1.8.59.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-morpholinoethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E10</b>)</h5><div class="NLM_p last">General Procedure VI, yield: 55%; retention time: 10.178 min, purity: 96.14%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 11.48 (s, 1H), 9.89 (s, 1H), 9.50 (s, 1H), 8.94 (s, 1H), 7.68 (s, 1H), 7.62–7.56 (m, 3H), 7.32 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 4.62–4.52 (m, 1H), 4.04–3.96 (m, 2H), 3.92–3.78 (m, 3H), 3.74 (s, 3H), 3.53 (d, <i>J</i> = 12.0 Hz, 1H), 3.50–3.39 (m, 2H), 3.35–3.06 (m, 6H), 2.42–2.29 (m, 2H), 2.21–2.10 (m, 1H), 2.04–1.96 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 155.51, 146.69, 142.56, 137.35, 136.63, 130.78, 130.57, 130.13, 129.39, 128.88, 127.73, 117.13, 110.15, 109.29, 63.06, 55.99, 52.10, 50.99, 50.75, 48.51, 46.14, 40.63, 38.33, 38.21, 31.67, 21.31. ESI-MS: <i>m</i>/<i>z</i> = 602 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>30</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 602.1068, found 602.1105.</div></div><div id="sec4_1_8_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95">4.1.8.60.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-(4-hydroxypiperidin-1-yl)ethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E11</b>)</h5><div class="NLM_p last">General Procedure VI, yield: 41%; retention time: 10.082 min, purity: 95.92%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.63 (d, <i>J</i> = 1.5 Hz, 1H), 7.54 (s, 1H), 7.46 (d, <i>J</i> = 8.3 Hz, 1H), 7.38–7.34 (m, 1H), 7.33 (s, 1H), 4.64–4.56 (m, 1H), 4.17–4.10 (m, 1H), 3.90–3.83 (m, 1H), 3.75 (s, 3H), 3.74–3.68 (m, 1H), 3.57–3.48 (m, 3H), 3.46–3.33 (m, 4H), 3.22–3.11 (m, 1H), 2.68–2.56 (m, 1H), 2.47–2.36 (m, 1H), 2.27–2.11 (m, 4H), 1.99–1.81 (m, 2H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.35, 147.75, 142.24, 140.30, 138.10, 133.43, 132.33, 131.78, 131.39, 130.80, 128.72, 118.79, 112.03, 111.99, 66.89, 54.39, 52.79, 51.32, 49.63, 42.71, 40.32, 38.57, 33.38, 32.83, 30.98. ESI-MS: <i>m</i>/<i>z</i> = 616 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>27</sub>H<sub>32</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 616.1224, found 616.1239.</div></div><div id="sec4_1_8_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96">4.1.8.61.  <i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-6-(2-(1<i>H</i>-1,2,4-Triazol-1-yl)ethyl)-4-(3,4-dichlorophenyl)piperidin-3-yl)-5-chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>E12</b>)</h5><div class="NLM_p last">General Procedure VI, yield: 37%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 9.51 (s, 1H), 8.63 (s, 1H), 7.59 (d, <i>J</i> = 1.9 Hz, 1H), 7.53 (s, 1H), 7.45 (d, <i>J</i> = 8.3 Hz, 1H), 7.33 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.32 (s, 1H), 4.76–4.69 (m, 1H), 4.67–4.57 (m, 2H), 3.96–3.90 (m, 1H), 3.75 (s, 3H), 3.50–3.38 (m, 3H), 2.82–2.70 (m, 1H), 2.65–2.56 (m, 1H), 2.32–2.22 (m, 1H), 2.22–2.14 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.39, 151.26, 147.89, 147.74, 142.26, 140.28, 138.11, 133.45, 132.32, 131.80, 131.25, 130.82, 128.78, 118.77, 111.99, 111.97, 51.24, 49.63, 49.28, 42.75, 40.46, 38.60, 33.53, 28.85. ESI-MS: <i>m</i>/<i>z</i> = 584 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>24</sub>Cl<sub>4</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup> 584.0711, found 584.0722.</div></div><div id="sec4_1_8_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97">4.1.8.62.  2-((2<i>S</i>,4<i>S</i>,5<i>S</i>)-5-(5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamido)-4-(3,4-dichlorophenyl)piperidin-2-yl)acetic Acid Hydrochloride (<b>E13</b>)</h5><div class="NLM_p last">General Procedure IV, yield: 92%; retention time: 10.688 min, purity: 97.32%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.54 (s, 1H), 7.53 (d, <i>J</i> = 1.2 Hz, 1H), 7.47–7.42 (m, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 2H), 4.64–4.54 (m, 1H), 4.21–4.10 (m, 1H), 3.74 (s, 3H), 3.49–3.42 (m, 1H), 3.40–3.32 (m, 2H), 3.21–3.10 (m, 1H), 3.01–2.92 (m, 1H), 2.35–2.22 (m, 1H), 2.18–2.09 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 173.53, 158.39, 147.77, 142.22, 140.22, 138.11, 133.52, 132.36, 131.85, 131.10, 130.78, 128.62, 118.81, 112.03, 111.99, 50.47, 49.28, 42.51, 40.77, 38.58, 34.52, 32.93. ESI-MS: <i>m</i>/<i>z</i> = 547 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>21</sub>Cl<sub>4</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 547.0282, found 547.0296.</div></div><div id="sec4_1_8_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98">4.1.8.63.  <i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-6-(2-Amino-2-oxoethyl)-4-(3,4-dichlorophenyl)piperidin-3-yl)-5-chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>E14</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 79%; retention time: 10.574 min, purity: 95.65%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.55 (s, 1H), 7.53 (s, 1H), 7.46 (dd, <i>J</i> = 8.1, 2.3 Hz, 1H), 7.34–7.28 (m, 2H), 4.61–4.51 (m, 1H), 4.16–4.08 (m, 1H), 3.75 (s, 3H), 3.49–3.33 (m, 3H), 3.13–3.05 (m, 1H), 2.86–2.77 (m, 1H), 2.31–2.22 (m, 1H), 2.12–2.05 (m, 1H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 174.54, 158.41, 147.78, 142.27, 140.27, 138.11, 133.53, 132.36, 131.85, 131.12, 130.80, 128.60, 118.79, 111.98, 112.00, 50.86, 49.28, 42.22, 40.75, 38.56, 34.66, 32.79. ESI-MS: <i>m</i>/<i>z</i> = 546 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>22</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 546.0442, found 546.0452.</div></div><div id="sec4_1_8_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99">4.1.8.64.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-(methylamino)-2-oxoethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E15</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 81%; retention time: 10.683 min, purity: 97.19%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.55 (s, 1H), 7.53 (s, 1H), 7.48–7.44 (m, 1H), 7.33–7.27 (m, 2H), 4.61–4.50 (m, 1H), 4.07–4.13 (m, 1H), 3.75 (s, 3H), 3.48–3.35 (m, 3H), 3.10–3.02 (m 1H), 2.83–2.83 (m, 4H), 2.33–2.22 (s, 1H), 2.09–2.03 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 172.28, 158.41, 147.77, 142.27, 140.28, 138.11, 133.51, 132.35, 131.84, 131.13, 130.81, 128.63, 118.78, 112.03, 112.00, 51.03, 49.29, 42.25, 40.71, 38.57, 34.63, 33.27, 26.35. ESI-MS: <i>m</i>/<i>z</i> = 560 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>24</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 560.0598, found 560.0612.</div></div><div id="sec4_1_8_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100">4.1.8.65.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-6-(2-(cyclopropylamino)-2-oxoethyl)-4-(3,4-dichlorophenyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E16</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 67%; retention time: 10.727 min, purity: 97.67%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.57–7.52 (m, 2H), 7.46 (d, <i>J</i> = 7.1 Hz, 1H), 7.34–7.26 (m, 2H), 4.60–4.51 (m, 1H), 4.13–4.08 (m, 1H), 3.75 (s, 3H), 3.48–3.33 (m, 3H), 3.05–2.97 (m, 1H), 2.77–2.70 (m, 2H), 2.32–2.20 (m, 1H), 2.09–2.02 (m, 1H), 0.79–0.70 (m, 2H), 0.61–0.52 (m, 2H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 173.19, 158.42, 147.79, 142.25, 140.26, 138.12, 133.54, 132.39, 131.87, 131.12, 130.79, 128.57, 118.81, 112.04, 112.01, 50.95, 49.29, 42.28, 40.71, 38.56, 34.68, 33.26, 23.45, 6.43, 6.30. ESI-MS: <i>m</i>/<i>z</i> = 586 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>26</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 586.0755, found 586.0768.</div></div><div id="sec4_1_8_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101">4.1.8.66.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-6-(2-(cyclobutylamino)-2-oxoethyl)-4-(3,4-dichlorophenyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E17</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 75%; retention time: 10.920 min, purity: 98.81%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.56–7.52 (m, 2H), 7.47 (d, <i>J</i> = 8.2 Hz, 1H), 7.31 (s, 1H), 7.28 (d, <i>J</i> = 8.3 Hz, 1H), 4.56–4.50 (m, 1H), 4.39–4.32 (m, 1H), 4.11–4.05 (m, 1H), 3.75 (s, 3H), 3.46–3.33 (m, 3H), 3.05–2.97 (m, 1H), 2.75–2.68 (m, 1H), 2.34–2.19 (m, 3H), 2.07–1.96 (m, 3H), 1.81–1.69 (m, 2H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 170.71, 158.42, 147.80, 142.22, 140.27, 138.13, 133.57, 132.41, 131.89, 131.11, 130.79, 128.55, 118.83, 112.07, 112.02, 50.98, 49.28, 46.00, 42.22, 40.74, 38.56, 34.75, 33.14, 31.43, 31.29, 16.01. ESI-MS: <i>m</i>/<i>z</i> = 600 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>26</sub>H<sub>28</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 600.0911, found 600.0922.</div></div><div id="sec4_1_8_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102">4.1.8.67.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-((2-hydroxyethyl)amino)-2-oxoethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E18</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 69%; retention time: 10.758 min, purity: 95.27%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.57–7.54 (m, 2H), 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 7.31–7.28 (m, 2H), 4.49–4.43 (m, 1H), 3.99–3.93 (m, 1H), 3.75 (s, 3H), 3.64 (t, <i>J</i> = 5.6 Hz, 2H), 3.36 (t, <i>J</i> = 5.6 Hz, 2H), 3.33–3.28 (m, 3H), 3.00–2.95 (m, 1H), 2.72–2.67 (m, 1H), 2.24–2.15 (m, 1H), 2.06–2.00 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 172.81, 158.41, 147.97, 143.00, 140.13, 138.12, 133.43, 132.11, 131.77, 131.13, 130.84, 128.59, 118.61, 112.01, 112.00, 61.44, 50.82, 49.83, 43.08, 42.99, 41.34, 38.55, 35.70, 34.66. ESI-MS: <i>m</i>/<i>z</i> = 590 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>26</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 590.0704, found 590.0717.</div></div><div id="sec4_1_8_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103">4.1.8.68.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-dichlorophenyl)-6-(2-((2,3-dihydroxypropyl)amino)-2-oxoethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E19</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 47%; retention time: 10.509 min, purity: 96.16%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.53 (s, 1H), 7.50 (d, <i>J</i> = 1.9 Hz, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 1H), 7.26 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 7.22 (s, 1H), 4.32–4.26 (m, 1H), 3.75 (s, 3H), 3.73–3.69 (m, 1H), 3.64–3.58 (m, 1H), 3.50 (d, <i>J</i> = 5.7 Hz, 2H), 3.47–3.34 (m, 2H), 3.27–3.21 (m, 1H), 3.08–3.02 (m, 1H), 3.00–2.94 (m, 1H), 2.85–2.79 (m, 1H), 2.58–2.53 (m, 1H), 2.07–2.01 (m, 1H), 1.90–1.84 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 174.44, 158.41, 148.32, 144.39, 139.85, 138.12, 133.26, 133.21, 131.61, 131.11, 130.91, 128.59, 118.24, 111.98, 111.96, 71.86, 65.09, 51.74, 50.47, 47.93, 44.69, 43.39, 42.50, 38.54, 37.13. ESI-MS: <i>m</i>/<i>z</i> = 620 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>25</sub>H<sub>28</sub>Cl<sub>4</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup> 620.0810, found 620.0819.</div></div><div id="sec4_1_8_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104">4.1.8.69.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-difluorophenyl)-6-(2-hydroxyethyl)piperidin-3-yl)furan-2-carboxamide (<b>E20</b>)</h5><div class="NLM_p last">General Procedure III, yield: 80%; retention time: 9.945 min, purity: 98.15%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.53 (s, 1H), 7.32–7.06 (m, 4H), 4.30–4.22 (m, 1H), 3.82–3.69 (m, 5H), 3.35 (s, 1H), 3.28–3.23 (m, 1H), 3.18–3.09 (m, 1H), 3.02–2.86 (m, 2H), 2.14–2.05 (m, 1H), 2.00–1.91 (m, 1H), 1.91–1.75 (m, 2H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 158.36, 151.50 (dd, <i>J</i> = 245.0, 13.0 Hz), 150.38 (dd, <i>J</i> = 244.0, 13.0 Hz), 148.43, 141.78, 139.71, 138.11, 130.92, 125.17, 118.08 (d, <i>J</i> = 16.0 Hz), 118.00, 117.48 (d, <i>J</i> = 17.0 Hz), 111.95, 111.88, 61.31, 52.39, 50.62, 45.16, 42.86, 38.68, 38.52, 33.44. ESI-MS: <i>m</i>/<i>z</i> = 499 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>23</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup> 499.1110, found 499.1123.</div></div><div id="sec4_1_8_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105">4.1.8.70.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-difluorophenyl)-6-(2,3-dihydroxypropyl)piperidin-3-yl)furan-2-carboxamide (<b>E21</b>)</h5><div class="NLM_p last">General Procedure III, yield: 47%; retention time: 9.935 min, purity: 98.07%; <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.54 (s, 1H), 7.29 (s, 1H), 7.28–7.24 (m, 1H), 7.24–7.16 (m, 1H), 7.16–7.11 (m, 1H), 4.59–4.52 (m, 1H), 4.03–3.97 (m, 1H), 3.90–3.86 (m, 1H), 3.75 (s, 3H), 3.66–3.57 (m, 2H), 3.45–3.33 (m, 3H), 2.36–2.28 (m, 1H), 2.25–2.15 (m, 2H), 1.99–1.92 (m, 1H). <sup>13</sup>C NMR (125 MHz, MeOD) δ 158.39, 151.60 (dd, <i>J</i> = 245.0, 12.5 Hz), 150.84 (dd, <i>J</i> = 245.0, 12.5 Hz), 147.87, 140.18, 139.30, 138.13, 130.78, 125.33, 118.72, 118.50 (d, <i>J</i> = 16.3 Hz), 117.59 (d, <i>J</i> = 17.5 Hz), 112.06, 112.00, 70.38, 66.62, 51.89, 49.28, 42.41, 40.77, 38.54, 35.90, 32.26. ESI-MS: <i>m</i>/<i>z</i> = 529 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>22</sub>H<sub>25</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 529.1215, found 529.1229.</div></div><div id="sec4_1_8_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106">4.1.8.71.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-difluorophenyl)-6-(2-(methylamino)-2-oxoethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E22</b>)</h5><div class="NLM_p last">General Procedure VII, yield: 81%; retention time: 9.842 min, purity: 97.73%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.53 (s, 1H), 7.38–7.26 (m, 2H), 7.22–7.12 (m, 2H), 4.61–4.51 (m, 1H), 4.17–4.07 (m, 1H), 3.75 (s, 3H), 3.50–3.33 (m, 3H), 3.09–2.99 (m, 1H), 2.84–2.70 (m, 4H), 2.31–2.22 (m, 1H), 2.11–2.00 (m, 1H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 172.25, 158.33, 151.52 (dd, <i>J</i> = 245.0, 12.0 Hz), 150.34 (dd, <i>J</i> = 245.0, 13.0 Hz), 147.83, 140.20, 139.04, 138.08, 130.79, 125.45, 118.70, 118.48 (d, <i>J</i> = 17.0 Hz), 117.67 (d, <i>J</i> = 18.0 Hz), 112.03, 111.97, 51.04, 48.90, 42.27, 40.70, 38.55, 34.87, 33.33, 26.34. ESI-MS: <i>m</i>/<i>z</i> = 526 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>24</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 526.1219, found 526.1229.</div></div><div id="sec4_1_8_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107">4.1.8.72.  5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)-<i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-4-(3,4-difluorophenyl)-6-(2-(methylsulfonamido)ethyl)piperidin-3-yl)furan-2-carboxamide Hydrochloride (<b>E23</b>)</h5><div class="NLM_p last">General Procedure VIII, yield: 86%; retention time: 9.939 min, purity: 96.04%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.54 (s, 1H), 7.34–7.26 (m, 2H), 7.24–7.13 (m, 3H), 4.58–4.48 (m, 1H), 3.93–3.84 (m, 1H), 3.75 (s, 3H), 3.55–3.34 (m, 3H), 3.30–3.23 (m, 2H), 2.99 (s, 3H), 2.32–2.08 (m, 4H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 158.36, 151.53 (dd, <i>J</i> = 245.0, 13.0 Hz), 150.47 (dd, <i>J</i> = 245.0, 13.0 Hz), 149.65, 149.52, 147.85, 140.18, 139.09, 138.12, 130.77, 125.40, 118.74, 118.51 (d, <i>J</i> = 18.0 Hz), 117.67 (d, <i>J</i> = 18.0 Hz), 112.06, 112.00, 51.45, 42.67, 40.60, 40.38, 39.59, 38.54, 34.15, 34.01, 29.82. ESI-MS: <i>m</i>/<i>z</i> = 576 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>23</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub>S [M + H]<sup>+</sup> 576.1045, found 576.1050.</div></div><div id="sec4_1_8_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108">4.1.8.73.  <i>N</i>-((3<i>S</i>,4<i>S</i>,6<i>S</i>)-6-(2-Acetamidoethyl)-4-(3,4-difluorophenyl)piperidin-3-yl)-5-chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamide Hydrochloride (<b>E24</b>)</h5><div class="NLM_p last">General Procedure VIII, yield: 78%; retention time: 10.043 min, purity: 95.35%; <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.67 (t, <i>J</i> = 10.3 Hz, 1H), 9.06 (d, <i>J</i> = 11.0 Hz, 1H), 8.80 (d, <i>J</i> = 9.2 Hz, 1H), 8.18 (t, <i>J</i> = 5.7 Hz, 1H), 7.68 (s, 1H), 7.53 (s, 1H), 7.38 (dd, <i>J</i> = 19.2, 8.6 Hz, 1H), 7.34–7.27 (m, 1H), 7.15–7.10 (m, 1H), 4.58–4.49 (m, 1H), 3.73 (s, 3H), 3.61–3.52 (m, 1H), 3.34–3.27 (m, 1H), 3.25–3.03 (m, 4H), 2.17–2.09 (m, 1H), 2.02–1.92 (m, 3H), 1.84 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO) δ 169.76, 155.52, 149.22 (dd, <i>J</i> = 243.8, 12.5 Hz), 148.34 (dd, <i>J</i> = 243.8, 13.8 Hz), 146.74, 139.25, 137.30, 136.65, 128.90, 124.29, 117.48 (d, <i>J</i> = 17.5 Hz), 117.17, 116.45 (d, <i>J</i> = 17.5 Hz), 110.23, 109.31, 49.15, 46.47, 40.77, 38.57, 38.24, 34.98, 32.11, 27.57, 22.60. ESI-MS: <i>m</i>/<i>z</i> = 540 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>26</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 540.1375, found 540.1395.</div></div><div id="sec4_1_8_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109">4.1.8.74.  2-((2<i>S</i>,4<i>S</i>,5<i>S</i>)-5-(5-Chloro-4-(4-chloro-1-methyl-1<i>H</i>-pyrazol-5-yl)furan-2-carboxamido)-4-(3,4-difluorophenyl)piperidin-2-yl)ethyl Acetate Hydrochloride (<b>E25</b>)</h5><div class="NLM_p">To the solution of compound <b>44b</b> (60 mg, 0.1 mmol) and DIPEA (62 μL,0.3 mmol) in THF (5 mL) was added acetylchloride (23 μL, 0.20 mmol) in ice bath. The mixture was stirred at RT for 4 h. After completion of reaction, it was poured into saturated NaHCO<sub>3</sub> (5 mL) and extracted with ethyl acetate (5 mL × 3). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue was purified by silica gel chromatography to afford a white solid.</div><div class="NLM_p last">To a solution of the above solid in ethyl acetate (0.3 mL) was added HCl-saturated ethyl acetate (3 mL) and stirred overnight at room temperature. Then, the reaction was added with saturated sodium bicarbonate (8 mL) and extracted with ethyl acetate (5 mL × 3). The combined organic extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated to afford a white solid (38.4 mg, 0.071 mmol). Yield: 71%; retention time: 10.802 min, purity: 95.31%; <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.52 (s, 1H), 7.35–7.05 (m, 4H), 4.42–4.08 (m, 3H), 3.74 (s, 3H), 3.25–3.08 (m, 2H), 3.03–2.94 (m, 1H), 2.92–2.81 (m, 1H), 2.20–2.12 (m, 1H), 2.04 (s, 3H), 2.00–1.89 (m, 2H), 1.88–1.80 (m, 1H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 172.91, 158.34, 151.50 (dd, <i>J</i> = 244.0, 12.0 Hz), 150.40 (dd, <i>J</i> = 243.0, 13.0 Hz), 148.44, 141.67, 139.69, 138.11, 130.91, 125.16, 118.09 (d, <i>J</i> = 18.0 Hz), 118.00, 117.48 (d, <i>J</i> = 17.0 Hz), 111.94, 111.89, 63.49, 52.41, 49.79, 45.15, 42.75, 38.52, 38.30, 30.36, 20.83. ESI-MS: <i>m</i>/<i>z</i> = 541 [M + H]<sup>+</sup>. HRMS (ESI) (<i>m</i>/<i>z</i>): calcd for C<sub>24</sub>H<sub>25</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup> 541.1215, found 541.1223.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110">4.2.  Akt1 Inhibitory Activity Assay</h3><div class="NLM_p last">The Akt1 inhibitory activities were determined using the homogeneous time-resolved fluorescence (HTRF) KinEASE-STK S1 kit (Cat. #62ST2PEC, Cisbio) according to the manufacturer’s instructions. Akt1 kinase was expressed and purified from <i>Escherichia coli</i> system in-house. In short, the kinase reactions were carried out in a 384 ProxiPlate with 10 μL reaction volume per well containing 0.25 μg/mL Akt1, 1 μM peptide substrate, test compound, and 20 μM ATP in assay buffer [50 mM <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES) pH 7.5, 0.01% BRIJ-35, 5 mM MgCl<sub>2</sub>, 1 mM ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid (EGTA)]. After incubation for 1 h at RT, the reaction was stopped by the addition of 5 μL of Sa-XL665 and 5 μL STK Antibody-Eu(K) in ethylenediaminetetraacetic acid (EDTA). The plate was sealed and incubated for 1 h at RT, and the resulting time-resolved fluorescence energy transfer signal was measured on Envision-PerkinElmer. The fluorescence emission was measured at 615 nm (cryptate) and 665 nm (XL665). Emission ratio was calculated (665/615) for each well, and the percent inhibition was expressed as follows: percent inhibition = (max – sample ratio)/(max – min) × 100 (“min” means the ratio of no enzyme control, and “max” means the ratio of DMSO control). Compounds were initially tested at a fixed concentration (1 μg/mL), and those displaying more than 50% inhibition were further tested for dose–response IC<sub>50</sub> values.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111">4.3.  Kinase Selectivity Assay</h3><div class="NLM_p">The representative compounds were assayed against a panel of 22 protein kinases at Shanghai ChemPartner Co., Ltd. All of the proteins and kinase assay kits were mainly purchased from Carna, Invitrogen, or Millipore. The compounds were tested at concentrations of 0.5 and 10 μM over most kinases, including ABL, ALK, Akt2, Akt3, JNK2, JAK2, ROCK1, RSK1, P70S6K, MSK1, SGK, PDK1, and PRKG1, using mobility shift assay with ATP concentration at <i>K</i><sub>m</sub>. PI3Kα inhibitory activity was screened by Kinase-Glo Luminescent Assay kit (Promege) with ATP concentration at 25 μM. CHK1 and TSSK1 inhibitory activities were determined using the Luminescent ADP-Glo assay kit (Promege). In addition, the inhibition of mTOR activity was evaluated in a Lance Ultra assay. Moreover, PKA, GSK3β, and CDK2/cyclin A activities were evaluated at the concentration of 1 μg/mL by Z-LYTE Kinase Assay kits (Invitrogen). Like Akt1 assay, the Aurora A and BRAF inhibitory activities of compounds were measured by the HTRF kinase assay kits purchased from Cisbio. The protocols for these assays could be found in the manufacturer’s instructions.</div><div class="NLM_p last">Compound <b>E22</b> was assayed against a panel of 468 protein kinases at DiscoverX Co. Kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an <i>E. coli</i> host derived from the BL21 strain. <i>E. coli</i> were grown to log phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32 °C until lysis (90–150 min). The lysates were centrifuged (6000<i>g</i>) and filtered (0.2 μm) to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for quantitative polymerase chain reaction (qPCR) detection. Streptavidin-coated magnetic beads were treated with biotinylated small-molecule ligands for 30 min at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer [SeaBlock (Pierce), 1% bovine serum albumin, 0.05% Tween 20, 1 mM dithiothreitol (DTT)] to remove unbound ligand and to reduce nonspecific phage binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer [20% SeaBlock, 0.17× phosphate-buffered saline (PBS), 0.05% Tween 20, 6 mM DTT]. <b>E22</b> was prepared as 40× stocks in 100% DMSO and directly diluted into the assay (1000 nM). All reactions were performed in polypropylene 384-well plates in a final volume of 0.02 mL. The assay plates were incubated at room temperature with shaking for 1 h, and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads were then resuspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM nonbiotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR. The results for primary screen binding interactions are reported as % Ctrl = (test compound signal – positive control signal)/(negative control signal – positive control signal) × 100.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112">4.4.  Cell Culture</h3><div class="NLM_p last">Human ovarian carcinoma cells (SKOV3, OVCAR8), human prostate cancer cells (LnCap), human colon cancer cells (HCT 116), and human umbilical vein endothelial cells (HUVEC) were obtained from the Cell Bank of the China Science Academy, Shanghai, and were cultured in Dulbecco’s modified Eagle’s medium, F-12K, or RPMI-1640 medium (Gibco Laboratories) and supplemented with 10% fetal bovine serum (Gibco Laboratories), 105 U/L penicillin, and 100 mg/L streptomycin at 37 °C in an atmosphere containing 5% CO<sub>2</sub>. Cells were grown to 70–80% confluency in dishes or cell culture plates and treated under various conditions as indicated.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113">4.5.  Antiproliferative Assay</h3><div class="NLM_p last">SKOV3 and HCT-116 cells were treated with the compounds at various doses for 72 h, and cell proliferation was tested by a sulforhodamine B (SRB) protein assay (Sigma, S1402). The cells (5000/well) were incubated with 10% trichloroacetic acid (TCA) for 1 h (4 °C) and then stained with SRB for 20 min. The SRB was washed away with 1% glacial acetic acid, and 100 μL of 1% Tris-base was added to each well. The optical density was determined at 515 nm by a Multiskan Spectrum plate reader (Thermo Electron Corporation, Marietta, OH).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114">4.6.  Western Blot Assay</h3><div class="NLM_p last">Whole protein extracts from cultured cells or tissues were prepared and subjected to western blotting. Protein samples were size-fractionated by 10% SDS-polyacrylamide gel electrophoresis, analyzed by immunoblotting, and visualized by enhanced chemiluminescence (ECL, Amersham Biosciences, Castle Hill, Australia) and then exposed on X-ray film. Proteins in the lysates were equalized and then analyzed by specific antibodies. The primary antibodies were listed as follows: AKT (CST, 9272S), pAKT-Thr308 (Santa, sc-16646), pAKT-Ser473 (Santa, sc-7985), PRAS40 (CST, 2691P), p-PRAS40 (CST, 13175P), GSK-3β (Santa, sc-7291), p-GSK-3β (CST, 8566S), and β-actin (Santa, SC-1615). Appropriate secondary antibodies and ECL were used to visualize the protein signaling.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115">4.7.  Flow Cytometry</h3><div class="NLM_p last">SKOV3 cells were seeded in six-well dish plates at 1 × 10<sup>5</sup> cells/well and exposed to different concentrations of <b>E22</b>. After 72 h, the cells were harvested and stained with Annexin-V–PI solution using the FITC Annexin V Apoptosis Detection Kit I (BD Bioscience, 556547) for 10–15 min and resuspended in binding buffer. Then, the fluorescence emission at 530 and 585 nm using 488 nm excitation was measured by flow cytometry (BD FACSCalibur).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116">4.8.  Enzyme-Linked Immunosorbent Assay (ELISA)</h3><div class="NLM_p last">ELISA plates were prepared by coating with anti-PRAS40 antibody (R&D Systems) and blocked with 5% milk/0.1% Tween 20. LNCaP cells were seeded at 25 000 cells/96-well overnight and treated with DMSO or various concentrations of compounds for 1 h. Subsequently, the cells were lysed in 20 mM Tris–HCl (pH 8.0), 137 mM NaCl, 2 mM EDTA, 10% glycerol, and 1% Triton X-100, and the lysates were transferred to ELISA plates and incubated overnight. The plates were washed and incubated with rabbit anti-PRAS40 (pThr246) antibody (R&D Systems) for 1 h. After washing, the plates were developed using horseradish peroxidase-linked antirabbit IgG and 3,39,5,59-tetramethylbenzidine as substrate. Absorption was measured in a microplate spectrophotometer at 450 nm, dose–response curves were generated using the four-parameter logistic model, and 50% inhibitory concentration (IC<sub>50</sub>) values were determined from these curve fits.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117">4.9.  Migration and Invasion Assay</h3><div class="NLM_p">HUVEC cells were cultured in six-well dish plates at a number of 3 × 10<sup>5</sup> cells/well and grown overnight to confluence. A wound was created by scratching a straight line in the monolayer with a 200 μL pipet tip. The cells were then incubated with <b>E22</b> in serum-free medium for 36 h, and the wound area was then photographed using a light microscope (Leica, DMI3000B). The rate of wound closure was assessed by measuring distances from six randomly selected fields.</div><div class="NLM_p last">Transwell invasion assays were performed using BD BioCoat matrigel invasion chambers (BD Biosciences, 354480) in 24-well cell culture plates following the manufacturer’s instruction. After 36 h, cells that had migrated through the Matrigel to the underside of the transwell filters were fixed in 4% paraformaldehyde, stained with 0.5% crystal violet, and counted under a light microscope in six random fields. Stained cells were further quantified by measuring the absorbance of dissolved crystals in 0.1% SDS at 540 nm.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118">4.10.  hERG Inhibition Assay</h3><div class="NLM_p last">Currents were recorded from HEK-293 cells, using the whole-cell patch–clamp technique. The cells were transferred to a perfusion chamber, and the perfusion was performed with extracellular fluid (mM): K aspartate, 130; MgCl<sub>2</sub>, 5; EGTA, 5; HEPES, 10; Tris–ATP, 4; pH 7.2. Electrodes were pulled using a dual-stage glass micropipette puller (Narishige PC-10, Japan). Current traces of hERG channels were elicited by applying a pulse from −80 to +40 mV for 4 s followed by a step to −40 mV for 2 s. The procedure was repeated every 20 s. After the maximum current was stabilized, the tested compounds (3 μM) were perfused. The inhibition rate was calculated when the current was stable. All data represent at least three independent experiments (<i>n</i> = 3).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119">4.11.  Liver Microsome Stability Assay</h3><div class="NLM_p last">A 1 mg/mL microsome solution (purchased from Ruide Research Institute for Liver Diseases (Shanghai) Co. Ltd.) was mixed with 20 mL of 50 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) (Aladdin) solution to prepare a microsome–NADPH solution. The microsome–NADPH solution (500 μL) was prewarmed at 37 °C for 5 min. A 100 μg/mL test article solution (5 μL) was then added to initiate the reaction. The incubation mixture was kept at 37 °C and 100 μL aliquots were taken at 0, 15, and 45 min. In each aliquot, the reaction was quenched using 400 μL of methanol containing 1 μg/mL internal standard compound (from the in-house database). After quenching, the mixtures were vortexed and centrifuged. The supernatant was transferred and 10 μL was injected into an API4000 + LC/MS system. The peak area ratio of a test article versus the internal standard was used in the calculation of the rate of disappearance of a test article.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120">4.12.  Plasma Stability Assay</h3><div class="NLM_p last">A 500 μL aliquot of rat plasma or human plasma (purchased from Shanghai Yuduo Biotechnology Company) was added to 5 μL of a test article solution at 100 μg/mL to give a final solution. The mixture was incubated at 37 °C with gentle agitation. An aliquot of 100 μL of the reaction mixture was taken at 0, 15, and 45 min and quenched using 400 μL of methanol containing 1 μg/mL internal standard compound (from the in-house database). After quenching, the mixture was vortexed and centrifuged and 10 μL of the resulting solution was injected into an API4000 + LC/MS system. The percentage remaining of the test article at incubation times of 15 and 45 min relative to that at 0 min was calculated using the peak area ratio of the test article versus the internal standard.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121">4.13.  Plasma Protein Binding Rate Assay</h3><div class="NLM_p last">A 300 μL mouse plasma containing 300 ng/mL <b>E22</b> was added to the sample chamber of Thermo Equilibrium Dialysis Device (Red Device Insert), and a 500 μL PBS dialysate was added to the buffer chamber. After sealing, the mixture was incubated at 37 °C for 8 h. An aliquot of 50 μL of each mixture was quenched using 500 μL of acetonitrile containing 0.5 ng/mL internal standard compound (Loratadine). After quenching, the mixture was vortexed and centrifuged, and the resulting solution was injected into a Waters XEVO TQ-S system. PPB % = (1 – concentration in PBS/concentration in plasma) × 100. The PPB rate was an average of three independent determinations.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122">4.14.  Pharmacokinetic Studies</h3><div class="NLM_p last">This study was performed in strict accordance with the Laboratory Animal Management Regulations (State Scientific and Technological Commission Publication No. 8-27 Rev. 2017) and approved by Zhejiang University Laboratory Animal Center (Hangzhou, China). Sprague Dawley rats or Institute of Cancer Research (ICR) mice (purchased from Zhejiang Academy of Medical Sciences) were administered compound by oral gavage in saline. As for the evaluation of compound <b>A12</b> and <b>E22</b> in mice, venous blood (100 μL) samples were collected at 0, 0.167, 0.5, 1, 2, 3, 4, 8, 24, and 48 h for oral gavage or 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, 24, and 48 h for intravenous injection. As for the evaluation of compounds <b>E20</b> and <b>E22</b> in rats, venous blood (100 μL) samples were collected at 0, 0.5, 1, 2, 4, 8, 12, and 24 h. Plasma was separated from whole blood by centrifugation and stored at −20 °C until analysis. Compound levels were determined using a Waters Xevo TQ LC–MS/MS system. <i>C</i><sub>max</sub>, <i>T</i><sub>max</sub>, <i>t</i><sub>1/2</sub>, and area under curve (AUC) were evaluated using Analyst 1.5.1.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123">4.15.  Xenotransplantation</h3><div class="NLM_p">BALB/c (nu/nu) mice (National Rodent Laboratory Animal Resource, Shanghai), 6–8 weeks of age, were used for all experiments. When MM1S xenograft tumors reached 100 mm<sup>3</sup>, the mice were randomly divided into five groups and received <b>A12</b> (10 mg/kg) orally once daily for 22 days. Other mice were orally administered normal saline as controls for 22 days. When SKOV3 xenograft tumors reached 100 mm<sup>3</sup>, the mice received <b>E22</b> (40, 80, 40 + 40 mg/kg) orally once daily for 21 days. Other mice were orally administered normal saline as controls for 21 days.</div><div class="NLM_p last">Statements of Ethical Approval: The animal studies were approved by the Institutional Animal Care & Use Committee (IACUC) at Zhejiang University, and all protocols were conducted in accordance with institutional guidelines.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124">4.16.  Toxicology Evaluation</h3><div class="NLM_p">ICR mice (National Rodent Laboratory Animal Resource, Shanghai), 6–8 weeks of age, were used for this experiment. The mice were randomly divided into six groups and received <b>A12</b> (10, 20, 40 mg/kg, i.g.), <b>E22</b> (80, 160 mg/kg, i.g.), or vehicle (saline, i.g.) once daily for 7 days. The body weight of the mice was recorded once daily. At the end of the experiment, the mice were sacrificed, and the serum hematological parameters and serum biochemistry parameters were recorded on Sysmex XT-2000i and Roche Cobas c 311, respectively.</div><div class="NLM_p last">Statements of Ethical Approval: The animal studies were approved by the Institutional Animal Care & Use Committee (IACUC) at Zhejiang University, and all protocols were conducted in accordance with institutional guidelines.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125">4.17.  Molecular Docking and Dynamic Simulation</h3><div class="NLM_p last">Molecular docking was performed using Ligand Docking implanted in Maestro. Parameters were maintained at the default configuration. The docked structure of compound <b>E22</b> complexed within the active pocket of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a> was used as the initial structures for MD calculations using Discovery Studio 2.5. A CHARMm force field was applied to the complex, and the resulting system was subjected to double-fold minimization (10 000 cycles of steepest descent minimization and 10 000 cycles of conjugate gradient minimization). The system was heated from 50 to 300 K over a period of 4 ps and subsequently equilibrated for 200 ps. Starting from the last frame of the equilibration, a production simulation was performed for 4000 ps using the NPT ensemble under a constant temperature of 300 K and pressure of 1 atm. Other parameters of MD simulation were maintained at the default Discovery Studio configuration.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00891" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00891" class="ext-link">10.1021/acs.jmedchem.9b00891</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">The proposed binding mode of <b>GSK-795</b> with Akt protein (Figure S1); synthesis and chemical information of compound (3<i>R</i>,4<i>S</i>)-<b>A6</b> (Figure S2); the proposed binding mode of <b>GSK-795</b> with Akt protein (Figure S3); in vivo antitumor effect of compound <b>A12</b> (Figure S4); comparison of the selectivity profile between compound <b>E22</b> and <b>GSK-795</b> (Figure S5); synthetic route of acid fragments (Figure S6); analysis of the configurations (Figure S7); the effect of <b>A12</b> and <b>E22</b> on organ-to-brain weight ratio during 7 days repeated dose toxicity study (Table S1); inhibition rate of compound <b>E22</b> against different ion channels (Table S2); selectivity profile of compound <b>E22</b> (Table S3); compound information for the intermediates; and NMR spectra and HPLC results for the target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Binding model of Akt1 with <b>E22</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf">jm9b00891_si_001.pdf (10.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_002.csv">jm9b00891_si_002.csv (7.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_003.pdb">jm9b00891_si_003.pdb (430.27 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a> was used. The authors will release the atomic coordinates upon article publication for the models between compound <b>E22</b> with Akt1, which was built on <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b00891" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qinjie Weng</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacology & Toxicology, Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d1a6b4bfb6a0b8bfbbb8b491abbba4ffb4b5a4ffb2bf"><span class="__cf_email__" data-cfemail="d7a0b2b9b0a6beb9bdbeb297adbda2f9b2b3a2f9b4b9">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongzhou Hu</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7349-4062" title="Orcid link">http://orcid.org/0000-0001-7349-4062</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c6aeb3bfbc86bcacb3e8a3a2b3e8a5a8"><span class="__cf_email__" data-cfemail="79110c00033903130c571c1d0c571a17">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaowu Dong</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2178-4372" title="Orcid link">http://orcid.org/0000-0002-2178-4372</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhu Zhan</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span>; 
    <span>Present Address:
                        Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Avenue, New York, New York 10065, United States (W.Z.)</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengting Zhao</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacology & Toxicology, Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinxin Che</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyang Dai</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacology & Toxicology, Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yizhe Wu</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Xu</span> - <span class="hlFld-Affiliation affiliation">National
Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yubo Zhou</span> - <span class="hlFld-Affiliation affiliation">National
Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanmei Zhao</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tian Tian</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Cheng</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmaceutical Science, Zhejiang Chinese
Medical University, Hangzhou 311402, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zegao Jin</span> - <span class="hlFld-Affiliation affiliation">ZJU-ENS
Joint Laboratory of Medicinal Chemistry, Hangzhou Institute
of Innovative Medicine and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Li</span> - <span class="hlFld-Affiliation affiliation">National
Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanfei Shao</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, Zhejiang Provincial People’s
Hospital, Hangzhou 310014, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiaojun He</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacology & Toxicology, Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bo Yang</span> - <span class="hlFld-Affiliation affiliation">Institute of Pharmacology & Toxicology, Zhejiang
Province Key Laboratory of Anti-Cancer Drug Research and , College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.D., W.Z., and M.Z. contributed equally to this work.</p><span class="author-information-subsection-header">Author Contributions</span><p>X.D. and W.Z. conceived the study, synthesized the compounds, and analyzed the data. M.Z., X.D., Q.W., L.X., Y.Z., and Y.S. performed the biological experiments and analyzed the data. J.C. synthesized the compounds and drafted the manuscript. Y.W., Y.Z., T.T., and Z.J. synthesized the compounds. G.C. performed the docking calculation. J.L., B.Y., Q.H., and Y.H. conceived the study.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8570-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Jianyang Pan (Research and Service Center, College of Pharmaceutical Sciences, Zhejiang University) for performing NMR spectrometry for structure elucidation. This work was supported by a grant from the National Natural Science Foundation of China (81673294, 81872878, 81741172), Zhejiang Provincial Natural Science Foundation of China (LGF18H310001, LGF19H310002), the Health Bureau of Zhejiang Province (2015RCB002), and National Major Scientific and Technological Special Project for “Significant New Drugs Development” (2018ZX09711002-007 and 2018ZX09711002-011-023).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">protein kinase A</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RBC</td><td class="NLM_def"><p class="first last">red blood cell</p></td></tr><tr><td class="NLM_term">RMSD</td><td class="NLM_def"><p class="first last">root-mean-square deviation</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoracetic acid</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">N,N-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">AKT/PKB signaling: Navigating downstream</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.cell.2007.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=17604717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotV2hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=AKT%2FPKB+signaling%3A+Navigating+downstream&doi=10.1016%2Fj.cell.2007.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">AKT/PKB signaling: navigating downstream</span></div><div class="casAuthors">Manning, Brendan D.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1261-1274</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli.  Aberrant loss or gain of Akt activation underlies the pathophysiol. properties of a variety of complex diseases, including type-2 diabetes and cancer.  Here, we review the mol. properties of Akt and the approaches used to characterize its true cellular targets.  In addn., we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metab., and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquDoFFShtwG7Vg90H21EOLACvtfcHk0liD2GKhUXe_hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotV2hs7g%253D&md5=1362a51f4d8a75b55f441dec99c04b1d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DAKT%252FPKB%2520signaling%253A%2520Navigating%2520downstream%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274%26doi%3D10.1016%2Fj.cell.2007.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsilieris, M.</span></span> <span> </span><span class="NLM_article-title">The Akt pathway: Molecular targets for anti-cancer drug development</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.2174/1568009043333032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.2174%2F1568009043333032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=15134532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-256&author=C.+S.+Mitsiadesauthor=N.+Mitsiadesauthor=M.+Koutsilieris&title=The+Akt+pathway%3A+Molecular+targets+for+anti-cancer+drug+development&doi=10.2174%2F1568009043333032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt pathway: Molecular targets for anti-cancer drug development</span></div><div class="casAuthors">Mitsiades, Constantine S.; Mitsiades, Nicholas; Koutsilieris, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt functions intracellularly as a cardinal nodal point for a constellation of converging upstream signaling pathways, which involve stimulation of receptor tyrosine kinases such as IGR-1R, HER2/Neu, VEGF-R, PDGF-R, and an assembly of membrane-localized complexes of receptor-PI-3K and activation of Akt through the second messenger PIP3.  The integration of these intracellular signals at the level of Akt and its kinase activity, regulates the phosphorylation of its several downstream effectors, such as NF-κB, mTOR, Forkhead, Bad, GSK-3 and MDM-2.  These phosphorylation events in turn mediate the effects of Akt on cell growth, proliferation, protection from pro-apoptotic stimuli, and stimulation of neoangiogenesis.  Because Akt and its upstream regulators are deregulated in a wide range of solid tumors and hematol. malignancies, and in view of the aforementioned biol. sequelae of this pathway, the Akt pathway is considered a key determinant of biol. aggressiveness of these tumors, and a major potential target for novel anti-cancer therapies.  This review focuses on ongoing translational efforts to therapeutically target Akt and its biol. sequelae, either at the level of Akt itself or at the levels of its upstream regulators and downstream effectors.  Because Akt is also important for proliferative and anti-apoptotic signaling pathways crit. for normal cells, particular emphasis is placed on the fine-tuning the targeting of individual components of this pathway to maximize the therapeutic index of anti-cancer strategies based on the PI-3K/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZbuqTPNYgLVg90H21EOLACvtfcHk0lgazFivKB_OFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D&md5=299909de4babdbbf0e242bd1a7abdab1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F1568009043333032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009043333032%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DKoutsilieris%26aufirst%3DM.%26atitle%3DThe%2520Akt%2520pathway%253A%2520Molecular%2520targets%2520for%2520anti-cancer%2520drug%2520development%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D256%26doi%3D10.2174%2F1568009043333032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+X.+Liuauthor=H.+L.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lgazFivKB_OFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BX.%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zippelius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy</span>. <i>JNCI, J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>107</i></span>, <span class="NLM_elocation-id">djv171</span> <span class="refDoi"> DOI: 10.1093/jnci/djv171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1093%2Fjnci%2Fdjv171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=26071042" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&author=G.+D.+Xueauthor=A.+Zippeliusauthor=A.+Wickiauthor=M.+Mandalaauthor=F.+Y.+Tangauthor=D.+Massiauthor=B.+A.+Hemmings&title=Integrated+Akt%2FPKB+signaling+in+immunomodulation+and+its+potential+role+in+cancer+immunotherapy&doi=10.1093%2Fjnci%2Fdjv171"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv171%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%2BD.%26aulast%3DZippelius%26aufirst%3DA.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DF.%2BY.%26aulast%3DMassi%26aufirst%3DD.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DIntegrated%2520Akt%252FPKB%2520signaling%2520in%2520immunomodulation%2520and%2520its%2520potential%2520role%2520in%2520cancer%2520immunotherapy%26jtitle%3DJNCI%252C%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2015%26volume%3D107%26doi%3D10.1093%2Fjnci%2Fdjv171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerniglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin-Anduix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">83</span> <span class="refDoi"> DOI: 10.1186/1476-4598-13-83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1186%2F1476-4598-13-83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24735930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&author=A.+Lassenauthor=M.+Atefiauthor=L.+Robertauthor=D.+J.+L.+Wongauthor=M.+Cernigliaauthor=B.+Comin-Anduixauthor=A.+Ribas&title=Effects+of+AKT+inhibitor+therapy+in+response+and+resistance+to+BRAF+inhibition+in+melanoma&doi=10.1186%2F1476-4598-13-83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma</span></div><div class="casAuthors">Lassen, Amanda; Atefi, Mohammad; Robert, Lidia; Wong, Deborah J. L.; Cerniglia, Michael; Comin-Anduix, Begonya; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83/1-83/14, 14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The clin. use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance.  In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide addnl. growth inhibitory effects in vitro.  Methods: Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi) in a panel of 23 BRAF mutated melanoma cell lines were evaluated on growth inhibition by an ATP-based luminescent assay, on cell cycle and apoptosis by flow cytometry and on cell signaling by western blot.  Moreover, we investigated the possibilities of delaying or reversing resistance or achieving further growth inhibition by combining AKTi with dabrafenib and/or the MEK inhibitor (MEKi) trametinib by using long term cultures.  Results: More than 40% of the cell lines, including PTEN-/- and AKT mutants showed sensitivity to AKTi (IC50 < 1.5 μM).  The combination of dabrafenib and AKTi synergistically potentiated growth inhibition in the majority of cell lines with IC50 > 5 nM dabrafenib.  Combinatorial treatment induced apoptosis only in cell lines sensitive to AKTi.  In long term cultures of a PTEN-/- cell line, combinatorial treatment with the MAPK inhibitors, dabrafenib and trametinib, and AKTi markedly delayed the emergence of drug resistance.  Moreover, combining AKTi with the MAPK inhibitors from the beginning provided superior growth inhibitory effects compared to addn. of AKTi upon development of resistance to MAPK inhibitors in this particular cell line.  Conclusions: AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF mutations and particularly PTEN deletions or AKT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzvjRyMnizmbVg90H21EOLACvtfcHk0lgazFivKB_OFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVamsbk%253D&md5=773466408a0ed70310b50e330f74af76</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-83%26sid%3Dliteratum%253Aachs%26aulast%3DLassen%26aufirst%3DA.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%2BJ.%2BL.%26aulast%3DCerniglia%26aufirst%3DM.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DEffects%2520of%2520AKT%2520inhibitor%2520therapy%2520in%2520response%2520and%2520resistance%2520to%2520BRAF%2520inhibition%2520in%2520melanoma%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26doi%3D10.1186%2F1476-4598-13-83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span> <span> </span><span class="NLM_article-title">Commentary - AKT plays a central role in tumorigenesis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">10983</span>– <span class="NLM_lpage">10985</span>, <span class="refDoi"> DOI: 10.1073/pnas.211430998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1073%2Fpnas.211430998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=11572954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1yqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=10983-10985&author=J.+R.+Testaauthor=A.+Bellacosa&title=Commentary+-+AKT+plays+a+central+role+in+tumorigenesis&doi=10.1073%2Fpnas.211430998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">AKT plays a central role in tumorigenesis</span></div><div class="casAuthors">Testa, Joseph R.; Bellacosa, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10983-10985</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review discussing the results of the different studies conducted on the role of AKT in human malignancy.  The involvement of AKT in diverse tumorigenic activities indicated that AKT activation alone might be sufficient to induce cancer.  It is anticipated that much attention will be given to the identification of inhibitors or modulators of the P13K/AKT pathway, with the intention of developing new therapeutic strategies directed at neoplasms showing AKT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULlRih-dwMLVg90H21EOLACvtfcHk0lh06R9AhjSXoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1yqsrY%253D&md5=7628999cc6685e8bc3520e91c297cca2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.211430998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.211430998%26sid%3Dliteratum%253Aachs%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26aulast%3DBellacosa%26aufirst%3DA.%26atitle%3DCommentary%2520-%2520AKT%2520plays%2520a%2520central%2520role%2520in%2520tumorigenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D10983%26epage%3D10985%26doi%3D10.1073%2Fpnas.211430998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, S. D.</span></span> <span> </span><span class="NLM_article-title">The activation of Akt/PKB signaling pathway and cell survival</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2005.tb00337.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1111%2Fj.1582-4934.2005.tb00337.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=15784165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1eqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=59-71&author=G.+Songauthor=G.+L.+Ouyangauthor=S.+D.+Bao&title=The+activation+of+Akt%2FPKB+signaling+pathway+and+cell+survival&doi=10.1111%2Fj.1582-4934.2005.tb00337.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The activation of Akt/PKB signaling pathway and cell survival</span></div><div class="casAuthors">Song, Gang; Ouyang, Gaoliang; Bao, Shideng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-71</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">"Carol Davila" University Press</span>)
        </div><div class="casAbstract">A review.  Akt/PKB is a serine/threonine protein kinase that functions as a crit. regulator of cell survival and proliferation.  Akt/PKB family comprises 3 highly homologous members known as PKBα/Akt1, PKBβ/Akt2, and PKBγ/Akt3 in mammalian cells.  Similar to many other protein kinases, Akt/PKB contains a conserved domain structure including a specific PH domain, central kinase domain, and C-terminal regulatory domain that mediates the interaction between signaling mols.  Akt/PKB plays important roles in the signaling pathways in response to growth factors and other extracellular stimuli to regulate several cellular functions including nutrient metab., cell growth, apoptosis, and survival.  This review surveys recent developments in understanding the mol. mechanisms of Akt/PKB activation and its roles in cell survival in normal and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodHk44d_FMbbVg90H21EOLACvtfcHk0lh06R9AhjSXoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1eqtLo%253D&md5=72e8cd3fbec2f8f9b5185ce8debd5c28</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2005.tb00337.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2005.tb00337.x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DG.%26aulast%3DOuyang%26aufirst%3DG.%2BL.%26aulast%3DBao%26aufirst%3DS.%2BD.%26atitle%3DThe%2520activation%2520of%2520Akt%252FPKB%2520signaling%2520pathway%2520and%2520cell%2520survival%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2005%26volume%3D9%26spage%3D59%26epage%3D71%26doi%3D10.1111%2Fj.1582-4934.2005.tb00337.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoeli-Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span> <span> </span><span class="NLM_article-title">Akt/PKB signaling in cancer - A function in cell motility and invasion</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.4161/cc.5.6.2561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.4161%2Fcc.5.6.2561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16582622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A280%3ADC%252BD287pt1ejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=603-605&author=M.+Yoeli-Lernerauthor=A.+Toker&title=Akt%2FPKB+signaling+in+cancer+-+A+function+in+cell+motility+and+invasion&doi=10.4161%2Fcc.5.6.2561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Akt/PKB signaling in cancer: a function in cell motility and invasion</span></div><div class="casAuthors">Yoeli-Lerner Merav; Toker Alex</div><div class="citationInfo"><span class="NLM_cas:title">Cell cycle (Georgetown, Tex.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The PI 3-K signaling pathway has been the subject of intense investigation for over a decade because it regulates a multitude of cellular processes.  Deregulation of this pathway often results in human diseases such as cancer.  The serine/threonine kinase Akt, a major PI 3-K target in all cells, has received considerable attention because it provides tumor cells with enhanced survival capacity.  Many tumors and tumor cells display elevated Akt protein expression and activity, and many of the proteins which regulate Akt itself are also often mutated in cancer.  For this reason, Akt has become a viable drug target for cancer therapy.  However, recent studies have shown that Akt can also function as a suppressor of tumor cell migration and invasion, phenotypes which are directly linked to metastatic tumor progression.  Here we review these findings and consider the unexpected notion that Akt may function as a metastasis suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoULEfkol6KhdUSIfHIn4FfW6udTcc2ebNJGn7AkJfsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287pt1ejug%253D%253D&md5=cf043a07952f2b1e485a55915bc47873</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4161%2Fcc.5.6.2561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.5.6.2561%26sid%3Dliteratum%253Aachs%26aulast%3DYoeli-Lerner%26aufirst%3DM.%26aulast%3DToker%26aufirst%3DA.%26atitle%3DAkt%252FPKB%2520signaling%2520in%2520cancer%2520-%2520A%2520function%2520in%2520cell%2520motility%2520and%2520invasion%26jtitle%3DCell%2520Cycle%26date%3D2006%26volume%3D5%26spage%3D603%26epage%3D605%26doi%3D10.4161%2Fcc.5.6.2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cristofano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span> <span> </span><span class="NLM_article-title">Activation of AKT kinases in cancer: Implications for therapeutic targeting</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/s0065-230x(05)94002-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fs0065-230x%2805%2994002-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16095999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=29-86&author=A.+Bellacosaauthor=C.+C.+Kumarauthor=A.+Di+Cristofanoauthor=J.+R.+Testa&title=Activation+of+AKT+kinases+in+cancer%3A+Implications+for+therapeutic+targeting&doi=10.1016%2Fs0065-230x%2805%2994002-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AKT kinases in cancer: implications for therapeutic targeting</span></div><div class="casAuthors">Bellacosa, Alfonso; Kumar, C. Chandra; Di Cristofano, Antonio; Testa, Joseph Robert</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-86</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The AKT1, AKT2, and AKT3 kinases have emerged as crit. mediators of signal transduction pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase.  An ever-increasing list of AKT substrates has precisely defined the multiple functions of this kinase family in normal physiol. and disease states.  Cellular processes regulated by AKT include cell proliferation and survival, cell size and response to nutrient availability, intermediary metab., angiogenesis, and tissue invasion.  All these processes represent hallmarks of cancer, and a burgeoning literature has defined the importance of AKT alterations in human cancer and exptl. models of tumorigenesis, continuing the legacy represented by the original identification of v-Akt as the transforming oncogene of a murine retrovirus.  Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classical metabolic regulation.  This careful balance is altered in human cancer by a variety of activating and inactivating mechanisms that target both AKT and interrelated proteins.  Reprogramming of this altered circuitry by pharmacol. modulation of the AKT pathway represents a powerful strategy for rational cancer therapy.  In this review, we summarize a large body of data, from many types of cancer, indicating that AKT activation is one of the most common mol. alterations in human malignancy.  We also review mechanisms of activation of AKT kinases, examples of therapeutic modulation of the AKT pathway in animal models, and the current status of efforts to target mol. components of the AKT pathway for cancer therapy and, possibly, cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbtUdzglK927Vg90H21EOLACvtfcHk0liY7hMQfcHicg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D&md5=556e3c5787e0179786db3cb2e2f1dcf6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fs0065-230x%2805%2994002-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0065-230x%252805%252994002-5%26sid%3Dliteratum%253Aachs%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BC.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DActivation%2520of%2520AKT%2520kinases%2520in%2520cancer%253A%2520Implications%2520for%2520therapeutic%2520targeting%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2005%26volume%3D94%26spage%3D29%26epage%3D86%26doi%3D10.1016%2Fs0065-230x%2805%2994002-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslyar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30450-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2FS1470-2045%2817%2930450-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=28800861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1360-1372&author=S.+B.+Kimauthor=R.+Dentauthor=S.+A.+Imauthor=M.+Espi%C3%A9author=S.+Blauauthor=A.+R.+Tanauthor=S.+J.+Isakoffauthor=M.+Oliveiraauthor=C.+Sauraauthor=M.+J.+Wongchenkoauthor=A.+V.+Kappauthor=W.+Y.+Chanauthor=S.+M.+Singelauthor=D.+J.+Maslyarauthor=J.+Baselga&title=Ipatasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28LOTUS%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2817%2930450-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Kim, Sung-Bae; Dent, Rebecca; Im, Seock-Ah; Espie, Marc; Blau, Sibel; Tan, Antoinette R.; Isakoff, Steven J.; Oliveira, Mafalda; Saura, Cristina; Wongchenko, Matthew J.; Kapp, Amy V.; Chan, Wai Y.; Singel, Stina M.; Maslyar, Daniel J.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-neg. breast cancer.  The LOTUS trial investigated the addn. of ipatasertib to paclitaxel as first-line therapy for triple-neg. breast cancer.  In this randomized, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-neg. breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.  Enrolled patients were randomly assigned (1:1) to receive i.v. paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity.  Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumor PTEN status.  The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochem.) population.  This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).  Between Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62).  Median follow-up was 10·4 mo (IQR 6·5-14·1) in the ipatasertib group and 10·2 mo (6·0-13·6) in the placebo group.  Median progression-free survival in the intention-to-treat population was 6·2 mo (95% CI 3·8-9·0) with ipatasertib vs. 4·9 mo (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumors, median progression-free survival was 6·2 mo (95% CI 3·6-9·1) with ipatasertib vs. 3·7 mo (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18).  The most common grade 3 or worse adverse events were diarrhea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).  No colitis, grade 4 diarrhea, or treatment-related deaths were reported with ipatasertib.  One treatment-related death occurred in the placebo group.  Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.  Progression-free survival was longer in patients who received ipatasertib than in those who received placebo.  To our knowledge, these are the first results supporting AKT-targeted therapy for triple-neg. breast cancer.  Ipatasertib warrants further investigation for the treatment of triple-neg. breast cancer.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHDoupzZvn7Vg90H21EOLACvtfcHk0liY7hMQfcHicg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO&md5=411d3aeae55045b4241c617922b711d5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930450-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930450-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DDent%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DEspi%25C3%25A9%26aufirst%3DM.%26aulast%3DBlau%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DKapp%26aufirst%3DA.%2BV.%26aulast%3DChan%26aufirst%3DW.%2BY.%26aulast%3DSingel%26aufirst%3DS.%2BM.%26aulast%3DMaslyar%26aufirst%3DD.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DIpatasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528LOTUS%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1360%26epage%3D1372%26doi%3D10.1016%2FS1470-2045%2817%2930450-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemsadze, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1007</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1200%2FJCO.2018.36.15_suppl.1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=29432078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1007&author=P.+Schmidauthor=J.+Abrahamauthor=S.+Chanauthor=D.+Wheatleyauthor=M.+Bruntauthor=G.+Nemsadze&title=AZD5363+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28PAKT%29%3A+A+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+II+trial&doi=10.1200%2FJCO.2018.36.15_suppl.1007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.1007%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DWheatley%26aufirst%3DD.%26aulast%3DBrunt%26aufirst%3DM.%26aulast%3DNemsadze%26aufirst%3DG.%26atitle%3DAZD5363%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528PAKT%2529%253A%2520A%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1007%26doi%3D10.1200%2FJCO.2018.36.15_suppl.1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. C.</span></span> <span> </span><span class="NLM_article-title">Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11010-011-0986-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1007%2Fs11010-011-0986-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=21769450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSis7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2012&pages=1-8&author=F.+Z.+Wangauthor=H.+R.+Feiauthor=X.+Q.+Liauthor=R.+J.+Shiauthor=D.+C.+Wang&title=Perifosine+as+potential+anti-cancer+agent+inhibits+proliferation%2C+migration%2C+and+tube+formation+of+human+umbilical+vein+endothelial+cells&doi=10.1007%2Fs11010-011-0986-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells</span></div><div class="casAuthors">Wang, Feng Ze; Fei, Hong Rong; Li, Xiao Qian; Shi, Renjiu; Wang, De Cai</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Targeting angiogenesis is considered an effective strategy for treating the expansion and metastasis of tumors.  The aim of this study is to assess the effects of perifosine, an inhibitor of Akt, on cell proliferation, apoptosis, angiogenesis, and VEGF-induced cell migration in cultured human umbilical vein endothelial cells (HUVECs) in vitro.  MTT and cell cycle anal. results indicated that perifosine inhibited the growth of HUVECs in a dose-dependent manner, arrested cell cycle progression at the G2 phase with regulation the expression of p21 and cyclinB1.  Apoptosis induced by the higher concns. of perifosine in HUVECs was also obsd.  In addn., tube formation of HUVECs and VEGF-induced cell migration were markedly inhibited by perifosine.  Western blotting anal. of cell signaling mols. indicated that perifosine inhibited ERK and p38 phosphorylation in HUVECs.  These results suggest that perifosine exerts anti-angiogenic activity in HUVECs and is a promising agent for treatment of angiogenesis related-diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ020Jvj8ttrVg90H21EOLACvtfcHk0lgM7SIDwY9kXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSis7%252FN&md5=8ba08521a5a7efa4e93148a02a95d3b8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11010-011-0986-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-011-0986-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%2BZ.%26aulast%3DFei%26aufirst%3DH.%2BR.%26aulast%3DLi%26aufirst%3DX.%2BQ.%26aulast%3DShi%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DD.%2BC.%26atitle%3DPerifosine%2520as%2520potential%2520anti-cancer%2520agent%2520inhibits%2520proliferation%252C%2520migration%252C%2520and%2520tube%2520formation%2520of%2520human%2520umbilical%2520vein%2520endothelial%2520cells%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2012%26volume%3D368%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11010-011-0986-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Pena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgan, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyamitra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofilon, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1510</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1535-7163.MCT-06-0091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16818509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1504-1510&author=L.+de%0Ala+Penaauthor=W.+E.+Burganauthor=D.+J.+Carterauthor=M.+G.+Hollingsheadauthor=M.+Satyamitraauthor=K.+Camphausenauthor=P.+J.+Tofilon&title=Inhibition+of+Akt+by+the+alkylphospholipid+perifosine+does+not+enhance+the+radiosensitivity+of+human+glioma+cells&doi=10.1158%2F1535-7163.MCT-06-0091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells</span></div><div class="casAuthors">De la Pena, Lorena; Burgan, William E.; Carter, Donna J.; Hollingshead, Melinda G.; Satyamitra, Merriline; Camphausen, Kevin; Tofilon, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1504-1510</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Akt has been implicated as a mol. determinant of cellular radiosensitivity.  Because it is often constitutively activated or overexpressed in malignant gliomas, it has been suggested as a target for brain tumor radiosensitization.  To evaluate the role of Akt in glioma radioresponse, we have detd. the effects of perifosine, a clin. relevant alkylphospholipid that inhibits Akt activation, on the radiosensitivity of three human glioma cell lines (U87, U251, and LN229).  Each of the glioma cell lines expressed clearly detectable levels of phosphorylated Akt indicative of constitutive Akt activity.  Exposure to a perifosine concn. that reduced survival by ∼50% significantly reduced the level of phosphorylated Akt as well as Akt activity.  Cell survival anal. using a clonogenic assay, however, revealed that this Akt-inhibiting perifosine treatment did not enhance the radiosensitivity of the glioma cell lines.  This evaluation was then extended to an in vivo model using U251 xenografts.  Perifosine delivered to mice bearing U251 xenografts substantially reduced tumor phosphorylated Akt levels and inhibited tumor growth rate.  However, the combination of perifosine and radiation resulted in a less than additive increase in tumor growth delay.  Thus, in vitro and in vivo data indicate that the perifosine-mediated decrease in Akt activity does not enhance the radiosensitivity of three genetically disparate glioma cell lines.  These results suggest that, although Akt may influence the radiosensitivity of other tumor types, it does not seem to be a target for glioma cell radiosensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbwPlDEi7AgbVg90H21EOLACvtfcHk0lgM7SIDwY9kXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVams7o%253D&md5=95230151934db74da1c6681e180b4805</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0091%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BPena%26aufirst%3DL.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BJ.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DSatyamitra%26aufirst%3DM.%26aulast%3DCamphausen%26aufirst%3DK.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26atitle%3DInhibition%2520of%2520Akt%2520by%2520the%2520alkylphospholipid%2520perifosine%2520does%2520not%2520enhance%2520the%2520radiosensitivity%2520of%2520human%2520glioma%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1504%26epage%3D1510%26doi%3D10.1158%2F1535-7163.MCT-06-0091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M. Z.</span></span> <span> </span><span class="NLM_article-title">The Akt inhibitor MK2206 synergizes, but Perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">E173</span>– <span class="NLM_lpage">E182</span>, <span class="refDoi"> DOI: 10.1210/jc.2011-1054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1210%2Fjc.2011-1054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22090271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=E173-E182&author=R.+X.+Liuauthor=D.+X.+Liuauthor=M.+Z.+Xing&title=The+Akt+inhibitor+MK2206+synergizes%2C+but+Perifosine+antagonizes%2C+the+BRAF%28V600E%29+inhibitor+PLX4032+and+the+MEK1%2F2+inhibitor+AZD6244+in+the+inhibition+of+thyroid+cancer+cells&doi=10.1210%2Fjc.2011-1054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells</span></div><div class="casAuthors">Liu, Ruixin; Liu, Dingxie; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E173-E182</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Purpose: The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras → Raf → MAPK kinase (MEK) → MAPK/ERK (MAPK) and the phosphatidylinositol 3-kinase/Akt pathways as effective treatments for thyroid cancer.  Exptl. Design: We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAFV600E inhibitor PLX4032 or the MEK1/2 inhibitor AZD6244 in thyroid cancer cells harboring both the BRAFV600E and PIK3CA mutations.  Results: We found that MK2206 could potently, when used alone, and synergistically, when combined with either PLX4032 or AZD6244, inhibit thyroid cancer cell growth with all the combination index values lower than 1.  Perifosine could potently inhibit thyroid cancer cell growth when used alone, but a strong antagonism occurred between this drug and PLX4032 or AZD6244 in the inhibition of thyroid cancer cell growth with all combination index values higher than 1.  Combinations of MK2206 with PLX4032 or AZD6244 dramatically enhanced G1 cell cycle arrest induced by each drug alone.  However, G2 cell cycle arrest uniquely induced by perifosine alone and G1 cell cycle arrest induced by PLX4032 or AZD6244 were both reversed by combination treatments, providing a mechanism for their antagonism.  All these drugs could correspondingly inhibit the MAPK and phosphatidylinositol 3-kinase/Akt signalings, confirming their expected target effects.  Conclusions: We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in their combinational treatments with BRAFV600E/MEK inhibitors in thyroid cancer cells.  The data may help appropriate selection of these prominent drugs for clin. trials of combination therapies for thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkIc9yMM23zrVg90H21EOLACvtfcHk0lgM7SIDwY9kXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOnsr8%253D&md5=c70cc0e1453c9d417230e2cfc6450a79</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fjc.2011-1054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2011-1054%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%2BX.%26aulast%3DLiu%26aufirst%3DD.%2BX.%26aulast%3DXing%26aufirst%3DM.%2BZ.%26atitle%3DThe%2520Akt%2520inhibitor%2520MK2206%2520synergizes%252C%2520but%2520Perifosine%2520antagonizes%252C%2520the%2520BRAF%2528V600E%2529%2520inhibitor%2520PLX4032%2520and%2520the%2520MEK1%252F2%2520inhibitor%2520AZD6244%2520in%2520the%2520inhibition%2520of%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26spage%3DE173%26epage%3DE182%26doi%3D10.1210%2Fjc.2011-1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">MK2206, an orally active allosteric AKT inhibitor, reverses progestin resistance in endometrial cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ygyno.2011.07.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=438-439&author=A.+Pantauthor=I.+Leeauthor=J.+Lurainauthor=J.+Schinkauthor=J.+Kim&title=MK2206%2C+an+orally+active+allosteric+AKT+inhibitor%2C+reverses+progestin+resistance+in+endometrial+cancer&doi=10.1016%2Fj.ygyno.2011.07.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DPant%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DLurain%26aufirst%3DJ.%26aulast%3DSchink%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DMK2206%252C%2520an%2520orally%2520active%2520allosteric%2520AKT%2520inhibitor%252C%2520reverses%2520progestin%2520resistance%2520in%2520endometrial%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2011%26volume%3D123%26spage%3D438%26epage%3D439%26doi%3D10.1016%2Fj.ygyno.2011.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safonov, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venslavsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1021/jm8004527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+H.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Y.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+AKT+kinase&doi=10.1021%2Fjm8004527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase</span></div><div class="casAuthors">Heerding, Dirk A.; Rhodes, Nelson; Leber, Jack D.; Clark, Tammy J.; Keenan, Richard M.; Lafrance, Louis V.; Li, Mei; Safonov, Igor G.; Takata, Dennis T.; Venslavsky, Joseph W.; Yamashita, Dennis S.; Choudhry, Anthony E.; Copeland, Robert A.; Lai, Zhihong; Schaber, Michael D.; Tummino, Peter J.; Strum, Susan L.; Wood, Edgar R.; Duckett, Derek R.; Eberwein, Derek; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Warren, Gregory L.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5663-5679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant neg. AKT blocks the ability of a variety of growth factors to promote survival.  Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT.  Herein, we describe our lead optimization studies culminating in the discovery of compd. 3g (GSK690693, I).  Compd. 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, resp.  An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket.  Compd. 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β.  I.p. administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAGkPktggErVg90H21EOLACvtfcHk0lipvzmyKs1x4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE&md5=c0e6f283a3ee79dffafdd90ec69513bc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%2BH.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520AKT%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5663%26epage%3D5679%26doi%3D10.1021%2Fjm8004527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">te Poele, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eve, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterlund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span> <span> </span><span class="NLM_article-title">AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3912</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1078-0432.CCR-11-3313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22781553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3912-3923&author=T.+A.+Yapauthor=M.+I.+Waltonauthor=K.+M.+Grimshawauthor=R.+H.+te+Poeleauthor=P.+D.+Eveauthor=M.+R.+Valentiauthor=A.+K.+D.+Brandonauthor=V.+Martinsauthor=A.+Zetterlundauthor=S.+P.+Heatonauthor=K.+Heinzmannauthor=P.+S.+Jonesauthor=R.+E.+Feltellauthor=M.+Reuleauthor=S.+J.+Woodheadauthor=T.+G.+Daviesauthor=J.+F.+Lyonsauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=P.+Workmanauthor=N.+T.+Thompsonauthor=M.+D.+Garrett&title=AT13148+is+a+novel%2C+oral+multi-AGC+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity&doi=10.1158%2F1078-0432.CCR-11-3313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity</span></div><div class="casAuthors">Yap, Timothy A.; Walton, Mike I.; Grimshaw, Kyla M.; te Poele, Robert H.; Eve, Paul D.; Valenti, Melanie R.; de Haven Brandon, Alexis K.; Martins, Vanessa; Zetterlund, Anna; Heaton, Simon P.; Heinzmann, Kathrin; Jones, Paul S.; Feltell, Ruth E.; Reule, Matthias; Woodhead, Steven J.; Davies, Thomas G.; Lyons, John F.; Raynaud, Florence I.; Eccles, Suzanne A.; Workman, Paul; Thompson, Neil T.; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3912-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers.  The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clin. resistance compared with a single pathway component.  Exptl. Design: We investigated the detailed pharmacol. and antitumor activity of the novel clin. drug candidate AT13148, an oral ATP-competitive multi-AGC kinase inhibitor.  Gene expression microarray studies were undertaken to characterize the mol. mechanisms of action of AT13148.  Results: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in a concn. and time-dependent manner in cancer cells with clin. relevant genetic defects in vitro and in vivo.  Antitumor efficacy in HER2-pos., PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer, and PTEN-deficient MES-SA uterine tumor xenografts was shown.  We show for the first time that induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step.  Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell-cycle genes.  Induction of upstream regulators including IRS2 and PIK3IP1 as a result of compensatory feedback loops was obsd.  Conclusions: The clin. candidate AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.  AT13148 will now be assessed in a first-in-human phase I trial.  Clin Cancer Res; 18(14); 3912-23. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3dYsAM8O1pLVg90H21EOLACvtfcHk0lipvzmyKs1x4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelur3O&md5=32dd4f817c4497762e678b8bb9df7503</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3313%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DGrimshaw%26aufirst%3DK.%2BM.%26aulast%3Dte%2BPoele%26aufirst%3DR.%2BH.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DBrandon%26aufirst%3DA.%2BK.%2BD.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DZetterlund%26aufirst%3DA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DHeinzmann%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DAT13148%2520is%2520a%2520novel%252C%2520oral%2520multi-AGC%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3912%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-11-3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Addie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, R. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1021/jm301762v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301762v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2059-2073&author=M.+Addieauthor=P.+Ballardauthor=D.+Buttarauthor=C.+Crafterauthor=G.+Currieauthor=B.+R.+Daviesauthor=J.+Debreczeniauthor=H.+Dryauthor=P.+Dudleyauthor=R.+Greenwoodauthor=P.+D.+Johnsonauthor=J.+G.+Kettleauthor=C.+Laneauthor=G.+Lamontauthor=A.+Leachauthor=R.+W.+A.+Lukeauthor=J.+Morrisauthor=D.+Ogilvieauthor=K.+Pageauthor=M.+Passauthor=S.+Pearsonauthor=L.+Ruston&title=Discovery+of+4-amino-N-%5B%281S%29-1-%284-chlorophenyl%29-3-hydroxypropyl%5D1-%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29piperidine-4-carboxamide+%28AZD5363%29%2C+an+orally+bioavailable%2C+potent+inhibitor+of+Akt+kinases&doi=10.1021%2Fjm301762v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases</span></div><div class="casAuthors">Addie, Matt; Ballard, Peter; Buttar, David; Crafter, Claire; Currie, Gordon; Davies, Barry R.; Debreczeni, Judit; Dry, Hannah; Dudley, Philippa; Greenwood, Ryan; Johnson, Paul D.; Kettle, Jason G.; Lane, Clare; Lamont, Gillian; Leach, Andrew; Luke, Richard W. A.; Morris, Jeff; Ogilvie, Donald; Page, Ken; Pass, Martin; Pearson, Stuart; Ruston, Linette</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2059-2073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-aralkyl aminopyrrolopyrimidinylpiperidinecarboxamides such as I (AZD5363) were prepd. as inhibitors of Akt kinases, particularly Akt1, Akt2, and Akt3 kinases, for potential use as antitumor agents based on a collaboratively-identified ATP-competitive pyrrolopyrimidine inhibitor of Akt kinases.  The selectivities of N-aralkyl aminopyrrolopyrimidinylpiperidinecarboxamides for Akt 1, Akt2, and Akt3 over ROCK2 and the hERG ion channel, their octanol-water partition coeffs., and their aq. solubilities were detd.  The oral pharmacokinetics of I in mice, rats, and dogs and the plasma protein binding of I in people, the inhibition of a panel of 75 kinases by I, and the activity of I against human cancer cell lines (particularly breast and prostate cancer) were detd.; I showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.  The structure of I bound to Akt1 was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFU3WrUUalYLVg90H21EOLACvtfcHk0lhqAcKgOF9-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsrw%253D&md5=847a03b036460fc14d85c860b0d08f5a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm301762v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301762v%26sid%3Dliteratum%253Aachs%26aulast%3DAddie%26aufirst%3DM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DCurrie%26aufirst%3DG.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DDebreczeni%26aufirst%3DJ.%26aulast%3DDry%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%2BD.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLeach%26aufirst%3DA.%26aulast%3DLuke%26aufirst%3DR.%2BW.%2BA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DPearson%26aufirst%3DS.%26aulast%3DRuston%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204-amino-N-%255B%25281S%2529-1-%25284-chlorophenyl%2529-3-hydroxypropyl%255D1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamide%2520%2528AZD5363%2529%252C%2520an%2520orally%2520bioavailable%252C%2520potent%2520inhibitor%2520of%2520Akt%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2059%26epage%3D2073%26doi%3D10.1021%2Fjm301762v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencsik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banka, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8110</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1021/jm301024w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301024w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8110-8127&author=J.+F.+Blakeauthor=R.+Xuauthor=J.+R.+Bencsikauthor=D.+Xiaoauthor=N.+C.+Kallanauthor=S.+Schlachterauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=A.+L.+Bankaauthor=E.+M.+Wallaceauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=R.+D.+Woessnerauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=J.+Liangauthor=B.+S.+Safinaauthor=J.+Liauthor=B.+R.+Zhangauthor=C.+Chabotauthor=S.+Doauthor=L.+Leeauthor=J.+Oehauthor=D.+Sampathauthor=B.+B.+Leeauthor=K.+Linauthor=B.+M.+Liedererauthor=N.+J.+Skelton&title=Discovery+and+preclinical+pharmacology+of+a+selective+ATP-competitive+Akt+inhibitor+%28GDC-0068%29+for+the+treatment+of+human+tumors&doi=10.1021%2Fjm301024w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors</span></div><div class="casAuthors">Blake, James F.; Xu, Rui; Bencsik, Josef R.; Xiao, Dengming; Kallan, Nicholas C.; Schlachter, Stephen; Mitchell, Ian S.; Spencer, Keith L.; Banka, Anna L.; Wallace, Eli M.; Gloor, Susan L.; Martinson, Matthew; Woessner, Richard D.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Liang, Jun; Safina, Brian S.; Li, Jun; Zhang, Birong; Chabot, Christine; Do, Steven; Lee, Leslie; Oeh, Jason; Sampath, Deepak; Lee, Brian B.; Lin, Kui; Liederer, Bianca M.; Skelton, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8110-8127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compds. that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported.  The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A.  The resulting compds. demonstrate potent inhibition of all three Akt isoforms in biochem. assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.  Biol. studies with one such compd., 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH24ZkuGlNLVg90H21EOLACvtfcHk0lhqAcKgOF9-oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K&md5=1fa690cda22a2548eb2795305e1c7253</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301024w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301024w%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBanka%26aufirst%3DA.%2BL.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%2BR.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520selective%2520ATP-competitive%2520Akt%2520inhibitor%2520%2528GDC-0068%2529%2520for%2520the%2520treatment%2520of%2520human%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8110%26epage%3D8127%26doi%3D10.1021%2Fjm301024w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e100880</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0100880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1371%2Fjournal.pone.0100880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24978597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1emur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Dumbleauthor=M.+C.+Crouthamelauthor=S.+Y.+Zhangauthor=M.+Schaberauthor=D.+Levyauthor=K.+Robellauthor=Q.+Liuauthor=D.+J.+Figueroaauthor=E.+A.+Minthornauthor=M.+A.+Seefeldauthor=M.+B.+Rouseauthor=S.+K.+Rabindranauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Discovery+of+novel+AKT+inhibitors+with+enhanced+anti-tumor+effects+in+combination+with+the+MEK+inhibitor&doi=10.1371%2Fjournal.pone.0100880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor</span></div><div class="casAuthors">Dumble, Melissa; Crouthamel, Ming-Chih; Zhang, Shu-Yun; Schaber, Michael; Levy, Dana; Robell, Kimberly; Liu, Qi; Figueroa, David J.; Minthorn, Elisabeth A.; Seefeld, Mark A.; Rouse, Meagan B.; Rabindran, Sridhar K.; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e100880/1-e100880/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies.  GSK2110183 and GSK2141795 are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to human clin. studies.  Both compds. are selective, ATP-competitive inhibitors of AKT 1, 2 and 3.  Cells treated with either compd. show decreased phosphorylation of several substrates downstream of AKT.  Both compds. have desirable pharmaceutical properties and daily oral dosing results in a sustained inhibition of AKT activity as well as inhibition of tumor growth in several mouse tumor models of various histol. origins.  Improved kinase selectivity was assocd. with reduced effects on glucose homeostasis as compared to previously reported ATP-competitive AKT kinase inhibitors.  In a diverse cell line proliferation screen, AKT inhibitors showed increased potency in cell lines with an activated AKT pathway (via PI3K/PTEN mutation or loss) while cell lines with activating mutations in the MAPK pathway (KRAS/BRAF) were less sensitive to AKT inhibition.  Further investigation in mouse models of KRAS driven pancreatic cancer confirmed that combining the AKT inhibitor, GSK2141795 with a MEK inhibitor (GSK2110212; trametinib) resulted in an enhanced anti-tumor effect accompanied with greater redn. in phospho-S6 levels.  Taken together these results support clin. evaluation of the AKT inhibitors in cancer, esp. in combination with MEK inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTrNdvuYoT8bVg90H21EOLACvtfcHk0lhDozNOm3K-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1emur3K&md5=893494388f4f390ae5a6bc3d30114c89</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0100880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0100880%26sid%3Dliteratum%253Aachs%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DCrouthamel%26aufirst%3DM.%2BC.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DRouse%26aufirst%3DM.%2BB.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520AKT%2520inhibitors%2520with%2520enhanced%2520anti-tumor%2520effects%2520in%2520combination%2520with%2520the%2520MEK%2520inhibitor%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0100880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span> <span> </span><span class="NLM_article-title">Ligand configurational entropy and protein binding</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1073/pnas.0610494104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1073%2Fpnas.0610494104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=17242351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslars7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=1534-1539&author=C.+E.+A.+Changauthor=W.+Chenauthor=M.+K.+Gilson&title=Ligand+configurational+entropy+and+protein+binding&doi=10.1073%2Fpnas.0610494104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand configurational entropy and protein binding</span></div><div class="casAuthors">Chang, Chia-en A.; Chen, Wei; Gilson, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1534-1539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The restriction of a small mol.'s motion on binding to a protein causes a loss of configurational entropy, and thus a penalty in binding affinity.  Some energy models used in computer-aided ligand design neglect this entropic penalty, whereas others account for it based on an expected drop in the no. of accessible rotamers upon binding.  However, the validity of the phys. assumptions underlying the various approaches is largely unexamd.  The present study addresses this issue by using Mining Min. calcns. to analyze the assocn. of amprenavir with HIV protease.  The computed loss in ligand configurational entropy is large, contributing ∼25 kcal/mol (4.184 kJ/kcal) to ΔGo.  Most of this loss results from narrower energy wells in the bound state, rather than a drop in the no. of accessible rotamers.  Coupling among rotation/translation and internal degrees of freedom complicates the decompn. of the entropy change into additive terms.  The results highlight the potential to gain affinity by designing conformationally restricted ligands and have implications for the formulation of energy models for ligand scoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQjA5K7LhZ7rVg90H21EOLACvtfcHk0lhDozNOm3K-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslars7o%253D&md5=4f02fd7cd32e6d605485efaebcb23ba8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0610494104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0610494104%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%2BE.%2BA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26atitle%3DLigand%2520configurational%2520entropy%2520and%2520protein%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D1534%26epage%3D1539%26doi%3D10.1073%2Fpnas.0610494104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&author=Z.+J.+Fangauthor=Y.+N.+Songauthor=P.+Zhanauthor=Q.+Z.+Zhangauthor=X.+Y.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%98follow-on%E2%80%99-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0lhDozNOm3K-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%2BJ.%26aulast%3DSong%26aufirst%3DY.%2BN.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%2BZ.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%2598follow-on%25E2%2580%2599-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9177</span>– <span class="NLM_lpage">9204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00819</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00819" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9177-9204&author=D.+Q.+Liauthor=X.+T.+Zhangauthor=X.+D.+Maauthor=L.+Xuauthor=J.+J.+Yuauthor=L.+X.+Gaoauthor=X.+B.+Huauthor=J.+K.+Zhangauthor=X.+W.+Dongauthor=J.+Liauthor=T.+Liuauthor=Y.+B.+Zhouauthor=Y.+Z.+Hu&title=Development+of+macrocyclic+peptides+containing+epoxyketone+with+oral+availability+as+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.8b00819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span></div><div class="casAuthors">Li, Daqiang; Zhang, Xiaotuan; Ma, Xiaodong; Xu, Lei; Yu, Jianjun; Gao, Lixin; Hu, Xiaobei; Zhang, Jiankang; Dong, Xiaowu; Li, Jia; Liu, Tao; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9177-9204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclization has been frequently utilized for optimizing peptide or peptidomimetic-based compds.  In an attempt to obtain potent, metabolically stable, and orally available proteasome inhibitors, 30 oprozomib-derived macrocyclic peptides with structural diversity in their N-terminus and linker were successively designed and synthesized for structure-activity relationship (SAR) studies.  As a consequence, the macrocyclic peptides with N-methyl-pyrazole, imidazole, and pyrazole as their resp. N-termini exhibited favorable in vitro activity and metabolic stability, which translated into their potent in vivo proteasome inhibitory activity after oral administration.  In particular, pyrazole-contg. compd. (I), as the most distinguished one among this series, displayed excellent chymotrypsin-like (ChT-L, β5) inhibitory potency (IC50 = 16 nM), low nanomolar antiproliferative activity against all three of the tested cell lines, and superior metabolic stability in mouse liver microsome (MLM), as well as favorable inhibition against ChT-L compared to that of oprozomib in BABL/c mice following administration at a comparatively low dose, thereby representing a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHTTVYr92xrVg90H21EOLACvtfcHk0lijseGVZLIHDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP&md5=958573573fe76d3b80e74fb0d7373c95</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00819%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%2BQ.%26aulast%3DZhang%26aufirst%3DX.%2BT.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DGao%26aufirst%3DL.%2BX.%26aulast%3DHu%26aufirst%3DX.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%2BK.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DDevelopment%2520of%2520macrocyclic%2520peptides%2520containing%2520epoxyketone%2520with%2520oral%2520availability%2520as%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9177%26epage%3D9204%26doi%3D10.1021%2Facs.jmedchem.8b00819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikamiyama-Iwata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvey, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span> <span> </span><span class="NLM_article-title">Carbamoyl pyridone HIV-1 integrase inhibitors. 2. bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1021/jm301550c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301550c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVeltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1124-1135&author=T.+Kawasujiauthor=B.+A.+Johnsauthor=H.+Yoshidaauthor=J.+G.+Weatherheadauthor=T.+Akiyamaauthor=T.+Taishiauthor=Y.+Taodaauthor=M.+Mikamiyama-Iwataauthor=H.+Muraiauthor=R.+Kiyamaauthor=M.+Fujiauthor=N.+Tanimotoauthor=T.+Yoshinagaauthor=T.+Sekiauthor=M.+Kobayashiauthor=A.+Satoauthor=E.+P.+Garveyauthor=T.+Fujiwara&title=Carbamoyl+pyridone+HIV-1+integrase+inhibitors.+2.+bi-+and+tricyclic+derivatives+result+in+superior+antiviral+and+pharmacokinetic+profiles&doi=10.1021%2Fjm301550c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles</span></div><div class="casAuthors">Kawasuji, Takashi; Johns, Brian A.; Yoshida, Hiroshi; Weatherhead, Jason G.; Akiyama, Toshiyuki; Taishi, Teruhiko; Taoda, Yoshiyuki; Mikamiyama-Iwata, Minako; Murai, Hitoshi; Kiyama, Ryuichi; Fuji, Masahiro; Tanimoto, Norihiko; Yoshinaga, Tomokazu; Seki, Takahiro; Kobayashi, Masanori; Sato, Akihiko; Garvey, Edward P.; Fujiwara, Tamio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1135</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties.  We report herein a series of bicyclic carbamoylpyridone (I; satd. and unsatd. bridge; R = e.g., alkoxyethyl) analogs to address conformational issues from our initial SAR studies.  This modification of the core unit succeeded to deliver low nanomolar potency in std. antiviral assays.  An addnl. hydroxyl substituent on the bicyclic scaffold provides remarkable improvement of antiviral efficacies against clin. relevant resistant viruses.  These findings led to addnl. cyclic tethering of the naked hydroxyl group resulting in tricyclic carbamoyl pyridone inhibitors (II; Y = O, N; n = 0-2; R' = e.g., alkyl, Ac, methanesulfonyl) to address remaining issues and deliver potential clin. candidates.  The tricyclic carbamoyl pyridone derivs. described herein served as the immediate leads in mols. to the next generation integrase inhibitor dolutegravir which is currently in late stage clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLpPj5UB1TbVg90H21EOLACvtfcHk0lijseGVZLIHDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVeltA%253D%253D&md5=4bfe919f8fdbbc84e346e3f01e084b70</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301550c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301550c%26sid%3Dliteratum%253Aachs%26aulast%3DKawasuji%26aufirst%3DT.%26aulast%3DJohns%26aufirst%3DB.%2BA.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DWeatherhead%26aufirst%3DJ.%2BG.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DTaishi%26aufirst%3DT.%26aulast%3DTaoda%26aufirst%3DY.%26aulast%3DMikamiyama-Iwata%26aufirst%3DM.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DKiyama%26aufirst%3DR.%26aulast%3DFuji%26aufirst%3DM.%26aulast%3DTanimoto%26aufirst%3DN.%26aulast%3DYoshinaga%26aufirst%3DT.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DGarvey%26aufirst%3DE.%2BP.%26aulast%3DFujiwara%26aufirst%3DT.%26atitle%3DCarbamoyl%2520pyridone%2520HIV-1%2520integrase%2520inhibitors.%25202.%2520bi-%2520and%2520tricyclic%2520derivatives%2520result%2520in%2520superior%2520antiviral%2520and%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1124%26epage%3D1135%26doi%3D10.1021%2Fjm301550c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2016.03.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=27089211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=47-58&author=W.+H.+Zhanauthor=L.+Xuauthor=X.+W.+Dongauthor=J.+Dongauthor=X.+Yiauthor=X.+D.+Maauthor=N.+Qiuauthor=J.+Liauthor=B.+Yangauthor=Y.+B.+Zhouauthor=Y.+Z.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+pyrazol-furan+carboxamide+analogues+as+novel+Akt+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2016.03.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Xu, Lei; Dong, Xiaowu; Dong, Jun; Yi, Xiao; Ma, Xiaodong; Qiu, Ni; Li, Jia; Yang, Bo; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-58</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel pyrazolylfuran carboxamides I (24a-d; X = S, R2 = R3 = H; R1, R4: a, H, 4-F; b, Cl, 4-F; c, Br, 4-F; d, H, 3,4-Cl2; 25a-e, X = O, R3 = H, R1, R2, R4: a, Cl, H, 4-F; b, Br, H, 4-F; c, Br, H, 3,4-Cl2; d, Cl, Cl, 4-F; e, Cl, Cl, 3,4-Cl2; 27a-c, X = NMe, R1, R2, R3, R4: a, Br, H, H, 3,4-Cl2; b, Br, Br, H, 3,4-Cl2; c, Cl, Cl, Cl, 3,4-Cl2) and II (26a-c; R1, R2, R4: a, H, Br, 3,4-Cl2; b, Cl, Br, 3,4-Cl2; c, Br, Br, 3,4-Cl2) were designed, synthesized and biol. evaluated for their Akt1 inhibitory activities, as well as anti-proliferative efficacies against HCT116 and OVCAR-8 cell lines.  Most compds. exhibited moderate to excellent Akt1 inhibitory activities, together with favorable cytotoxicities.  Further kinase selectivity assay of the most promising compd. 25e illustrated that it was also potent against the structurally related AGC kinases, including Akt2, Akt3, ROCK1 and PKA, but was specific over kinases from other subfamilies.  In addn., the Western blot anal. indicated that 25e could significantly suppress the phosphorylation level of Akt substrate GSK3β in PC-3 cell.  Moreover, 25e demonstrated a concn.-dependent inhibition of phosphorylation of PRAS40 in LNCaP cell, with IC50 value of 30.4 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQIDQke8QD2bVg90H21EOLACvtfcHk0lijseGVZLIHDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyms7g%253D&md5=d51bdaff3ed97681b60ce4bd451d2dec</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.074%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DQiu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520pyrazol-furan%2520carboxamide%2520analogues%2520as%2520novel%2520Akt%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D117%26spage%3D47%26epage%3D58%26doi%3D10.1016%2Fj.ejmech.2016.03.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24389511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=167-176&author=T.+Liuauthor=W.+H.+Zhanauthor=Y.+M.+Wangauthor=L.+R.+Zhangauthor=B.+Yangauthor=X.+W.+Dongauthor=Y.+Z.+Hu&title=Structure-based+design%2C+synthesis+and+biological+evaluation+of+diphenylmethylamine+derivatives+as+novel+Akt1+inhibitors&doi=10.1016%2Fj.ejmech.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors</span></div><div class="casAuthors">Liu, Tao; Zhan, Wenhu; Wang, Yanming; Zhang, Liangren; Yang, Bo; Dong, Xiaowu; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of diphenylmethylamines, e.g. I [R = Ph, PhCH2, i-Pr, etc.] were rationally designed, synthesized and biol. evaluated.  Most of them exhibited moderate to good Akt1 inhibitory activities, as well as promising antiproliferative efficacy against cancer cell lines.  Mol. docking studies were carried out to probe their binding modes with Akt1.  Kinase selectivity studies of compd. I [R = t-Bu] were performed, indicating its excellent selectivity against Aurora A, Drak, IKKβ, GSK3β, SYK and JAK2, and moderate selectivity against PKC and BRAF.  Finally, a refined pharmacophore model was generated using three active compds. including I [R = t-Bu] via application of HipHop program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIQGyEG5nUbVg90H21EOLACvtfcHk0ljIRK73Bo70Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSju70%253D&md5=95c280f28d1af9788de6f29e0f90bc49</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520diphenylmethylamine%2520derivatives%2520as%2520novel%2520Akt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D167%26epage%3D176%26doi%3D10.1016%2Fj.ejmech.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W. T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1111%2Fcbdd.12489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=25453512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1ajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2015&pages=770-779&author=W.+H.+Zhanauthor=S.+D.+Linauthor=J.+Chenauthor=X.+W.+Dongauthor=J.+B.+Chuauthor=W.+T.+Du&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+molecular+docking+of+novel+benzopyran+and+phenylpyrazole+derivatives+as+Akt+inhibitors&doi=10.1111%2Fcbdd.12489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Lin, Sendong; Chen, Jing; Dong, Xiaowu; Chu, Jianbo; Du, Wenting</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">770-779</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">By inspiration of good Akt1 inhibitory and cytotoxic activity of the authors' previously screened hits (I) and (II), a series of novel benzopyrans and phenylpyrazoles were designed, synthesized, and biol. evaluated for their in vitro Akt1 inhibitory and cytotoxic activity.  The results revealed that all of these compds. showed moderate-to-excellent antiproliferative effects against the tested cancer cell lines (i.e., HL-60, OVCAR, PC-3, and HepG2).  Among them, compds. 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-6-(morpholinomethyl)-4H-chromen-4-one (3a) and 6-[[benzyl(methyl)amino]methyl]-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one (3c) exhibited preferable Akt1 inhibitory activities (IC50 of 3a and 3c are 6.18 and 5.28 μM, resp.), while the other compds. only showed weak Akt1 inhibitory activities.  Consequently, the authors used mol. docking and dynamic simulation to propose a mode of binding between Akt1 and the 3c compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrItReU0mg_-rVg90H21EOLACvtfcHk0ljIRK73Bo70Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1ajs7g%253D&md5=b36863fb8a392b7f97f52a8cea9fbeaa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12489%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DLin%26aufirst%3DS.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DChu%26aufirst%3DJ.%2BB.%26aulast%3DDu%26aufirst%3DW.%2BT.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520of%2520novel%2520benzopyran%2520and%2520phenylpyrazole%2520derivatives%2520as%2520Akt%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D85%26spage%3D770%26epage%3D779%26doi%3D10.1111%2Fcbdd.12489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span> <span> </span><span class="NLM_article-title">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2014.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24508830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1Krsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2014&pages=11-20&author=W.+H.+Zhanauthor=D.+Q.+Liauthor=J.+X.+Cheauthor=L.+R.+Zhangauthor=B.+Yangauthor=Y.+Z.+Huauthor=T.+Liuauthor=X.+W.+Dong&title=Integrating+docking+scores%2C+interaction+profiles+and+molecular+descriptors+to+improve+the+accuracy+of+molecular+docking%3A+Toward+the+discovery+of+novel+Akt1+inhibitors&doi=10.1016%2Fj.ejmech.2014.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Li, Daqiang; Che, Jinxin; Zhang, Liangren; Yang, Bo; Hu, Yongzhou; Liu, Tao; Dong, Xiaowu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of forty-seven Akt1 inhibitors was used for the development of mol. docking based QSAR model by using nonlinear regression.  The integration of docking scores, key interaction profiles and mol. descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R2train = 0.948, R2test = 0.907 and Q2cv = 0.794).  The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivs. was further performed, and six compds. 56a,b and 60a-d with good prediction activities were synthesized and biol. evaluated.  All of these compds. exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofYK7H5o1DO7Vg90H21EOLACvtfcHk0ljIRK73Bo70Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1Krsb0%253D&md5=8c21718c0d9a2e19d97004f7061dce62</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BQ.%26aulast%3DChe%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DX.%2BW.%26atitle%3DIntegrating%2520docking%2520scores%252C%2520interaction%2520profiles%2520and%2520molecular%2520descriptors%2520to%2520improve%2520the%2520accuracy%2520of%2520molecular%2520docking%253A%2520Toward%2520the%2520discovery%2520of%2520novel%2520Akt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D75%26spage%3D11%26epage%3D20%26doi%3D10.1016%2Fj.ejmech.2014.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5958</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2011.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22027102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKqtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5949-5958&author=X.+W.+Dongauthor=X.+L.+Zhouauthor=H.+Jingauthor=J.+Z.+Chenauthor=T.+Liuauthor=B.+Yangauthor=Q.+J.+Heauthor=Y.+Z.+Hu&title=Pharmacophore+identification%2C+virtual+screening+and+biological+evaluation+of+prenylated+flavonoids+derivatives+as+PKB%2FAkt1+inhibitors&doi=10.1016%2Fj.ejmech.2011.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors</span></div><div class="casAuthors">Dong, Xiaowu; Zhou, Xinglu; Jing, Hui; Chen, Jianzhong; Liu, Tao; Yang, Bo; He, Qiaojun; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5949-5958</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A total of 24 well-defined PKB/Akt1 inhibitors were used to generate pharmacophore models applying Catalyst/HypoGen program.  The best ranked model (Hypo_1) was then validated by cost anal., prediction capability, Cat-Scramble and receiver operating characteristic (ROC) studies.  Then, pharmacophore-based virtual screening combined with docking study was performed to search an inhouse compd. database.  Nine preferable hits 75-80, HTS-02143, BTB-14740 and HTS-08006 were prepd. and biol. evaluated.  Several compds. were identified as good PKB/Akt1 inhibitors, suggesting that Hypo_1 would be reliable and useful in virtual screening.  Flow cytometric and western blotting anal. on compds. 79 and 80 further demonstrated that the inhibition of phosphorylation of PKB/Akt1 and its substrates (such as GSK3β) was responsible for their cytotoxic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTEc-nFDC_rVg90H21EOLACvtfcHk0ljIRK73Bo70Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKqtLnE&md5=e563fb1a3ea5bbbc7c1ebff8753f38cf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DZhou%26aufirst%3DX.%2BL.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%2BJ.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DPharmacophore%2520identification%252C%2520virtual%2520screening%2520and%2520biological%2520evaluation%2520of%2520prenylated%2520flavonoids%2520derivatives%2520as%2520PKB%252FAkt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5949%26epage%3D5958%26doi%3D10.1016%2Fj.ejmech.2011.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span> <span> </span><span class="NLM_article-title">Aminofurazans as potent inhibitors of AKT kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1511</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=19179070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Wmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1508-1511&author=M.+B.+Rouseauthor=M.+A.+Seefeldauthor=J.+D.+Leberauthor=K.+C.+McNultyauthor=L.+Sunauthor=W.+H.+Millerauthor=S.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=A.+E.+Choudhryauthor=M.+D.+Schaberauthor=D.+A.+Heerding&title=Aminofurazans+as+potent+inhibitors+of+AKT+kinase&doi=10.1016%2Fj.bmcl.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aminofurazans as potent inhibitors of AKT kinase</span></div><div class="casAuthors">Rouse, Meagan B.; Seefeld, Mark A.; Leber, Jack D.; McNulty, Kenneth C.; Sun, Lihui; Miller, William H.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Choudhry, Anthony E.; Schaber, Michael D.; Heerding, Dirk A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1508-1511</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">AKT inhibitors contg. an imidazopyridine aminofurazan scaffold have been optimized.  The AKT inhibitor GSK690693 has been evaluated in clin. trials in cancer patients.  Recent efforts focusing on investigating a distinct region of this scaffold that have afforded compds. with comparable activity profiles to that of GSK690693 are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLJTnRWaL7-rVg90H21EOLACvtfcHk0lh2mxBQ27bPhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Wmt70%253D&md5=76d4a0780040e628b40001d687ecfab6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRouse%26aufirst%3DM.%2BB.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMcNulty%26aufirst%3DK.%2BC.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26atitle%3DAminofurazans%2520as%2520potent%2520inhibitors%2520of%2520AKT%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1508%26epage%3D1511%26doi%3D10.1016%2Fj.bmcl.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bencsik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dizon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7037</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.09.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+M.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.+I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors&doi=10.1016%2Fj.bmcl.2010.09.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0lh2mxBQ27bPhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.%2BI.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041%26doi%3D10.1016%2Fj.bmcl.2010.09.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferson, A. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: Synthesis and SAR studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4163</span>– <span class="NLM_lpage">4168</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2006.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16765046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFersLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4163-4168&author=X.+D.+Linauthor=J.+M.+Murrayauthor=A.+C.+Ricoauthor=M.+X.+Wangauthor=D.+T.+Chuauthor=Y.+S.+Zhouauthor=M.+Del+Rosarioauthor=S.+Kaufmanauthor=S.+Maauthor=E.+Fangauthor=K.+Crawfordauthor=A.+B.+Jefferson&title=Discovery+of+2-pyrimidyl-5-amidothiophenes+as+potent+inhibitors+for+AKT%3A+Synthesis+and+SAR+studies&doi=10.1016%2Fj.bmcl.2006.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: Synthesis and SAR studies</span></div><div class="casAuthors">Lin, Xiaodong; Murray, Jeremy M.; Rico, Alice C.; Wang, Michael X.; Chu, Daniel T.; Zhou, Yasheen; Del Rosario, Merci; Kaufman, Susan; Ma, Sylvia; Fang, Eric; Crawford, Kenneth; Jefferson, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4163-4168</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-pyrimidyl-5-amidothiophenes I (R1 = R2 = H, Me; R1 = H, R2 = Me, Et, n-Pr; R3 = 4-FC6H4, 4-FC6H4CH2, 2,4-Cl2C6H3CH2CH2, (S)-PhCH(NH2)CH2, etc.) has been synthesized and evaluated for AKT kinase inhibition.  SAR studies resulted in potent inhibitors of AKT with IC50 values as low as single digit nanomolar as represented by I [R1 = H; R2 = Me; R3 = (S)-2,4-Cl2C6H3CH2CH(CH2NH2); (II)].  II showed cellular activity including antiproliferation and downstream target modulation.  Selectivity profile is described.  A co-crystal of II with PKA is detd. and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr13M2t7ZYPSrVg90H21EOLACvtfcHk0liIZrZSlRJbcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFersLg%253D&md5=b1ef161c712fc4c0cf6415b5caf407f5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DRico%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BX.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DZhou%26aufirst%3DY.%2BS.%26aulast%3DDel%2BRosario%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DJefferson%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%25202-pyrimidyl-5-amidothiophenes%2520as%2520potent%2520inhibitors%2520for%2520AKT%253A%2520Synthesis%2520and%2520SAR%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4163%26epage%3D4168%26doi%3D10.1016%2Fj.bmcl.2006.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. W.</span></span> <span> </span><span class="NLM_article-title">Assembly of 4-substituted 3-nitro-1,2,3,4-tetrahydropyridines via organocatalytic Michael addition</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1002/adsc.201100903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1002%2Fadsc.201100903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2012&pages=991-994&author=L.+L.+Huoauthor=A.+Q.+Maauthor=Y.+H.+Zhangauthor=D.+W.+Ma&title=Assembly+of+4-substituted+3-nitro-1%2C2%2C3%2C4-tetrahydropyridines+via+organocatalytic+Michael+addition&doi=10.1002%2Fadsc.201100903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly of 4-Substituted 3-Nitro-1,2,3,4-tetrahydropyridines via Organocatalytic Michael Addition</span></div><div class="casAuthors">Huo, Lele; Ma, Anqi; Zhang, Yihua; Ma, Dawei</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-994</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An organocatalytic Michael addn. of protected 2-amino-1-nitroethanes to α,β-unsatd. aldehydes followed by treatment with TFA afforded 4-substituted 3-nitro-1,2,3,4-tetrahydropyridines with good diastereoselectivity and excellent enantioselectivity.  Good yields were obsd. in the case of β-aryl-substituted α,β-unsatd. aldehydes as the substrates, while moderate yields were obtained when β-alkyl-substituted α,β-unsatd. aldehydes were used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjw3Plra58LVg90H21EOLACvtfcHk0liIZrZSlRJbcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGrt7w%253D&md5=5b7d4721dad948c135b09819da174ef6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201100903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201100903%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DA.%2BQ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BW.%26atitle%3DAssembly%2520of%25204-substituted%25203-nitro-1%252C2%252C3%252C4-tetrahydropyridines%2520via%2520organocatalytic%2520Michael%2520addition%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2012%26volume%3D354%26spage%3D991%26epage%3D994%26doi%3D10.1002%2Fadsc.201100903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. F.</span></span> <span> </span><span class="NLM_article-title">DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6944</span>– <span class="NLM_lpage">6958</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.18632%2Foncotarget.3128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=25749514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A280%3ADC%252BC2MnitFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6944-6958&author=J.+Qinauthor=J.+Jiauthor=R.+Dengauthor=J.+Tangauthor=F.+Yangauthor=G.+K.+Fengauthor=W.+D.+Chenauthor=X.+Q.+Wuauthor=X.+J.+Qianauthor=K.+Dingauthor=X.+F.+Zhu&title=DC120%2C+a+novel+AKT+inhibitor%2C+preferentially+suppresses+nasopharyngeal+carcinoma+cancer+stem-like+cells+by+downregulating+Sox2&doi=10.18632%2Foncotarget.3128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2</span></div><div class="casAuthors">Qin Juan; Ji Jiao; Deng Rong; Tang Jun; Yang Fen; Feng Gong-Kan; Chen Wen-Dan; Wu Xiao-Qi; Qian Xiao-Jun; Zhu Xiao-Feng; Tang Jun; Ding Ke; Ding Ke</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6944-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Side population (SP) contains cancer stem-like cells (CSLCs).  In this study, we characterized SP cells from nasopharyngeal carcinoma (NPC) cell lines and found that SP cells had a higher self-renewal ability in vitro and greater tumorigenicity in vivo.  The AKT pathway was activated in NPC SP cells.  DC120, a 2-pyrimidyl-5-amidothiazole inhibitor of the ATP binding site of AKT, inhibited phosphorylation of FKHRL1 and GSK-3β.  DC120 inhibited SP fraction, the sphere-forming ability in vitro and growth of primary xenografts as well as secondary xenografts' tumor recurrence.  This inhibition was accompanied by reduced expression of stem-related gene Sox2 due to induction of p27 and miR-30a.  A combination of DC120 and CDDP more effectively inhibited NPC cells compared with monotherapy in vitro and in vivo.  Clinical evaluation of DC120 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5Ma1donXoAmLFM_lbR1VmfW6udTcc2ebVB94JCoyTH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnitFGkuw%253D%253D&md5=121bde0f172b2be926daae6de66365a8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3128%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BD.%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DQian%26aufirst%3DX.%2BJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%2BF.%26atitle%3DDC120%252C%2520a%2520novel%2520AKT%2520inhibitor%252C%2520preferentially%2520suppresses%2520nasopharyngeal%2520carcinoma%2520cancer%2520stem-like%2520cells%2520by%2520downregulating%2520Sox2%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D6944%26epage%3D6958%26doi%3D10.18632%2Foncotarget.3128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricketts, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chresta, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0824-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1535-7163.MCT-11-0824-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22294718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-887&author=B.+R.+Daviesauthor=H.+Greenwoodauthor=P.+Dudleyauthor=C.+Crafterauthor=D.+H.+Yuauthor=J.+C.+Zhangauthor=J.+Liauthor=B.+R.+Gaoauthor=Q.+S.+Jiauthor=J.+Maynardauthor=S.+A.+Rickettsauthor=D.+Crossauthor=S.+Cosulichauthor=C.+C.+Chrestaauthor=K.+Pageauthor=J.+Yatesauthor=C.+Laneauthor=R.+Watsonauthor=R.+Lukeauthor=D.+Ogilvieauthor=M.+Pass&title=Preclinical+pharmacology+of+AZD5363%2C+an+inhibitor+of+AKT%3A+pharmacodynamics%2C+antitumor+activity%2C+and+correlation+of+monotherapy+activity+with+genetic+background&doi=10.1158%2F1535-7163.MCT-11-0824-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background</span></div><div class="casAuthors">Davies, Barry R.; Greenwood, Hannah; Dudley, Phillippa; Crafter, Claire; Yu, De-Hua; Zhang, Jingchuan; Li, Jing; Gao, Beirong; Ji, Qunsheng; Maynard, Juliana; Ricketts, Sally-Ann; Cross, Darren; Cosulich, Sabina; Chresta, Christine C.; Page, Ken; Yates, James; Lane, Clare; Watson, Rebecca; Luke, Richard; Ogilvie, Donald; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AKT is a key node in the most frequently deregulated signaling network in human cancer.  AZD5363, a novel pyrrolopyrimidine-derived compd., inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approx. 0.3 to 0.8 μmol/L.  AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematol. tumor cell lines with a potency of 3 μmol/L or less.  Cell lines derived from breast cancers showed the highest frequency of sensitivity.  There was a significant relationship between the presence of PIK3CA and/or PTEN mutations and sensitivity to AZD5363 and between RAS mutations and resistance.  Oral dosing of AZD5363 to nude mice caused dose- and time-dependent redn. of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 ∼ 0.1 μmol/L total plasma exposure), reversible increases in blood glucose concns., and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts.  Chronic oral dosing of AZD5363 caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab.  AZD5363 also significantly enhanced the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts.  It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematol. tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS.  AZD5363 is currently in phase I clin. trials.  Mol Cancer Ther; 11(4); 873-87.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjG0wV4TyO57Vg90H21EOLACvtfcHk0lgSb5wvIlSmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D&md5=6ddcc67247fd07fd086baa03077983bd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0824-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0824-T%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DGreenwood%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DB.%2BR.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMaynard%26aufirst%3DJ.%26aulast%3DRicketts%26aufirst%3DS.%2BA.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DChresta%26aufirst%3DC.%2BC.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacology%2520of%2520AZD5363%252C%2520an%2520inhibitor%2520of%2520AKT%253A%2520pharmacodynamics%252C%2520antitumor%2520activity%252C%2520and%2520correlation%2520of%2520monotherapy%2520activity%2520with%2520genetic%2520background%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D887%26doi%3D10.1158%2F1535-7163.MCT-11-0824-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirtcliff, L. D.</span></span> <span> </span><span class="NLM_article-title">Syntheses and properties of 1,6 and 1,7 perylene diimides and tetracarboxylic dianhydrides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4724</span>– <span class="NLM_lpage">4727</span>, <span class="refDoi"> DOI: 10.1021/ol2019407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol2019407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=4724-4727&author=N.+V.+Handaauthor=K.+D.+Mendozaauthor=L.+D.+Shirtcliff&title=Syntheses+and+properties+of+1%2C6+and+1%2C7+perylene+diimides+and+tetracarboxylic+dianhydrides&doi=10.1021%2Fol2019407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Properties of 1,6 and 1,7 Perylene Diimides and Tetracarboxylic Dianhydrides</span></div><div class="casAuthors">Handa, Nisha V.; Mendoza, Kayla D.; Shirtcliff, Laura D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4724-4727</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,6 And 1,7 perylene diimides (PDIs) and perylene tetracarboxylic dianhydrides (PTCDs), e.g., I, were synthesized from the corresponding regioisomeric mixt. of 1,6/1,7-dibromo precursors, via Sonogashira cross-coupling with different alkynes,.  Both bulky tri-Ph propyne (TPP) groups and nonbulky hexyl groups allow for facile chromatog. sepn.  The optical properties of these compds. are discussed.  Neutral bay substituents hypsochromically shift both the absorption and emission through deformation from planarity of the perylene core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojeGhh4Q9jF7Vg90H21EOLACvtfcHk0lgSb5wvIlSmgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtLvI&md5=b12fab3f848d16a8519b3505b9e5b73e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol2019407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol2019407%26sid%3Dliteratum%253Aachs%26aulast%3DHanda%26aufirst%3DN.%2BV.%26aulast%3DMendoza%26aufirst%3DK.%2BD.%26aulast%3DShirtcliff%26aufirst%3DL.%2BD.%26atitle%3DSyntheses%2520and%2520properties%2520of%25201%252C6%2520and%25201%252C7%2520perylene%2520diimides%2520and%2520tetracarboxylic%2520dianhydrides%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D4724%26epage%3D4727%26doi%3D10.1021%2Fol2019407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jinxin Che, Zegao Jin, Fangjie Yan, Jieqiong You, Jiangfeng Xie, Binhui Chen, Gang Cheng, Hong Zhu, Qiaojun He, Yongzhou Hu, Bo Yang, Ji Cao, <span class="NLM_string-name hlFld-ContribAuthor">Xiaowu Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 5,6-Bis(4-methoxy-3-methylphenyl)pyridin-2-amine as a WSB1 Degrader to Inhibit Cancer Cell Metastasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8621-8643. <a href="https://doi.org/10.1021/acs.jmedchem.1c00586" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00586%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B5%25252C6-Bis%2525284-methoxy-3-methylphenyl%252529pyridin-2-amine%252Bas%252Ba%252BWSB1%252BDegrader%252Bto%252BInhibit%252BCancer%252BCell%252BMetastasis%26aulast%3DChe%26aufirst%3DJinxin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D31032021%26date%3D01062021%26volume%3D64%26issue%3D12%26spage%3D8621%26epage%3D8643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F.  Sadeghi</span>, <span class="hlFld-ContribAuthor ">A.  Afkhami</span>, <span class="hlFld-ContribAuthor ">T.  Madrakian</span>, <span class="hlFld-ContribAuthor ">R.  Ghavami</span>. </span><span class="cited-content_cbyCitation_article-title">Computational study on subfamilies of piperidine derivatives: QSAR modelling, model external verification, the inter-subset similarity determination, and structure-based drug designing. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2021,</strong> <em>32 </em>
                                    (6)
                                     , 433-462. <a href="https://doi.org/10.1080/1062936X.2021.1891568" title="DOI URL">https://doi.org/10.1080/1062936X.2021.1891568</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2021.1891568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2021.1891568%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DComputational%252Bstudy%252Bon%252Bsubfamilies%252Bof%252Bpiperidine%252Bderivatives%25253A%252BQSAR%252Bmodelling%25252C%252Bmodel%252Bexternal%252Bverification%25252C%252Bthe%252Binter-subset%252Bsimilarity%252Bdetermination%25252C%252Band%252Bstructure-based%252Bdrug%252Bdesigning%26aulast%3DSadeghi%26aufirst%3DF.%26date%3D2021%26date%3D2021%26volume%3D32%26issue%3D6%26spage%3D433%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Yizhen  Jin</span>, <span class="hlFld-ContribAuthor ">Bingxue  Qu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">An updated patent review of Akt inhibitors (2016-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>129 </em>, 1-13. <a href="https://doi.org/10.1080/13543776.2021.1915291" title="DOI URL">https://doi.org/10.1080/13543776.2021.1915291</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1915291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1915291%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAn%252Bupdated%252Bpatent%252Breview%252Bof%252BAkt%252Binhibitors%252B%2525282016-present%252529%26aulast%3DGuo%26aufirst%3DYu%26date%3D2021%26date%3D2021%26volume%3D129%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">彦凯  王</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Small Molecule Inhibitors of Akt Kinase—Overview of ATP Competitive Inhibitor Research. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organic Chemistry Research</span><span> <strong>2021,</strong> <em>09 </em>
                                    (02)
                                     , 13-21. <a href="https://doi.org/10.12677/JOCR.2021.92003" title="DOI URL">https://doi.org/10.12677/JOCR.2021.92003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/JOCR.2021.92003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FJOCR.2021.92003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organic%2520Chemistry%2520Research%26atitle%3DResearch%252BProgress%252Bof%252BSmall%252BMolecule%252BInhibitors%252Bof%252BAkt%252BKinase%2525E2%252580%252594Overview%252Bof%252BATP%252BCompetitive%252BInhibitor%252BResearch%26aulast%3D%25E7%258E%258B%26aufirst%3D%25E5%25BD%25A6%25E5%2587%25AF%26date%3D2021%26volume%3D09%26issue%3D02%26spage%3D13%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxin  Che</span>, <span class="hlFld-ContribAuthor ">Feng  Huang</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoya  Xu</span>, <span class="hlFld-ContribAuthor ">Bingxue  Qu</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Binhui  Chen</span>, <span class="hlFld-ContribAuthor ">Jianjun  Zhang</span>, <span class="hlFld-ContribAuthor ">Huazhou  Ying</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Anhui  Gao</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112491. <a href="https://doi.org/10.1016/j.ejmech.2020.112491" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112491%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%25252C%252Bsynthesis%252Band%252Bbioactivity%252Bevaluation%252Bof%252Bmacrocyclic%252Binhibitors%252Bof%252Bmutant%252Bisocitrate%252Bdehydrogenase%252B2%252B%252528IDH2%252529%252Bdisplaying%252Bactivity%252Bin%252Bacute%252Bmyeloid%252Bleukemia%252Bcells%26aulast%3DChe%26aufirst%3DJinxin%26date%3D2020%26volume%3D203%26spage%3D112491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayesha  Bari</span>, <span class="hlFld-ContribAuthor ">Ahsan  Iqbal</span>, <span class="hlFld-ContribAuthor ">Zulfiqar Ali  Khan</span>, <span class="hlFld-ContribAuthor ">Sohail Anjum  Shahzad</span>, <span class="hlFld-ContribAuthor ">Muhammad  Yar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic approaches toward piperidine related structures: A review. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2020,</strong> <em>50 </em>
                                    (17)
                                     , 2572-2589. <a href="https://doi.org/10.1080/00397911.2020.1776878" title="DOI URL">https://doi.org/10.1080/00397911.2020.1776878</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2020.1776878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2020.1776878%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthetic%252Bapproaches%252Btoward%252Bpiperidine%252Brelated%252Bstructures%25253A%252BA%252Breview%26aulast%3DBari%26aufirst%3DAyesha%26date%3D2020%26date%3D2020%26volume%3D50%26issue%3D17%26spage%3D2572%26epage%3D2589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samaresh  Jana</span>, <span class="hlFld-ContribAuthor ">Sohini  Sarkar</span>, <span class="hlFld-ContribAuthor ">Scott A.  Morris</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments towards the synthesis of paroxetine: A 3,4-disubstituted piperidine. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>25 </em>, 131215. <a href="https://doi.org/10.1016/j.tet.2020.131215" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131215%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DRecent%252Bdevelopments%252Btowards%252Bthe%252Bsynthesis%252Bof%252Bparoxetine%25253A%252BA%252B3%25252C4-disubstituted%252Bpiperidine%26aulast%3DJana%26aufirst%3DSamaresh%26date%3D2020%26volume%3D25%26spage%3D131215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative Akt inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design rationale based on the structures of <b>GSK-795</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Profiles of in vitro and in vivo biological activities and safety issues of compound <b>A12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Strategies for further optimization of compound <b>A12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>E22</b> inhibits cell growth and induces apoptosis in vitro. (A) Cells (SKOV3, OVCAR8, and A2780) were exposed to <b>E22</b> and <b>GSK-795</b> for 72 h, and cell viability was then determined by sulforhodamine B (SRB) assay. (B) Western blot analysis of total AKT, p-AKT, PRAS40, p-PRAS40, and p-FOX3a was conducted in the ovarian cancer cell line SKOV3. (C) Apoptosis was assessed upon treatment with the indicated concentrations (0.4–10 μM) by flow cytometry using the FL1-H channel (Annexin-V) and FL2-H channel (PI) of a Becton Dickinson FACSCalibur. Representative dot plots are shown, and the results are summarized in (D). The results are presented as the mean ± standard deviation (SD) from three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>E22</b> suppresses the migratory capacity of ovarian cancer cells. (A) Human umbilical vein endothelial cells (HUVECs) were treated with <b>E22</b> (0–2.5 μM) for 36 h. Afterward, images were captured, and cell migration was determined using image analysis software; these results are summarized in (B). (C) HUVECs were placed in the upper Matrigel-coated invasion chamber, with <b>E22</b> (0–2.5 μM) in the bottom chamber for 36 h. Invaded cells were stained with crystal violet and quantified by measuring the absorbance of dissolved crystals in 0.1% sodium dodecyl sulfate (SDS) at 540 nm; these results are summarized in (D). The results are presented as the mean ± SD from three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control. The scale bars represent 200 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>E22</b> develops an antitumor effect through inhibiting the kinase activity of Akt. (A–C) The mice transplanted with SKOV3 human xenografts were randomly divided into five groups (<i>N</i> = 5 mice/group) and were administered injections of <b>E22</b> at different doses (60, 40 + 40, or 80 mg/kg, i.g.), <b>GSK-795</b> (60 mg/kg, i.g.) or vehicle daily for a period of 21 days. The relative tumor volume, tumor weight, tumor growth inhibition, and T/C values were measured after the mice were sacrificed. Data represent the mean ± SD. (D) Western blot analysis of total AKT, p-AKT, PRAS40, p-PRAS40, and p-FOX3a in tumor tissues. The results are presented as the mean ± SD of three independent experiments. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, and *** <i>p</i> < 0.005 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. MD simulations and analysis of the interaction of compound <b>E22</b> with Akt1 protein (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>). (A) RMSD of Akt backbone during the 4000 ps simulation time; (B) distance plot of Glu234 and Glu278 with <b>E22</b>; (C) plot of the inhibitor–residue interaction spectrum; and (D) three-dimensional plot of the binding pattern.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) Malonic acid, piperidine, pyridine; (b) dimethyl sulfate, K<sub>2</sub>CO<sub>3</sub>, acetone; (c) nitromethane, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), MeCN; (d) paraformaldehyde, benzylamine, EtOH; (e) borane–methyl sulfide complex in tetrahydrofuran (THF); (f) Zn, AcOH, EtOH; (g) nitromethane, ammonium acetate, AcOH; (h) CF<sub>3</sub>COOH, <i>N</i>-(methoxymethyl)-<i>N</i>-(trimethylsilylmethyl)benzylamine, dichloromethane (DCM); (i) SnCl<sub>2</sub>, EtOAc.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route of Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) (<i>S</i>) or (<i>R</i>)-2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, dichloromethane; ii. trifluoracetic acid (TFA), dichloromethane; (b) i. Et<sub>3</sub>SiH, TFA; ii. Boc<sub>2</sub>O, triethylamine, dichloromethane; (c) Fe, NH<sub>4</sub>Cl, EtOH/H<sub>2</sub>O; (d) i. (<i>S</i>)-2-(diphenyl((trimethylsilyl)oxy)methyl)pyrrolidine, DCM; ii. allyltrimethylsilane, boron trifluoride etherate, DCM; (e) borane–methyl sulfide complex, NaOH, H<sub>2</sub>O<sub>2</sub>.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 1-Ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBT), <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), DCM; (b) chloroethyl chloroformate, 1,2-dichloroethane; (c) <span class="smallcaps smallerCapital">l</span>-tartrate; (d) HCl/ethyl acetate (EA).</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) EDCI, HOBT, DIPEA, DCM; (b) <span class="smallcaps smallerCapital">l</span>-tartrate; (c) HCl/EA.</p></p></figure><figure data-id="sch5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/medium/jm-2019-00891d_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthetic Route of Target Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-15/acs.jmedchem.9b00891/20190801/images/large/jm-2019-00891d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00891&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) EDCI, HOBT, DIPEA, DCM; (b) OsO<sub>4</sub>, <i>N</i>-methylmorpholine <i>N</i>-oxide, THF/H<sub>2</sub>O; (c) NaIO<sub>4</sub>, THF/H<sub>2</sub>O; (d) NaClO<sub>2</sub>, KH<sub>2</sub>PO<sub>4</sub>, 2-methylbut-2-ene; (e) NaBH<sub>4</sub>, THF/MeOH; (f) MsCl, DIPEA, DCM; (g) NaN<sub>3</sub>, DCM; (h) Pd/C, H<sub>2</sub>, EtOAc; (i) HCl/EA; (j) amines or CH<sub>3</sub>ONa; (k) MsCl or AcCl, DIPEA.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">AKT/PKB signaling: Navigating downstream</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.cell.2007.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=17604717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotV2hs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2007&pages=1261-1274&author=B.+D.+Manningauthor=L.+C.+Cantley&title=AKT%2FPKB+signaling%3A+Navigating+downstream&doi=10.1016%2Fj.cell.2007.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">AKT/PKB signaling: navigating downstream</span></div><div class="casAuthors">Manning, Brendan D.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1261-1274</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli.  Aberrant loss or gain of Akt activation underlies the pathophysiol. properties of a variety of complex diseases, including type-2 diabetes and cancer.  Here, we review the mol. properties of Akt and the approaches used to characterize its true cellular targets.  In addn., we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metab., and migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquDoFFShtwG7Vg90H21EOLACvtfcHk0ljHQ-hhVTlrlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotV2hs7g%253D&md5=1362a51f4d8a75b55f441dec99c04b1d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DAKT%252FPKB%2520signaling%253A%2520Navigating%2520downstream%26jtitle%3DCell%26date%3D2007%26volume%3D129%26spage%3D1261%26epage%3D1274%26doi%3D10.1016%2Fj.cell.2007.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsilieris, M.</span></span> <span> </span><span class="NLM_article-title">The Akt pathway: Molecular targets for anti-cancer drug development</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.2174/1568009043333032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.2174%2F1568009043333032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=15134532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=235-256&author=C.+S.+Mitsiadesauthor=N.+Mitsiadesauthor=M.+Koutsilieris&title=The+Akt+pathway%3A+Molecular+targets+for+anti-cancer+drug+development&doi=10.2174%2F1568009043333032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt pathway: Molecular targets for anti-cancer drug development</span></div><div class="casAuthors">Mitsiades, Constantine S.; Mitsiades, Nicholas; Koutsilieris, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serine/threonine kinase Akt functions intracellularly as a cardinal nodal point for a constellation of converging upstream signaling pathways, which involve stimulation of receptor tyrosine kinases such as IGR-1R, HER2/Neu, VEGF-R, PDGF-R, and an assembly of membrane-localized complexes of receptor-PI-3K and activation of Akt through the second messenger PIP3.  The integration of these intracellular signals at the level of Akt and its kinase activity, regulates the phosphorylation of its several downstream effectors, such as NF-κB, mTOR, Forkhead, Bad, GSK-3 and MDM-2.  These phosphorylation events in turn mediate the effects of Akt on cell growth, proliferation, protection from pro-apoptotic stimuli, and stimulation of neoangiogenesis.  Because Akt and its upstream regulators are deregulated in a wide range of solid tumors and hematol. malignancies, and in view of the aforementioned biol. sequelae of this pathway, the Akt pathway is considered a key determinant of biol. aggressiveness of these tumors, and a major potential target for novel anti-cancer therapies.  This review focuses on ongoing translational efforts to therapeutically target Akt and its biol. sequelae, either at the level of Akt itself or at the levels of its upstream regulators and downstream effectors.  Because Akt is also important for proliferative and anti-apoptotic signaling pathways crit. for normal cells, particular emphasis is placed on the fine-tuning the targeting of individual components of this pathway to maximize the therapeutic index of anti-cancer strategies based on the PI-3K/Akt pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZbuqTPNYgLVg90H21EOLACvtfcHk0ljHQ-hhVTlrlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1Gnu78%253D&md5=299909de4babdbbf0e242bd1a7abdab1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F1568009043333032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009043333032%26sid%3Dliteratum%253Aachs%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DMitsiades%26aufirst%3DN.%26aulast%3DKoutsilieris%26aufirst%3DM.%26atitle%3DThe%2520Akt%2520pathway%253A%2520Molecular%2520targets%2520for%2520anti-cancer%2520drug%2520development%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2004%26volume%3D4%26spage%3D235%26epage%3D256%26doi%3D10.2174%2F1568009043333032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+X.+Liuauthor=H.+L.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0ljHQ-hhVTlrlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%2BX.%26aulast%3DCheng%26aufirst%3DH.%2BL.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zippelius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemmings, B. A.</span></span> <span> </span><span class="NLM_article-title">Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy</span>. <i>JNCI, J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>107</i></span>, <span class="NLM_elocation-id">djv171</span> <span class="refDoi"> DOI: 10.1093/jnci/djv171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1093%2Fjnci%2Fdjv171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=26071042" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2015&author=G.+D.+Xueauthor=A.+Zippeliusauthor=A.+Wickiauthor=M.+Mandalaauthor=F.+Y.+Tangauthor=D.+Massiauthor=B.+A.+Hemmings&title=Integrated+Akt%2FPKB+signaling+in+immunomodulation+and+its+potential+role+in+cancer+immunotherapy&doi=10.1093%2Fjnci%2Fdjv171"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjv171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjv171%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DG.%2BD.%26aulast%3DZippelius%26aufirst%3DA.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DF.%2BY.%26aulast%3DMassi%26aufirst%3DD.%26aulast%3DHemmings%26aufirst%3DB.%2BA.%26atitle%3DIntegrated%2520Akt%252FPKB%2520signaling%2520in%2520immunomodulation%2520and%2520its%2520potential%2520role%2520in%2520cancer%2520immunotherapy%26jtitle%3DJNCI%252C%2520J.%2520Natl.%2520Cancer%2520Inst.%26date%3D2015%26volume%3D107%26doi%3D10.1093%2Fjnci%2Fdjv171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lassen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerniglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comin-Anduix, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">83</span> <span class="refDoi"> DOI: 10.1186/1476-4598-13-83</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1186%2F1476-4598-13-83" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24735930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVamsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&author=A.+Lassenauthor=M.+Atefiauthor=L.+Robertauthor=D.+J.+L.+Wongauthor=M.+Cernigliaauthor=B.+Comin-Anduixauthor=A.+Ribas&title=Effects+of+AKT+inhibitor+therapy+in+response+and+resistance+to+BRAF+inhibition+in+melanoma&doi=10.1186%2F1476-4598-13-83"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma</span></div><div class="casAuthors">Lassen, Amanda; Atefi, Mohammad; Robert, Lidia; Wong, Deborah J. L.; Cerniglia, Michael; Comin-Anduix, Begonya; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83/1-83/14, 14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The clin. use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance.  In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide addnl. growth inhibitory effects in vitro.  Methods: Anti-tumor effects of the combination of the BRAF inhibitor (BRAFi) dabrafenib and GSK2141795B (AKTi) in a panel of 23 BRAF mutated melanoma cell lines were evaluated on growth inhibition by an ATP-based luminescent assay, on cell cycle and apoptosis by flow cytometry and on cell signaling by western blot.  Moreover, we investigated the possibilities of delaying or reversing resistance or achieving further growth inhibition by combining AKTi with dabrafenib and/or the MEK inhibitor (MEKi) trametinib by using long term cultures.  Results: More than 40% of the cell lines, including PTEN-/- and AKT mutants showed sensitivity to AKTi (IC50 < 1.5 μM).  The combination of dabrafenib and AKTi synergistically potentiated growth inhibition in the majority of cell lines with IC50 > 5 nM dabrafenib.  Combinatorial treatment induced apoptosis only in cell lines sensitive to AKTi.  In long term cultures of a PTEN-/- cell line, combinatorial treatment with the MAPK inhibitors, dabrafenib and trametinib, and AKTi markedly delayed the emergence of drug resistance.  Moreover, combining AKTi with the MAPK inhibitors from the beginning provided superior growth inhibitory effects compared to addn. of AKTi upon development of resistance to MAPK inhibitors in this particular cell line.  Conclusions: AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF mutations and particularly PTEN deletions or AKT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzvjRyMnizmbVg90H21EOLACvtfcHk0lh0aWe6MwZ-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVamsbk%253D&md5=773466408a0ed70310b50e330f74af76</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-13-83&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-13-83%26sid%3Dliteratum%253Aachs%26aulast%3DLassen%26aufirst%3DA.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DD.%2BJ.%2BL.%26aulast%3DCerniglia%26aufirst%3DM.%26aulast%3DComin-Anduix%26aufirst%3DB.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DEffects%2520of%2520AKT%2520inhibitor%2520therapy%2520in%2520response%2520and%2520resistance%2520to%2520BRAF%2520inhibition%2520in%2520melanoma%26jtitle%3DMol.%2520Cancer%26date%3D2014%26volume%3D13%26doi%3D10.1186%2F1476-4598-13-83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span> <span> </span><span class="NLM_article-title">Commentary - AKT plays a central role in tumorigenesis</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">10983</span>– <span class="NLM_lpage">10985</span>, <span class="refDoi"> DOI: 10.1073/pnas.211430998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1073%2Fpnas.211430998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=11572954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1yqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=10983-10985&author=J.+R.+Testaauthor=A.+Bellacosa&title=Commentary+-+AKT+plays+a+central+role+in+tumorigenesis&doi=10.1073%2Fpnas.211430998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">AKT plays a central role in tumorigenesis</span></div><div class="casAuthors">Testa, Joseph R.; Bellacosa, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10983-10985</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A review discussing the results of the different studies conducted on the role of AKT in human malignancy.  The involvement of AKT in diverse tumorigenic activities indicated that AKT activation alone might be sufficient to induce cancer.  It is anticipated that much attention will be given to the identification of inhibitors or modulators of the P13K/AKT pathway, with the intention of developing new therapeutic strategies directed at neoplasms showing AKT activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULlRih-dwMLVg90H21EOLACvtfcHk0lh0aWe6MwZ-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1yqsrY%253D&md5=7628999cc6685e8bc3520e91c297cca2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.211430998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.211430998%26sid%3Dliteratum%253Aachs%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26aulast%3DBellacosa%26aufirst%3DA.%26atitle%3DCommentary%2520-%2520AKT%2520plays%2520a%2520central%2520role%2520in%2520tumorigenesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2001%26volume%3D98%26spage%3D10983%26epage%3D10985%26doi%3D10.1073%2Fpnas.211430998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, S. D.</span></span> <span> </span><span class="NLM_article-title">The activation of Akt/PKB signaling pathway and cell survival</span>. <i>J. Cell. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1111/j.1582-4934.2005.tb00337.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1111%2Fj.1582-4934.2005.tb00337.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=15784165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1eqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=59-71&author=G.+Songauthor=G.+L.+Ouyangauthor=S.+D.+Bao&title=The+activation+of+Akt%2FPKB+signaling+pathway+and+cell+survival&doi=10.1111%2Fj.1582-4934.2005.tb00337.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The activation of Akt/PKB signaling pathway and cell survival</span></div><div class="casAuthors">Song, Gang; Ouyang, Gaoliang; Bao, Shideng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-71</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-1838</span>.
    
            (<span class="NLM_cas:orgname">"Carol Davila" University Press</span>)
        </div><div class="casAbstract">A review.  Akt/PKB is a serine/threonine protein kinase that functions as a crit. regulator of cell survival and proliferation.  Akt/PKB family comprises 3 highly homologous members known as PKBα/Akt1, PKBβ/Akt2, and PKBγ/Akt3 in mammalian cells.  Similar to many other protein kinases, Akt/PKB contains a conserved domain structure including a specific PH domain, central kinase domain, and C-terminal regulatory domain that mediates the interaction between signaling mols.  Akt/PKB plays important roles in the signaling pathways in response to growth factors and other extracellular stimuli to regulate several cellular functions including nutrient metab., cell growth, apoptosis, and survival.  This review surveys recent developments in understanding the mol. mechanisms of Akt/PKB activation and its roles in cell survival in normal and cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodHk44d_FMbbVg90H21EOLACvtfcHk0lh0aWe6MwZ-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1eqtLo%253D&md5=72e8cd3fbec2f8f9b5185ce8debd5c28</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1582-4934.2005.tb00337.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1582-4934.2005.tb00337.x%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DG.%26aulast%3DOuyang%26aufirst%3DG.%2BL.%26aulast%3DBao%26aufirst%3DS.%2BD.%26atitle%3DThe%2520activation%2520of%2520Akt%252FPKB%2520signaling%2520pathway%2520and%2520cell%2520survival%26jtitle%3DJ.%2520Cell.%2520Mol.%2520Med.%26date%3D2005%26volume%3D9%26spage%3D59%26epage%3D71%26doi%3D10.1111%2Fj.1582-4934.2005.tb00337.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoeli-Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span> <span> </span><span class="NLM_article-title">Akt/PKB signaling in cancer - A function in cell motility and invasion</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">605</span>, <span class="refDoi"> DOI: 10.4161/cc.5.6.2561</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.4161%2Fcc.5.6.2561" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16582622" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A280%3ADC%252BD287pt1ejug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=603-605&author=M.+Yoeli-Lernerauthor=A.+Toker&title=Akt%2FPKB+signaling+in+cancer+-+A+function+in+cell+motility+and+invasion&doi=10.4161%2Fcc.5.6.2561"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Akt/PKB signaling in cancer: a function in cell motility and invasion</span></div><div class="casAuthors">Yoeli-Lerner Merav; Toker Alex</div><div class="citationInfo"><span class="NLM_cas:title">Cell cycle (Georgetown, Tex.)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">603-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The PI 3-K signaling pathway has been the subject of intense investigation for over a decade because it regulates a multitude of cellular processes.  Deregulation of this pathway often results in human diseases such as cancer.  The serine/threonine kinase Akt, a major PI 3-K target in all cells, has received considerable attention because it provides tumor cells with enhanced survival capacity.  Many tumors and tumor cells display elevated Akt protein expression and activity, and many of the proteins which regulate Akt itself are also often mutated in cancer.  For this reason, Akt has become a viable drug target for cancer therapy.  However, recent studies have shown that Akt can also function as a suppressor of tumor cell migration and invasion, phenotypes which are directly linked to metastatic tumor progression.  Here we review these findings and consider the unexpected notion that Akt may function as a metastasis suppressor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQoULEfkol6KhdUSIfHIn4FfW6udTcc2eb6lf-rQFKJy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287pt1ejug%253D%253D&md5=cf043a07952f2b1e485a55915bc47873</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.4161%2Fcc.5.6.2561&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.5.6.2561%26sid%3Dliteratum%253Aachs%26aulast%3DYoeli-Lerner%26aufirst%3DM.%26aulast%3DToker%26aufirst%3DA.%26atitle%3DAkt%252FPKB%2520signaling%2520in%2520cancer%2520-%2520A%2520function%2520in%2520cell%2520motility%2520and%2520invasion%26jtitle%3DCell%2520Cycle%26date%3D2006%26volume%3D5%26spage%3D603%26epage%3D605%26doi%3D10.4161%2Fcc.5.6.2561" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bellacosa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cristofano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, J. R.</span></span> <span> </span><span class="NLM_article-title">Activation of AKT kinases in cancer: Implications for therapeutic targeting</span>. <i>Adv. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/s0065-230x(05)94002-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fs0065-230x%2805%2994002-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16095999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=29-86&author=A.+Bellacosaauthor=C.+C.+Kumarauthor=A.+Di+Cristofanoauthor=J.+R.+Testa&title=Activation+of+AKT+kinases+in+cancer%3A+Implications+for+therapeutic+targeting&doi=10.1016%2Fs0065-230x%2805%2994002-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of AKT kinases in cancer: implications for therapeutic targeting</span></div><div class="casAuthors">Bellacosa, Alfonso; Kumar, C. Chandra; Di Cristofano, Antonio; Testa, Joseph Robert</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-86</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The AKT1, AKT2, and AKT3 kinases have emerged as crit. mediators of signal transduction pathways downstream of activated tyrosine kinases and phosphatidylinositol 3-kinase.  An ever-increasing list of AKT substrates has precisely defined the multiple functions of this kinase family in normal physiol. and disease states.  Cellular processes regulated by AKT include cell proliferation and survival, cell size and response to nutrient availability, intermediary metab., angiogenesis, and tissue invasion.  All these processes represent hallmarks of cancer, and a burgeoning literature has defined the importance of AKT alterations in human cancer and exptl. models of tumorigenesis, continuing the legacy represented by the original identification of v-Akt as the transforming oncogene of a murine retrovirus.  Many oncoproteins and tumor suppressors intersect in the AKT pathway, finely regulating cellular functions at the interface of signal transduction and classical metabolic regulation.  This careful balance is altered in human cancer by a variety of activating and inactivating mechanisms that target both AKT and interrelated proteins.  Reprogramming of this altered circuitry by pharmacol. modulation of the AKT pathway represents a powerful strategy for rational cancer therapy.  In this review, we summarize a large body of data, from many types of cancer, indicating that AKT activation is one of the most common mol. alterations in human malignancy.  We also review mechanisms of activation of AKT kinases, examples of therapeutic modulation of the AKT pathway in animal models, and the current status of efforts to target mol. components of the AKT pathway for cancer therapy and, possibly, cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbtUdzglK927Vg90H21EOLACvtfcHk0lgTOkXxkjFVgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1elur4%253D&md5=556e3c5787e0179786db3cb2e2f1dcf6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fs0065-230x%2805%2994002-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0065-230x%252805%252994002-5%26sid%3Dliteratum%253Aachs%26aulast%3DBellacosa%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DC.%2BC.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26aulast%3DTesta%26aufirst%3DJ.%2BR.%26atitle%3DActivation%2520of%2520AKT%2520kinases%2520in%2520cancer%253A%2520Implications%2520for%2520therapeutic%2520targeting%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2005%26volume%3D94%26spage%3D29%26epage%3D86%26doi%3D10.1016%2Fs0065-230x%2805%2994002-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isakoff, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapp, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maslyar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1360</span>– <span class="NLM_lpage">1372</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(17)30450-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2FS1470-2045%2817%2930450-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=28800861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1360-1372&author=S.+B.+Kimauthor=R.+Dentauthor=S.+A.+Imauthor=M.+Espi%C3%A9author=S.+Blauauthor=A.+R.+Tanauthor=S.+J.+Isakoffauthor=M.+Oliveiraauthor=C.+Sauraauthor=M.+J.+Wongchenkoauthor=A.+V.+Kappauthor=W.+Y.+Chanauthor=S.+M.+Singelauthor=D.+J.+Maslyarauthor=J.+Baselga&title=Ipatasertib+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28LOTUS%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2817%2930450-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicenter, randomized, double-blind, placebo-controlled, phase 2 trial</span></div><div class="casAuthors">Kim, Sung-Bae; Dent, Rebecca; Im, Seock-Ah; Espie, Marc; Blau, Sibel; Tan, Antoinette R.; Isakoff, Steven J.; Oliveira, Mafalda; Saura, Cristina; Wongchenko, Matthew J.; Kapp, Amy V.; Chan, Wai Y.; Singel, Stina M.; Maslyar, Daniel J.; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1360-1372</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-neg. breast cancer.  The LOTUS trial investigated the addn. of ipatasertib to paclitaxel as first-line therapy for triple-neg. breast cancer.  In this randomized, placebo-controlled, double-blind, phase 2 trial, women aged 18 years or older with measurable, inoperable, locally advanced or metastatic triple-neg. breast cancer previously untreated with systemic therapy were recruited from 44 hospitals in South Korea, the USA, France, Spain, Taiwan, Singapore, Italy, and Belgium.  Enrolled patients were randomly assigned (1:1) to receive i.v. paclitaxel 80 mg/m2 (days 1, 8, 15) with either ipatasertib 400 mg or placebo once per day (days 1-21) every 28 days until disease progression or unacceptable toxicity.  Randomisation was by stratified permuted blocks (block size of four) using an interactive web-response system with three stratification criteria: previous (neo)adjuvant therapy, chemotherapy-free interval, and tumor PTEN status.  The co-primary endpoints were progression-free survival in the intention-to-treat population and progression-free survival in the PTEN-low (by immunohistochem.) population.  This ongoing trial is registered with ClinicalTrials.gov (NCT02162719).  Between Sept 2, 2014, and Feb 4, 2016, 166 patients were assessed for eligibility and 124 patients were enrolled and randomly assigned to paclitaxel plus ipatasertib (n=62) or paclitaxel plus placebo (n=62).  Median follow-up was 10·4 mo (IQR 6·5-14·1) in the ipatasertib group and 10·2 mo (6·0-13·6) in the placebo group.  Median progression-free survival in the intention-to-treat population was 6·2 mo (95% CI 3·8-9·0) with ipatasertib vs. 4·9 mo (3·6-5·4) with placebo (stratified hazard ratio [HR] 0·60, 95% CI 0·37-0·98; p=0·037) and in the 48 patients with PTEN-low tumors, median progression-free survival was 6·2 mo (95% CI 3·6-9·1) with ipatasertib vs. 3·7 mo (1·9-7·3) with placebo (stratified HR 0·59, 95% CI 0·26-1·32, p=0·18).  The most common grade 3 or worse adverse events were diarrhea (14 [23%] of 61 ipatasertib-treated patients vs none of 62 placebo-treated patients), neutrophil count decreased (five [8%] vs four [6%]), and neutropenia (six [10%] vs one [2%]).  No colitis, grade 4 diarrhea, or treatment-related deaths were reported with ipatasertib.  One treatment-related death occurred in the placebo group.  Serious adverse events were reported in 17 (28%) of 61 patients in the ipatasertib group and nine (15%) of 62 patients in the placebo group.  Progression-free survival was longer in patients who received ipatasertib than in those who received placebo.  To our knowledge, these are the first results supporting AKT-targeted therapy for triple-neg. breast cancer.  Ipatasertib warrants further investigation for the treatment of triple-neg. breast cancer.F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUHDoupzZvn7Vg90H21EOLACvtfcHk0lgTOkXxkjFVgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSrtbjO&md5=411d3aeae55045b4241c617922b711d5</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2817%2930450-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252817%252930450-3%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DDent%26aufirst%3DR.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DEspi%25C3%25A9%26aufirst%3DM.%26aulast%3DBlau%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DA.%2BR.%26aulast%3DIsakoff%26aufirst%3DS.%2BJ.%26aulast%3DOliveira%26aufirst%3DM.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DKapp%26aufirst%3DA.%2BV.%26aulast%3DChan%26aufirst%3DW.%2BY.%26aulast%3DSingel%26aufirst%3DS.%2BM.%26aulast%3DMaslyar%26aufirst%3DD.%2BJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DIpatasertib%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528LOTUS%2529%253A%2520a%2520multicentre%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26spage%3D1360%26epage%3D1372%26doi%3D10.1016%2FS1470-2045%2817%2930450-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheatley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemsadze, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1007</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1200%2FJCO.2018.36.15_suppl.1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=29432078" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1007&author=P.+Schmidauthor=J.+Abrahamauthor=S.+Chanauthor=D.+Wheatleyauthor=M.+Bruntauthor=G.+Nemsadze&title=AZD5363+plus+paclitaxel+versus+placebo+plus+paclitaxel+as+first-line+therapy+for+metastatic+triple-negative+breast+cancer+%28PAKT%29%3A+A+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+II+trial&doi=10.1200%2FJCO.2018.36.15_suppl.1007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.1007%26sid%3Dliteratum%253Aachs%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DS.%26aulast%3DWheatley%26aufirst%3DD.%26aulast%3DBrunt%26aufirst%3DM.%26aulast%3DNemsadze%26aufirst%3DG.%26atitle%3DAZD5363%2520plus%2520paclitaxel%2520versus%2520placebo%2520plus%2520paclitaxel%2520as%2520first-line%2520therapy%2520for%2520metastatic%2520triple-negative%2520breast%2520cancer%2520%2528PAKT%2529%253A%2520A%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1007%26doi%3D10.1200%2FJCO.2018.36.15_suppl.1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fei, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. C.</span></span> <span> </span><span class="NLM_article-title">Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1007/s11010-011-0986-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1007%2Fs11010-011-0986-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=21769450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFSis7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2012&pages=1-8&author=F.+Z.+Wangauthor=H.+R.+Feiauthor=X.+Q.+Liauthor=R.+J.+Shiauthor=D.+C.+Wang&title=Perifosine+as+potential+anti-cancer+agent+inhibits+proliferation%2C+migration%2C+and+tube+formation+of+human+umbilical+vein+endothelial+cells&doi=10.1007%2Fs11010-011-0986-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells</span></div><div class="casAuthors">Wang, Feng Ze; Fei, Hong Rong; Li, Xiao Qian; Shi, Renjiu; Wang, De Cai</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Targeting angiogenesis is considered an effective strategy for treating the expansion and metastasis of tumors.  The aim of this study is to assess the effects of perifosine, an inhibitor of Akt, on cell proliferation, apoptosis, angiogenesis, and VEGF-induced cell migration in cultured human umbilical vein endothelial cells (HUVECs) in vitro.  MTT and cell cycle anal. results indicated that perifosine inhibited the growth of HUVECs in a dose-dependent manner, arrested cell cycle progression at the G2 phase with regulation the expression of p21 and cyclinB1.  Apoptosis induced by the higher concns. of perifosine in HUVECs was also obsd.  In addn., tube formation of HUVECs and VEGF-induced cell migration were markedly inhibited by perifosine.  Western blotting anal. of cell signaling mols. indicated that perifosine inhibited ERK and p38 phosphorylation in HUVECs.  These results suggest that perifosine exerts anti-angiogenic activity in HUVECs and is a promising agent for treatment of angiogenesis related-diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ020Jvj8ttrVg90H21EOLACvtfcHk0lgTOkXxkjFVgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFSis7%252FN&md5=8ba08521a5a7efa4e93148a02a95d3b8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11010-011-0986-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-011-0986-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%2BZ.%26aulast%3DFei%26aufirst%3DH.%2BR.%26aulast%3DLi%26aufirst%3DX.%2BQ.%26aulast%3DShi%26aufirst%3DR.%2BJ.%26aulast%3DWang%26aufirst%3DD.%2BC.%26atitle%3DPerifosine%2520as%2520potential%2520anti-cancer%2520agent%2520inhibits%2520proliferation%252C%2520migration%252C%2520and%2520tube%2520formation%2520of%2520human%2520umbilical%2520vein%2520endothelial%2520cells%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2012%26volume%3D368%26spage%3D1%26epage%3D8%26doi%3D10.1007%2Fs11010-011-0986-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
la Pena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgan, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollingshead, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satyamitra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camphausen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofilon, P. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1510</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1535-7163.MCT-06-0091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16818509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVams7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1504-1510&author=L.+de%0Ala+Penaauthor=W.+E.+Burganauthor=D.+J.+Carterauthor=M.+G.+Hollingsheadauthor=M.+Satyamitraauthor=K.+Camphausenauthor=P.+J.+Tofilon&title=Inhibition+of+Akt+by+the+alkylphospholipid+perifosine+does+not+enhance+the+radiosensitivity+of+human+glioma+cells&doi=10.1158%2F1535-7163.MCT-06-0091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells</span></div><div class="casAuthors">De la Pena, Lorena; Burgan, William E.; Carter, Donna J.; Hollingshead, Melinda G.; Satyamitra, Merriline; Camphausen, Kevin; Tofilon, Philip J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1504-1510</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Akt has been implicated as a mol. determinant of cellular radiosensitivity.  Because it is often constitutively activated or overexpressed in malignant gliomas, it has been suggested as a target for brain tumor radiosensitization.  To evaluate the role of Akt in glioma radioresponse, we have detd. the effects of perifosine, a clin. relevant alkylphospholipid that inhibits Akt activation, on the radiosensitivity of three human glioma cell lines (U87, U251, and LN229).  Each of the glioma cell lines expressed clearly detectable levels of phosphorylated Akt indicative of constitutive Akt activity.  Exposure to a perifosine concn. that reduced survival by ∼50% significantly reduced the level of phosphorylated Akt as well as Akt activity.  Cell survival anal. using a clonogenic assay, however, revealed that this Akt-inhibiting perifosine treatment did not enhance the radiosensitivity of the glioma cell lines.  This evaluation was then extended to an in vivo model using U251 xenografts.  Perifosine delivered to mice bearing U251 xenografts substantially reduced tumor phosphorylated Akt levels and inhibited tumor growth rate.  However, the combination of perifosine and radiation resulted in a less than additive increase in tumor growth delay.  Thus, in vitro and in vivo data indicate that the perifosine-mediated decrease in Akt activity does not enhance the radiosensitivity of three genetically disparate glioma cell lines.  These results suggest that, although Akt may influence the radiosensitivity of other tumor types, it does not seem to be a target for glioma cell radiosensitization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbwPlDEi7AgbVg90H21EOLACvtfcHk0lgjzZCe43GYfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVams7o%253D&md5=95230151934db74da1c6681e180b4805</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0091%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2Bla%2BPena%26aufirst%3DL.%26aulast%3DBurgan%26aufirst%3DW.%2BE.%26aulast%3DCarter%26aufirst%3DD.%2BJ.%26aulast%3DHollingshead%26aufirst%3DM.%2BG.%26aulast%3DSatyamitra%26aufirst%3DM.%26aulast%3DCamphausen%26aufirst%3DK.%26aulast%3DTofilon%26aufirst%3DP.%2BJ.%26atitle%3DInhibition%2520of%2520Akt%2520by%2520the%2520alkylphospholipid%2520perifosine%2520does%2520not%2520enhance%2520the%2520radiosensitivity%2520of%2520human%2520glioma%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1504%26epage%3D1510%26doi%3D10.1158%2F1535-7163.MCT-06-0091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, M. Z.</span></span> <span> </span><span class="NLM_article-title">The Akt inhibitor MK2206 synergizes, but Perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">E173</span>– <span class="NLM_lpage">E182</span>, <span class="refDoi"> DOI: 10.1210/jc.2011-1054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1210%2Fjc.2011-1054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22090271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFOnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=E173-E182&author=R.+X.+Liuauthor=D.+X.+Liuauthor=M.+Z.+Xing&title=The+Akt+inhibitor+MK2206+synergizes%2C+but+Perifosine+antagonizes%2C+the+BRAF%28V600E%29+inhibitor+PLX4032+and+the+MEK1%2F2+inhibitor+AZD6244+in+the+inhibition+of+thyroid+cancer+cells&doi=10.1210%2Fjc.2011-1054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAFV600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells</span></div><div class="casAuthors">Liu, Ruixin; Liu, Dingxie; Xing, Mingzhao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">E173-E182</span>CODEN:
                <span class="NLM_cas:coden">JCEMAZ</span>;
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Purpose: The purpose of the study was to explore optimal combinations of currently actively developed drugs for dually targeting the Ras → Raf → MAPK kinase (MEK) → MAPK/ERK (MAPK) and the phosphatidylinositol 3-kinase/Akt pathways as effective treatments for thyroid cancer.  Exptl. Design: We tested the combinations of the Akt inhibitors MK2206 or perifosine with the BRAFV600E inhibitor PLX4032 or the MEK1/2 inhibitor AZD6244 in thyroid cancer cells harboring both the BRAFV600E and PIK3CA mutations.  Results: We found that MK2206 could potently, when used alone, and synergistically, when combined with either PLX4032 or AZD6244, inhibit thyroid cancer cell growth with all the combination index values lower than 1.  Perifosine could potently inhibit thyroid cancer cell growth when used alone, but a strong antagonism occurred between this drug and PLX4032 or AZD6244 in the inhibition of thyroid cancer cell growth with all combination index values higher than 1.  Combinations of MK2206 with PLX4032 or AZD6244 dramatically enhanced G1 cell cycle arrest induced by each drug alone.  However, G2 cell cycle arrest uniquely induced by perifosine alone and G1 cell cycle arrest induced by PLX4032 or AZD6244 were both reversed by combination treatments, providing a mechanism for their antagonism.  All these drugs could correspondingly inhibit the MAPK and phosphatidylinositol 3-kinase/Akt signalings, confirming their expected target effects.  Conclusions: We demonstrated, unexpectedly, opposite outcomes of MK2206 and perifosine in their combinational treatments with BRAFV600E/MEK inhibitors in thyroid cancer cells.  The data may help appropriate selection of these prominent drugs for clin. trials of combination therapies for thyroid cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkIc9yMM23zrVg90H21EOLACvtfcHk0lil4YZri7RbzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFOnsr8%253D&md5=c70cc0e1453c9d417230e2cfc6450a79</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1210%2Fjc.2011-1054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjc.2011-1054%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DR.%2BX.%26aulast%3DLiu%26aufirst%3DD.%2BX.%26aulast%3DXing%26aufirst%3DM.%2BZ.%26atitle%3DThe%2520Akt%2520inhibitor%2520MK2206%2520synergizes%252C%2520but%2520Perifosine%2520antagonizes%252C%2520the%2520BRAF%2528V600E%2529%2520inhibitor%2520PLX4032%2520and%2520the%2520MEK1%252F2%2520inhibitor%2520AZD6244%2520in%2520the%2520inhibition%2520of%2520thyroid%2520cancer%2520cells%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D2012%26volume%3D97%26spage%3DE173%26epage%3DE182%26doi%3D10.1210%2Fjc.2011-1054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pant, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lurain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schink, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">MK2206, an orally active allosteric AKT inhibitor, reverses progestin resistance in endometrial cancer</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ygyno.2011.07.062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2011&pages=438-439&author=A.+Pantauthor=I.+Leeauthor=J.+Lurainauthor=J.+Schinkauthor=J.+Kim&title=MK2206%2C+an+orally+active+allosteric+AKT+inhibitor%2C+reverses+progestin+resistance+in+endometrial+cancer&doi=10.1016%2Fj.ygyno.2011.07.062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DPant%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DLurain%26aufirst%3DJ.%26aulast%3DSchink%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DMK2206%252C%2520an%2520orally%2520active%2520allosteric%2520AKT%2520inhibitor%252C%2520reverses%2520progestin%2520resistance%2520in%2520endometrial%2520cancer%26jtitle%3DGynecol.%2520Oncol.%26date%3D2011%26volume%3D123%26spage%3D438%26epage%3D439%26doi%3D10.1016%2Fj.ygyno.2011.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafrance, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safonov, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takata, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venslavsky, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knick, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lansing, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5663</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1021/jm8004527</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8004527" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5663-5679&author=D.+A.+Heerdingauthor=N.+Rhodesauthor=J.+D.+Leberauthor=T.+J.+Clarkauthor=R.+M.+Keenanauthor=L.+V.+Lafranceauthor=M.+Liauthor=I.+G.+Safonovauthor=D.+T.+Takataauthor=J.+W.+Venslavskyauthor=D.+S.+Yamashitaauthor=A.+E.+Choudhryauthor=R.+A.+Copelandauthor=Z.+H.+Laiauthor=M.+D.+Schaberauthor=P.+J.+Tumminoauthor=S.+L.+Strumauthor=E.+R.+Woodauthor=D.+R.+Duckettauthor=D.+Eberweinauthor=V.+B.+Knickauthor=T.+J.+Lansingauthor=R.+T.+McConnellauthor=S.+Y.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=G.+L.+Warrenauthor=R.+Kumar&title=Identification+of+4-%282-%284-amino-1%2C2%2C5-oxadiazol-3-yl%29-1-ethyl-7-%7B%5B%283S%29-3-piperidinylmethyl%5Doxy%7D-1H-imidazo%5B4%2C5-c%5Dpyridin-4-yl%29-2-methyl-3-butyn-2-ol+%28GSK690693%29%2C+a+novel+inhibitor+of+AKT+kinase&doi=10.1021%2Fjm8004527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase</span></div><div class="casAuthors">Heerding, Dirk A.; Rhodes, Nelson; Leber, Jack D.; Clark, Tammy J.; Keenan, Richard M.; Lafrance, Louis V.; Li, Mei; Safonov, Igor G.; Takata, Dennis T.; Venslavsky, Joseph W.; Yamashita, Dennis S.; Choudhry, Anthony E.; Copeland, Robert A.; Lai, Zhihong; Schaber, Michael D.; Tummino, Peter J.; Strum, Susan L.; Wood, Edgar R.; Duckett, Derek R.; Eberwein, Derek; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Warren, Gregory L.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5663-5679</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant neg. AKT blocks the ability of a variety of growth factors to promote survival.  Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT.  Herein, we describe our lead optimization studies culminating in the discovery of compd. 3g (GSK690693, I).  Compd. 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, resp.  An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket.  Compd. 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β.  I.p. administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAGkPktggErVg90H21EOLACvtfcHk0lil4YZri7RbzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVChs7bE&md5=c0e6f283a3ee79dffafdd90ec69513bc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm8004527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8004527%26sid%3Dliteratum%253Aachs%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DRhodes%26aufirst%3DN.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DClark%26aufirst%3DT.%2BJ.%26aulast%3DKeenan%26aufirst%3DR.%2BM.%26aulast%3DLafrance%26aufirst%3DL.%2BV.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DSafonov%26aufirst%3DI.%2BG.%26aulast%3DTakata%26aufirst%3DD.%2BT.%26aulast%3DVenslavsky%26aufirst%3DJ.%2BW.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DLai%26aufirst%3DZ.%2BH.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DStrum%26aufirst%3DS.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DDuckett%26aufirst%3DD.%2BR.%26aulast%3DEberwein%26aufirst%3DD.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMcConnell%26aufirst%3DR.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DWarren%26aufirst%3DG.%2BL.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DIdentification%2520of%25204-%25282-%25284-amino-1%252C2%252C5-oxadiazol-3-yl%2529-1-ethyl-7-%257B%255B%25283S%2529-3-piperidinylmethyl%255Doxy%257D-1H-imidazo%255B4%252C5-c%255Dpyridin-4-yl%2529-2-methyl-3-butyn-2-ol%2520%2528GSK690693%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520AKT%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5663%26epage%3D5679%26doi%3D10.1021%2Fjm8004527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">te Poele, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eve, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandon, A. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterlund, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaton, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinzmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltell, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodhead, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span> <span> </span><span class="NLM_article-title">AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3912</span>– <span class="NLM_lpage">3923</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-3313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1078-0432.CCR-11-3313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22781553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVelur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3912-3923&author=T.+A.+Yapauthor=M.+I.+Waltonauthor=K.+M.+Grimshawauthor=R.+H.+te+Poeleauthor=P.+D.+Eveauthor=M.+R.+Valentiauthor=A.+K.+D.+Brandonauthor=V.+Martinsauthor=A.+Zetterlundauthor=S.+P.+Heatonauthor=K.+Heinzmannauthor=P.+S.+Jonesauthor=R.+E.+Feltellauthor=M.+Reuleauthor=S.+J.+Woodheadauthor=T.+G.+Daviesauthor=J.+F.+Lyonsauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=P.+Workmanauthor=N.+T.+Thompsonauthor=M.+D.+Garrett&title=AT13148+is+a+novel%2C+oral+multi-AGC+kinase+inhibitor+with+potent+pharmacodynamic+and+antitumor+activity&doi=10.1158%2F1078-0432.CCR-11-3313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity</span></div><div class="casAuthors">Yap, Timothy A.; Walton, Mike I.; Grimshaw, Kyla M.; te Poele, Robert H.; Eve, Paul D.; Valenti, Melanie R.; de Haven Brandon, Alexis K.; Martins, Vanessa; Zetterlund, Anna; Heaton, Simon P.; Heinzmann, Kathrin; Jones, Paul S.; Feltell, Ruth E.; Reule, Matthias; Woodhead, Steven J.; Davies, Thomas G.; Lyons, John F.; Raynaud, Florence I.; Eccles, Suzanne A.; Workman, Paul; Thompson, Neil T.; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3912-3923</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers.  The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clin. resistance compared with a single pathway component.  Exptl. Design: We investigated the detailed pharmacol. and antitumor activity of the novel clin. drug candidate AT13148, an oral ATP-competitive multi-AGC kinase inhibitor.  Gene expression microarray studies were undertaken to characterize the mol. mechanisms of action of AT13148.  Results: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in a concn. and time-dependent manner in cancer cells with clin. relevant genetic defects in vitro and in vivo.  Antitumor efficacy in HER2-pos., PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer, and PTEN-deficient MES-SA uterine tumor xenografts was shown.  We show for the first time that induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step.  Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell-cycle genes.  Induction of upstream regulators including IRS2 and PIK3IP1 as a result of compensatory feedback loops was obsd.  Conclusions: The clin. candidate AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.  AT13148 will now be assessed in a first-in-human phase I trial.  Clin Cancer Res; 18(14); 3912-23. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3dYsAM8O1pLVg90H21EOLACvtfcHk0li7cLgIyPdtMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVelur3O&md5=32dd4f817c4497762e678b8bb9df7503</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-3313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-3313%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DGrimshaw%26aufirst%3DK.%2BM.%26aulast%3Dte%2BPoele%26aufirst%3DR.%2BH.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DBrandon%26aufirst%3DA.%2BK.%2BD.%26aulast%3DMartins%26aufirst%3DV.%26aulast%3DZetterlund%26aufirst%3DA.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DHeinzmann%26aufirst%3DK.%26aulast%3DJones%26aufirst%3DP.%2BS.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26aulast%3DReule%26aufirst%3DM.%26aulast%3DWoodhead%26aufirst%3DS.%2BJ.%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DLyons%26aufirst%3DJ.%2BF.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DAT13148%2520is%2520a%2520novel%252C%2520oral%2520multi-AGC%2520kinase%2520inhibitor%2520with%2520potent%2520pharmacodynamic%2520and%2520antitumor%2520activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3912%26epage%3D3923%26doi%3D10.1158%2F1078-0432.CCR-11-3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Addie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dry, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, R. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2073</span>, <span class="refDoi"> DOI: 10.1021/jm301762v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301762v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2059-2073&author=M.+Addieauthor=P.+Ballardauthor=D.+Buttarauthor=C.+Crafterauthor=G.+Currieauthor=B.+R.+Daviesauthor=J.+Debreczeniauthor=H.+Dryauthor=P.+Dudleyauthor=R.+Greenwoodauthor=P.+D.+Johnsonauthor=J.+G.+Kettleauthor=C.+Laneauthor=G.+Lamontauthor=A.+Leachauthor=R.+W.+A.+Lukeauthor=J.+Morrisauthor=D.+Ogilvieauthor=K.+Pageauthor=M.+Passauthor=S.+Pearsonauthor=L.+Ruston&title=Discovery+of+4-amino-N-%5B%281S%29-1-%284-chlorophenyl%29-3-hydroxypropyl%5D1-%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29piperidine-4-carboxamide+%28AZD5363%29%2C+an+orally+bioavailable%2C+potent+inhibitor+of+Akt+kinases&doi=10.1021%2Fjm301762v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases</span></div><div class="casAuthors">Addie, Matt; Ballard, Peter; Buttar, David; Crafter, Claire; Currie, Gordon; Davies, Barry R.; Debreczeni, Judit; Dry, Hannah; Dudley, Philippa; Greenwood, Ryan; Johnson, Paul D.; Kettle, Jason G.; Lane, Clare; Lamont, Gillian; Leach, Andrew; Luke, Richard W. A.; Morris, Jeff; Ogilvie, Donald; Page, Ken; Pass, Martin; Pearson, Stuart; Ruston, Linette</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2059-2073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-aralkyl aminopyrrolopyrimidinylpiperidinecarboxamides such as I (AZD5363) were prepd. as inhibitors of Akt kinases, particularly Akt1, Akt2, and Akt3 kinases, for potential use as antitumor agents based on a collaboratively-identified ATP-competitive pyrrolopyrimidine inhibitor of Akt kinases.  The selectivities of N-aralkyl aminopyrrolopyrimidinylpiperidinecarboxamides for Akt 1, Akt2, and Akt3 over ROCK2 and the hERG ion channel, their octanol-water partition coeffs., and their aq. solubilities were detd.  The oral pharmacokinetics of I in mice, rats, and dogs and the plasma protein binding of I in people, the inhibition of a panel of 75 kinases by I, and the activity of I against human cancer cell lines (particularly breast and prostate cancer) were detd.; I showed pharmacodynamic knockdown of phosphorylation of Akt and downstream biomarkers in vivo and inhibition of tumor growth in a breast cancer xenograft model.  The structure of I bound to Akt1 was detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFU3WrUUalYLVg90H21EOLACvtfcHk0li7cLgIyPdtMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Ghsrw%253D&md5=847a03b036460fc14d85c860b0d08f5a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm301762v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301762v%26sid%3Dliteratum%253Aachs%26aulast%3DAddie%26aufirst%3DM.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DButtar%26aufirst%3DD.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DCurrie%26aufirst%3DG.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DDebreczeni%26aufirst%3DJ.%26aulast%3DDry%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DP.%2BD.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLeach%26aufirst%3DA.%26aulast%3DLuke%26aufirst%3DR.%2BW.%2BA.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DPearson%26aufirst%3DS.%26aulast%3DRuston%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25204-amino-N-%255B%25281S%2529-1-%25284-chlorophenyl%2529-3-hydroxypropyl%255D1-%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529piperidine-4-carboxamide%2520%2528AZD5363%2529%252C%2520an%2520orally%2520bioavailable%252C%2520potent%2520inhibitor%2520of%2520Akt%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2059%26epage%3D2073%26doi%3D10.1021%2Fjm301762v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bencsik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlachter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banka, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8110</span>– <span class="NLM_lpage">8127</span>, <span class="refDoi"> DOI: 10.1021/jm301024w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301024w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8110-8127&author=J.+F.+Blakeauthor=R.+Xuauthor=J.+R.+Bencsikauthor=D.+Xiaoauthor=N.+C.+Kallanauthor=S.+Schlachterauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=A.+L.+Bankaauthor=E.+M.+Wallaceauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=R.+D.+Woessnerauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=J.+Liangauthor=B.+S.+Safinaauthor=J.+Liauthor=B.+R.+Zhangauthor=C.+Chabotauthor=S.+Doauthor=L.+Leeauthor=J.+Oehauthor=D.+Sampathauthor=B.+B.+Leeauthor=K.+Linauthor=B.+M.+Liedererauthor=N.+J.+Skelton&title=Discovery+and+preclinical+pharmacology+of+a+selective+ATP-competitive+Akt+inhibitor+%28GDC-0068%29+for+the+treatment+of+human+tumors&doi=10.1021%2Fjm301024w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors</span></div><div class="casAuthors">Blake, James F.; Xu, Rui; Bencsik, Josef R.; Xiao, Dengming; Kallan, Nicholas C.; Schlachter, Stephen; Mitchell, Ian S.; Spencer, Keith L.; Banka, Anna L.; Wallace, Eli M.; Gloor, Susan L.; Martinson, Matthew; Woessner, Richard D.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Liang, Jun; Safina, Brian S.; Li, Jun; Zhang, Birong; Chabot, Christine; Do, Steven; Lee, Leslie; Oeh, Jason; Sampath, Deepak; Lee, Brian B.; Lin, Kui; Liederer, Bianca M.; Skelton, Nicholas J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8110-8127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compds. that are ATP-competitive, selective inhibitors of protein kinase B/Akt is reported.  The initial design and optimization was guided by the use of X-ray structures of inhibitors in complex with Akt1 and the closely related protein kinase A.  The resulting compds. demonstrate potent inhibition of all three Akt isoforms in biochem. assays and poor inhibition of other members of the cAMP-dependent protein kinase/protein kinase G/protein kinase C extended family and block the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.  Biol. studies with one such compd., 28 (GDC-0068), demonstrate good oral exposure resulting in dose-dependent pharmacodynamic effects on downstream biomarkers and a robust antitumor response in xenograft models in which the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway is activated. 28 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowH24ZkuGlNLVg90H21EOLACvtfcHk0ljPqD-s9Fw2xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yrtr7K&md5=1fa690cda22a2548eb2795305e1c7253</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301024w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301024w%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DSchlachter%26aufirst%3DS.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DBanka%26aufirst%3DA.%2BL.%26aulast%3DWallace%26aufirst%3DE.%2BM.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DB.%2BR.%26aulast%3DChabot%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520pharmacology%2520of%2520a%2520selective%2520ATP-competitive%2520Akt%2520inhibitor%2520%2528GDC-0068%2529%2520for%2520the%2520treatment%2520of%2520human%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8110%26epage%3D8127%26doi%3D10.1021%2Fjm301024w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figueroa, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e100880</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0100880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1371%2Fjournal.pone.0100880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24978597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1emur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=M.+Dumbleauthor=M.+C.+Crouthamelauthor=S.+Y.+Zhangauthor=M.+Schaberauthor=D.+Levyauthor=K.+Robellauthor=Q.+Liuauthor=D.+J.+Figueroaauthor=E.+A.+Minthornauthor=M.+A.+Seefeldauthor=M.+B.+Rouseauthor=S.+K.+Rabindranauthor=D.+A.+Heerdingauthor=R.+Kumar&title=Discovery+of+novel+AKT+inhibitors+with+enhanced+anti-tumor+effects+in+combination+with+the+MEK+inhibitor&doi=10.1371%2Fjournal.pone.0100880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor</span></div><div class="casAuthors">Dumble, Melissa; Crouthamel, Ming-Chih; Zhang, Shu-Yun; Schaber, Michael; Levy, Dana; Robell, Kimberly; Liu, Qi; Figueroa, David J.; Minthorn, Elisabeth A.; Seefeld, Mark A.; Rouse, Meagan B.; Rabindran, Sridhar K.; Heerding, Dirk A.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e100880/1-e100880/11, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Tumor cells upregulate many cell signaling pathways, with AKT being one of the key kinases to be activated in a variety of malignancies.  GSK2110183 and GSK2141795 are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to human clin. studies.  Both compds. are selective, ATP-competitive inhibitors of AKT 1, 2 and 3.  Cells treated with either compd. show decreased phosphorylation of several substrates downstream of AKT.  Both compds. have desirable pharmaceutical properties and daily oral dosing results in a sustained inhibition of AKT activity as well as inhibition of tumor growth in several mouse tumor models of various histol. origins.  Improved kinase selectivity was assocd. with reduced effects on glucose homeostasis as compared to previously reported ATP-competitive AKT kinase inhibitors.  In a diverse cell line proliferation screen, AKT inhibitors showed increased potency in cell lines with an activated AKT pathway (via PI3K/PTEN mutation or loss) while cell lines with activating mutations in the MAPK pathway (KRAS/BRAF) were less sensitive to AKT inhibition.  Further investigation in mouse models of KRAS driven pancreatic cancer confirmed that combining the AKT inhibitor, GSK2141795 with a MEK inhibitor (GSK2110212; trametinib) resulted in an enhanced anti-tumor effect accompanied with greater redn. in phospho-S6 levels.  Taken together these results support clin. evaluation of the AKT inhibitors in cancer, esp. in combination with MEK inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTrNdvuYoT8bVg90H21EOLACvtfcHk0ljPqD-s9Fw2xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1emur3K&md5=893494388f4f390ae5a6bc3d30114c89</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0100880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0100880%26sid%3Dliteratum%253Aachs%26aulast%3DDumble%26aufirst%3DM.%26aulast%3DCrouthamel%26aufirst%3DM.%2BC.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DSchaber%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DRobell%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DFigueroa%26aufirst%3DD.%2BJ.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DRouse%26aufirst%3DM.%2BB.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DDiscovery%2520of%2520novel%2520AKT%2520inhibitors%2520with%2520enhanced%2520anti-tumor%2520effects%2520in%2520combination%2520with%2520the%2520MEK%2520inhibitor%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0100880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilson, M. K.</span></span> <span> </span><span class="NLM_article-title">Ligand configurational entropy and protein binding</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1534</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1073/pnas.0610494104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1073%2Fpnas.0610494104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=17242351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslars7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=1534-1539&author=C.+E.+A.+Changauthor=W.+Chenauthor=M.+K.+Gilson&title=Ligand+configurational+entropy+and+protein+binding&doi=10.1073%2Fpnas.0610494104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand configurational entropy and protein binding</span></div><div class="casAuthors">Chang, Chia-en A.; Chen, Wei; Gilson, Michael K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1534-1539</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The restriction of a small mol.'s motion on binding to a protein causes a loss of configurational entropy, and thus a penalty in binding affinity.  Some energy models used in computer-aided ligand design neglect this entropic penalty, whereas others account for it based on an expected drop in the no. of accessible rotamers upon binding.  However, the validity of the phys. assumptions underlying the various approaches is largely unexamd.  The present study addresses this issue by using Mining Min. calcns. to analyze the assocn. of amprenavir with HIV protease.  The computed loss in ligand configurational entropy is large, contributing ∼25 kcal/mol (4.184 kJ/kcal) to ΔGo.  Most of this loss results from narrower energy wells in the bound state, rather than a drop in the no. of accessible rotamers.  Coupling among rotation/translation and internal degrees of freedom complicates the decompn. of the entropy change into additive terms.  The results highlight the potential to gain affinity by designing conformationally restricted ligands and have implications for the formulation of energy models for ligand scoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQjA5K7LhZ7rVg90H21EOLACvtfcHk0liWlcZp6HVb5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslars7o%253D&md5=4f02fd7cd32e6d605485efaebcb23ba8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0610494104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0610494104%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%2BE.%2BA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DGilson%26aufirst%3DM.%2BK.%26atitle%3DLigand%2520configurational%2520entropy%2520and%2520protein%2520binding%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D1534%26epage%3D1539%26doi%3D10.1073%2Fpnas.0610494104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&author=Z.+J.+Fangauthor=Y.+N.+Songauthor=P.+Zhanauthor=Q.+Z.+Zhangauthor=X.+Y.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%98follow-on%E2%80%99-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0liWlcZp6HVb5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%2BJ.%26aulast%3DSong%26aufirst%3DY.%2BN.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%2BZ.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%2598follow-on%25E2%2580%2599-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9177</span>– <span class="NLM_lpage">9204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00819</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00819" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9177-9204&author=D.+Q.+Liauthor=X.+T.+Zhangauthor=X.+D.+Maauthor=L.+Xuauthor=J.+J.+Yuauthor=L.+X.+Gaoauthor=X.+B.+Huauthor=J.+K.+Zhangauthor=X.+W.+Dongauthor=J.+Liauthor=T.+Liuauthor=Y.+B.+Zhouauthor=Y.+Z.+Hu&title=Development+of+macrocyclic+peptides+containing+epoxyketone+with+oral+availability+as+proteasome+inhibitors&doi=10.1021%2Facs.jmedchem.8b00819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of macrocyclic peptides containing epoxyketone with oral availability as proteasome inhibitors</span></div><div class="casAuthors">Li, Daqiang; Zhang, Xiaotuan; Ma, Xiaodong; Xu, Lei; Yu, Jianjun; Gao, Lixin; Hu, Xiaobei; Zhang, Jiankang; Dong, Xiaowu; Li, Jia; Liu, Tao; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9177-9204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Macrocyclization has been frequently utilized for optimizing peptide or peptidomimetic-based compds.  In an attempt to obtain potent, metabolically stable, and orally available proteasome inhibitors, 30 oprozomib-derived macrocyclic peptides with structural diversity in their N-terminus and linker were successively designed and synthesized for structure-activity relationship (SAR) studies.  As a consequence, the macrocyclic peptides with N-methyl-pyrazole, imidazole, and pyrazole as their resp. N-termini exhibited favorable in vitro activity and metabolic stability, which translated into their potent in vivo proteasome inhibitory activity after oral administration.  In particular, pyrazole-contg. compd. (I), as the most distinguished one among this series, displayed excellent chymotrypsin-like (ChT-L, β5) inhibitory potency (IC50 = 16 nM), low nanomolar antiproliferative activity against all three of the tested cell lines, and superior metabolic stability in mouse liver microsome (MLM), as well as favorable inhibition against ChT-L compared to that of oprozomib in BABL/c mice following administration at a comparatively low dose, thereby representing a promising candidate for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYHTTVYr92xrVg90H21EOLACvtfcHk0liWlcZp6HVb5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVantLzP&md5=958573573fe76d3b80e74fb0d7373c95</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00819%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%2BQ.%26aulast%3DZhang%26aufirst%3DX.%2BT.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DJ.%2BJ.%26aulast%3DGao%26aufirst%3DL.%2BX.%26aulast%3DHu%26aufirst%3DX.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%2BK.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DDevelopment%2520of%2520macrocyclic%2520peptides%2520containing%2520epoxyketone%2520with%2520oral%2520availability%2520as%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9177%26epage%3D9204%26doi%3D10.1021%2Facs.jmedchem.8b00819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherhead, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taoda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikamiyama-Iwata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshinaga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garvey, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span> <span> </span><span class="NLM_article-title">Carbamoyl pyridone HIV-1 integrase inhibitors. 2. bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1135</span>, <span class="refDoi"> DOI: 10.1021/jm301550c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301550c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVeltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1124-1135&author=T.+Kawasujiauthor=B.+A.+Johnsauthor=H.+Yoshidaauthor=J.+G.+Weatherheadauthor=T.+Akiyamaauthor=T.+Taishiauthor=Y.+Taodaauthor=M.+Mikamiyama-Iwataauthor=H.+Muraiauthor=R.+Kiyamaauthor=M.+Fujiauthor=N.+Tanimotoauthor=T.+Yoshinagaauthor=T.+Sekiauthor=M.+Kobayashiauthor=A.+Satoauthor=E.+P.+Garveyauthor=T.+Fujiwara&title=Carbamoyl+pyridone+HIV-1+integrase+inhibitors.+2.+bi-+and+tricyclic+derivatives+result+in+superior+antiviral+and+pharmacokinetic+profiles&doi=10.1021%2Fjm301550c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Carbamoyl Pyridone HIV-1 Integrase Inhibitors. 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles</span></div><div class="casAuthors">Kawasuji, Takashi; Johns, Brian A.; Yoshida, Hiroshi; Weatherhead, Jason G.; Akiyama, Toshiyuki; Taishi, Teruhiko; Taoda, Yoshiyuki; Mikamiyama-Iwata, Minako; Murai, Hitoshi; Kiyama, Ryuichi; Fuji, Masahiro; Tanimoto, Norihiko; Yoshinaga, Tomokazu; Seki, Takahiro; Kobayashi, Masanori; Sato, Akihiko; Garvey, Edward P.; Fujiwara, Tamio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1135</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This work is a continuation of our initial discovery of a potent monocyclic carbamoyl pyridone human immunodeficiency virus type-1 (HIV-1) integrase inhibitor that displayed favorable antiviral and pharmacokinetic properties.  We report herein a series of bicyclic carbamoylpyridone (I; satd. and unsatd. bridge; R = e.g., alkoxyethyl) analogs to address conformational issues from our initial SAR studies.  This modification of the core unit succeeded to deliver low nanomolar potency in std. antiviral assays.  An addnl. hydroxyl substituent on the bicyclic scaffold provides remarkable improvement of antiviral efficacies against clin. relevant resistant viruses.  These findings led to addnl. cyclic tethering of the naked hydroxyl group resulting in tricyclic carbamoyl pyridone inhibitors (II; Y = O, N; n = 0-2; R' = e.g., alkyl, Ac, methanesulfonyl) to address remaining issues and deliver potential clin. candidates.  The tricyclic carbamoyl pyridone derivs. described herein served as the immediate leads in mols. to the next generation integrase inhibitor dolutegravir which is currently in late stage clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQLpPj5UB1TbVg90H21EOLACvtfcHk0ljxpqHju522mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVeltA%253D%253D&md5=4bfe919f8fdbbc84e346e3f01e084b70</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm301550c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301550c%26sid%3Dliteratum%253Aachs%26aulast%3DKawasuji%26aufirst%3DT.%26aulast%3DJohns%26aufirst%3DB.%2BA.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DWeatherhead%26aufirst%3DJ.%2BG.%26aulast%3DAkiyama%26aufirst%3DT.%26aulast%3DTaishi%26aufirst%3DT.%26aulast%3DTaoda%26aufirst%3DY.%26aulast%3DMikamiyama-Iwata%26aufirst%3DM.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DKiyama%26aufirst%3DR.%26aulast%3DFuji%26aufirst%3DM.%26aulast%3DTanimoto%26aufirst%3DN.%26aulast%3DYoshinaga%26aufirst%3DT.%26aulast%3DSeki%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DA.%26aulast%3DGarvey%26aufirst%3DE.%2BP.%26aulast%3DFujiwara%26aufirst%3DT.%26atitle%3DCarbamoyl%2520pyridone%2520HIV-1%2520integrase%2520inhibitors.%25202.%2520bi-%2520and%2520tricyclic%2520derivatives%2520result%2520in%2520superior%2520antiviral%2520and%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1124%26epage%3D1135%26doi%3D10.1021%2Fjm301550c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2016.03.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=27089211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=47-58&author=W.+H.+Zhanauthor=L.+Xuauthor=X.+W.+Dongauthor=J.+Dongauthor=X.+Yiauthor=X.+D.+Maauthor=N.+Qiuauthor=J.+Liauthor=B.+Yangauthor=Y.+B.+Zhouauthor=Y.+Z.+Hu&title=Design%2C+synthesis+and+biological+evaluation+of+pyrazol-furan+carboxamide+analogues+as+novel+Akt+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2016.03.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Xu, Lei; Dong, Xiaowu; Dong, Jun; Yi, Xiao; Ma, Xiaodong; Qiu, Ni; Li, Jia; Yang, Bo; Zhou, Yubo; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">47-58</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of novel pyrazolylfuran carboxamides I (24a-d; X = S, R2 = R3 = H; R1, R4: a, H, 4-F; b, Cl, 4-F; c, Br, 4-F; d, H, 3,4-Cl2; 25a-e, X = O, R3 = H, R1, R2, R4: a, Cl, H, 4-F; b, Br, H, 4-F; c, Br, H, 3,4-Cl2; d, Cl, Cl, 4-F; e, Cl, Cl, 3,4-Cl2; 27a-c, X = NMe, R1, R2, R3, R4: a, Br, H, H, 3,4-Cl2; b, Br, Br, H, 3,4-Cl2; c, Cl, Cl, Cl, 3,4-Cl2) and II (26a-c; R1, R2, R4: a, H, Br, 3,4-Cl2; b, Cl, Br, 3,4-Cl2; c, Br, Br, 3,4-Cl2) were designed, synthesized and biol. evaluated for their Akt1 inhibitory activities, as well as anti-proliferative efficacies against HCT116 and OVCAR-8 cell lines.  Most compds. exhibited moderate to excellent Akt1 inhibitory activities, together with favorable cytotoxicities.  Further kinase selectivity assay of the most promising compd. 25e illustrated that it was also potent against the structurally related AGC kinases, including Akt2, Akt3, ROCK1 and PKA, but was specific over kinases from other subfamilies.  In addn., the Western blot anal. indicated that 25e could significantly suppress the phosphorylation level of Akt substrate GSK3β in PC-3 cell.  Moreover, 25e demonstrated a concn.-dependent inhibition of phosphorylation of PRAS40 in LNCaP cell, with IC50 value of 30.4 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQIDQke8QD2bVg90H21EOLACvtfcHk0ljxpqHju522mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyms7g%253D&md5=d51bdaff3ed97681b60ce4bd451d2dec</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.074%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DQiu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520pyrazol-furan%2520carboxamide%2520analogues%2520as%2520novel%2520Akt%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D117%26spage%3D47%26epage%3D58%26doi%3D10.1016%2Fj.ejmech.2016.03.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2013.11.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24389511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=167-176&author=T.+Liuauthor=W.+H.+Zhanauthor=Y.+M.+Wangauthor=L.+R.+Zhangauthor=B.+Yangauthor=X.+W.+Dongauthor=Y.+Z.+Hu&title=Structure-based+design%2C+synthesis+and+biological+evaluation+of+diphenylmethylamine+derivatives+as+novel+Akt1+inhibitors&doi=10.1016%2Fj.ejmech.2013.11.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors</span></div><div class="casAuthors">Liu, Tao; Zhan, Wenhu; Wang, Yanming; Zhang, Liangren; Yang, Bo; Dong, Xiaowu; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">167-176</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of diphenylmethylamines, e.g. I [R = Ph, PhCH2, i-Pr, etc.] were rationally designed, synthesized and biol. evaluated.  Most of them exhibited moderate to good Akt1 inhibitory activities, as well as promising antiproliferative efficacy against cancer cell lines.  Mol. docking studies were carried out to probe their binding modes with Akt1.  Kinase selectivity studies of compd. I [R = t-Bu] were performed, indicating its excellent selectivity against Aurora A, Drak, IKKβ, GSK3β, SYK and JAK2, and moderate selectivity against PKC and BRAF.  Finally, a refined pharmacophore model was generated using three active compds. including I [R = t-Bu] via application of HipHop program.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYIQGyEG5nUbVg90H21EOLACvtfcHk0ljxpqHju522mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSju70%253D&md5=95c280f28d1af9788de6f29e0f90bc49</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.036%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DWang%26aufirst%3DY.%2BM.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DStructure-based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520diphenylmethylamine%2520derivatives%2520as%2520novel%2520Akt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D167%26epage%3D176%26doi%3D10.1016%2Fj.ejmech.2013.11.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, W. T.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">770</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1111%2Fcbdd.12489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=25453512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1ajs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2015&pages=770-779&author=W.+H.+Zhanauthor=S.+D.+Linauthor=J.+Chenauthor=X.+W.+Dongauthor=J.+B.+Chuauthor=W.+T.+Du&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+molecular+docking+of+novel+benzopyran+and+phenylpyrazole+derivatives+as+Akt+inhibitors&doi=10.1111%2Fcbdd.12489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Lin, Sendong; Chen, Jing; Dong, Xiaowu; Chu, Jianbo; Du, Wenting</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">770-779</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">By inspiration of good Akt1 inhibitory and cytotoxic activity of the authors' previously screened hits (I) and (II), a series of novel benzopyrans and phenylpyrazoles were designed, synthesized, and biol. evaluated for their in vitro Akt1 inhibitory and cytotoxic activity.  The results revealed that all of these compds. showed moderate-to-excellent antiproliferative effects against the tested cancer cell lines (i.e., HL-60, OVCAR, PC-3, and HepG2).  Among them, compds. 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-6-(morpholinomethyl)-4H-chromen-4-one (3a) and 6-[[benzyl(methyl)amino]methyl]-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one (3c) exhibited preferable Akt1 inhibitory activities (IC50 of 3a and 3c are 6.18 and 5.28 μM, resp.), while the other compds. only showed weak Akt1 inhibitory activities.  Consequently, the authors used mol. docking and dynamic simulation to propose a mode of binding between Akt1 and the 3c compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrItReU0mg_-rVg90H21EOLACvtfcHk0lihyjtEwmUxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1ajs7g%253D&md5=b36863fb8a392b7f97f52a8cea9fbeaa</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12489%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DLin%26aufirst%3DS.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DChu%26aufirst%3DJ.%2BB.%26aulast%3DDu%26aufirst%3DW.%2BT.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520molecular%2520docking%2520of%2520novel%2520benzopyran%2520and%2520phenylpyrazole%2520derivatives%2520as%2520Akt%2520inhibitors%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2015%26volume%3D85%26spage%3D770%26epage%3D779%26doi%3D10.1111%2Fcbdd.12489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span> <span> </span><span class="NLM_article-title">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2014.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=24508830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1Krsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2014&pages=11-20&author=W.+H.+Zhanauthor=D.+Q.+Liauthor=J.+X.+Cheauthor=L.+R.+Zhangauthor=B.+Yangauthor=Y.+Z.+Huauthor=T.+Liuauthor=X.+W.+Dong&title=Integrating+docking+scores%2C+interaction+profiles+and+molecular+descriptors+to+improve+the+accuracy+of+molecular+docking%3A+Toward+the+discovery+of+novel+Akt1+inhibitors&doi=10.1016%2Fj.ejmech.2014.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: Toward the discovery of novel Akt1 inhibitors</span></div><div class="casAuthors">Zhan, Wenhu; Li, Daqiang; Che, Jinxin; Zhang, Liangren; Yang, Bo; Hu, Yongzhou; Liu, Tao; Dong, Xiaowu</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-20</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A set of forty-seven Akt1 inhibitors was used for the development of mol. docking based QSAR model by using nonlinear regression.  The integration of docking scores, key interaction profiles and mol. descriptors remarkably improved the accuracy of the QSAR models, providing reasonable statistical parameters (R2train = 0.948, R2test = 0.907 and Q2cv = 0.794).  The established MD-SVR model based structural modification of new 4-amino-pyrimidine derivs. was further performed, and six compds. 56a,b and 60a-d with good prediction activities were synthesized and biol. evaluated.  All of these compds. exhibited promising Akt1 inhibitory and antiproliferative activities, suggesting the reliability and good application value of the established MD-SVR model in the development of Akt1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofYK7H5o1DO7Vg90H21EOLACvtfcHk0lihyjtEwmUxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1Krsb0%253D&md5=8c21718c0d9a2e19d97004f7061dce62</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DW.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BQ.%26aulast%3DChe%26aufirst%3DJ.%2BX.%26aulast%3DZhang%26aufirst%3DL.%2BR.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DDong%26aufirst%3DX.%2BW.%26atitle%3DIntegrating%2520docking%2520scores%252C%2520interaction%2520profiles%2520and%2520molecular%2520descriptors%2520to%2520improve%2520the%2520accuracy%2520of%2520molecular%2520docking%253A%2520Toward%2520the%2520discovery%2520of%2520novel%2520Akt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D75%26spage%3D11%26epage%3D20%26doi%3D10.1016%2Fj.ejmech.2014.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">5949</span>– <span class="NLM_lpage">5958</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.ejmech.2011.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22027102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKqtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5949-5958&author=X.+W.+Dongauthor=X.+L.+Zhouauthor=H.+Jingauthor=J.+Z.+Chenauthor=T.+Liuauthor=B.+Yangauthor=Q.+J.+Heauthor=Y.+Z.+Hu&title=Pharmacophore+identification%2C+virtual+screening+and+biological+evaluation+of+prenylated+flavonoids+derivatives+as+PKB%2FAkt1+inhibitors&doi=10.1016%2Fj.ejmech.2011.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors</span></div><div class="casAuthors">Dong, Xiaowu; Zhou, Xinglu; Jing, Hui; Chen, Jianzhong; Liu, Tao; Yang, Bo; He, Qiaojun; Hu, Yongzhou</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5949-5958</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A total of 24 well-defined PKB/Akt1 inhibitors were used to generate pharmacophore models applying Catalyst/HypoGen program.  The best ranked model (Hypo_1) was then validated by cost anal., prediction capability, Cat-Scramble and receiver operating characteristic (ROC) studies.  Then, pharmacophore-based virtual screening combined with docking study was performed to search an inhouse compd. database.  Nine preferable hits 75-80, HTS-02143, BTB-14740 and HTS-08006 were prepd. and biol. evaluated.  Several compds. were identified as good PKB/Akt1 inhibitors, suggesting that Hypo_1 would be reliable and useful in virtual screening.  Flow cytometric and western blotting anal. on compds. 79 and 80 further demonstrated that the inhibition of phosphorylation of PKB/Akt1 and its substrates (such as GSK3β) was responsible for their cytotoxic activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXTEc-nFDC_rVg90H21EOLACvtfcHk0lihyjtEwmUxcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKqtLnE&md5=e563fb1a3ea5bbbc7c1ebff8753f38cf</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DZhou%26aufirst%3DX.%2BL.%26aulast%3DJing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%2BJ.%26aulast%3DHu%26aufirst%3DY.%2BZ.%26atitle%3DPharmacophore%2520identification%252C%2520virtual%2520screening%2520and%2520biological%2520evaluation%2520of%2520prenylated%2520flavonoids%2520derivatives%2520as%2520PKB%252FAkt1%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5949%26epage%3D5958%26doi%3D10.1016%2Fj.ejmech.2011.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouse, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seefeld, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minthorn, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concha, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaber, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerding, D. A.</span></span> <span> </span><span class="NLM_article-title">Aminofurazans as potent inhibitors of AKT kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1508</span>– <span class="NLM_lpage">1511</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2009.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=19179070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1Wmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1508-1511&author=M.+B.+Rouseauthor=M.+A.+Seefeldauthor=J.+D.+Leberauthor=K.+C.+McNultyauthor=L.+Sunauthor=W.+H.+Millerauthor=S.+Zhangauthor=E.+A.+Minthornauthor=N.+O.+Conchaauthor=A.+E.+Choudhryauthor=M.+D.+Schaberauthor=D.+A.+Heerding&title=Aminofurazans+as+potent+inhibitors+of+AKT+kinase&doi=10.1016%2Fj.bmcl.2009.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aminofurazans as potent inhibitors of AKT kinase</span></div><div class="casAuthors">Rouse, Meagan B.; Seefeld, Mark A.; Leber, Jack D.; McNulty, Kenneth C.; Sun, Lihui; Miller, William H.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Choudhry, Anthony E.; Schaber, Michael D.; Heerding, Dirk A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1508-1511</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">AKT inhibitors contg. an imidazopyridine aminofurazan scaffold have been optimized.  The AKT inhibitor GSK690693 has been evaluated in clin. trials in cancer patients.  Recent efforts focusing on investigating a distinct region of this scaffold that have afforded compds. with comparable activity profiles to that of GSK690693 are reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLJTnRWaL7-rVg90H21EOLACvtfcHk0lihsWiQHxbPBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1Wmt70%253D&md5=76d4a0780040e628b40001d687ecfab6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DRouse%26aufirst%3DM.%2BB.%26aulast%3DSeefeld%26aufirst%3DM.%2BA.%26aulast%3DLeber%26aufirst%3DJ.%2BD.%26aulast%3DMcNulty%26aufirst%3DK.%2BC.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DMinthorn%26aufirst%3DE.%2BA.%26aulast%3DConcha%26aufirst%3DN.%2BO.%26aulast%3DChoudhry%26aufirst%3DA.%2BE.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DHeerding%26aufirst%3DD.%2BA.%26atitle%3DAminofurazans%2520as%2520potent%2520inhibitors%2520of%2520AKT%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1508%26epage%3D1511%26doi%3D10.1016%2Fj.bmcl.2009.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bencsik, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallan, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dizon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G. P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prior, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, L. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">7037</span>– <span class="NLM_lpage">7041</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.09.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2010.09.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=20971641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7037-7041&author=J.+R.+Bencsikauthor=D.+M.+Xiaoauthor=J.+F.+Blakeauthor=N.+C.+Kallanauthor=I.+S.+Mitchellauthor=K.+L.+Spencerauthor=R.+Xuauthor=S.+L.+Gloorauthor=M.+Martinsonauthor=T.+Risomauthor=R.+D.+Woessnerauthor=F.+Dizonauthor=W.+I.+Wuauthor=G.+P.+A.+Vigersauthor=B.+J.+Brandhuberauthor=N.+J.+Skeltonauthor=W.+W.+Priorauthor=L.+J.+Murray&title=Discovery+of+dihydrothieno-+and+dihydrofuropyrimidines+as+potent+pan+Akt+inhibitors&doi=10.1016%2Fj.bmcl.2010.09.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors</span></div><div class="casAuthors">Bencsik, Josef R.; Xiao, Dengming; Blake, James F.; Kallan, Nicholas C.; Mitchell, Ian S.; Spencer, Keith L.; Xu, Rui; Gloor, Susan L.; Martinson, Matthew; Risom, Tyler; Woessner, Richard D.; Dizon, Faith; Wu, Wen-I.; Vigers, Guy P. A.; Brandhuber, Barbara J.; Skelton, Nicholas J.; Prior, Wei Wei; Murray, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7037-7041</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors is reported.  Inhibitors displaying increased PKA and general kinase selectivity with improved tolerability compared to the progenitor pyrrolopyrimidine were developed using previous SAR and anal. of the amino acid sequences in the binding site.  Dihydrothieno compd. I was advanced into a PC3-NCI prostate mouse tumor model in which it demonstrated a dose-dependent redn. in tumor growth and stasis when dosed orally daily at 200 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8-bp6rwVWNrVg90H21EOLACvtfcHk0lihsWiQHxbPBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2gtLnJ&md5=d6aed3020c07ed85e83379c40d53394e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.09.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.09.112%26sid%3Dliteratum%253Aachs%26aulast%3DBencsik%26aufirst%3DJ.%2BR.%26aulast%3DXiao%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DJ.%2BF.%26aulast%3DKallan%26aufirst%3DN.%2BC.%26aulast%3DMitchell%26aufirst%3DI.%2BS.%26aulast%3DSpencer%26aufirst%3DK.%2BL.%26aulast%3DXu%26aufirst%3DR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DMartinson%26aufirst%3DM.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DWoessner%26aufirst%3DR.%2BD.%26aulast%3DDizon%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DW.%2BI.%26aulast%3DVigers%26aufirst%3DG.%2BP.%2BA.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DPrior%26aufirst%3DW.%2BW.%26aulast%3DMurray%26aufirst%3DL.%2BJ.%26atitle%3DDiscovery%2520of%2520dihydrothieno-%2520and%2520dihydrofuropyrimidines%2520as%2520potent%2520pan%2520Akt%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7037%26epage%3D7041%26doi%3D10.1016%2Fj.bmcl.2010.09.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferson, A. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: Synthesis and SAR studies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4163</span>– <span class="NLM_lpage">4168</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.05.092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1016%2Fj.bmcl.2006.05.092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=16765046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFersLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4163-4168&author=X.+D.+Linauthor=J.+M.+Murrayauthor=A.+C.+Ricoauthor=M.+X.+Wangauthor=D.+T.+Chuauthor=Y.+S.+Zhouauthor=M.+Del+Rosarioauthor=S.+Kaufmanauthor=S.+Maauthor=E.+Fangauthor=K.+Crawfordauthor=A.+B.+Jefferson&title=Discovery+of+2-pyrimidyl-5-amidothiophenes+as+potent+inhibitors+for+AKT%3A+Synthesis+and+SAR+studies&doi=10.1016%2Fj.bmcl.2006.05.092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: Synthesis and SAR studies</span></div><div class="casAuthors">Lin, Xiaodong; Murray, Jeremy M.; Rico, Alice C.; Wang, Michael X.; Chu, Daniel T.; Zhou, Yasheen; Del Rosario, Merci; Kaufman, Susan; Ma, Sylvia; Fang, Eric; Crawford, Kenneth; Jefferson, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4163-4168</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-pyrimidyl-5-amidothiophenes I (R1 = R2 = H, Me; R1 = H, R2 = Me, Et, n-Pr; R3 = 4-FC6H4, 4-FC6H4CH2, 2,4-Cl2C6H3CH2CH2, (S)-PhCH(NH2)CH2, etc.) has been synthesized and evaluated for AKT kinase inhibition.  SAR studies resulted in potent inhibitors of AKT with IC50 values as low as single digit nanomolar as represented by I [R1 = H; R2 = Me; R3 = (S)-2,4-Cl2C6H3CH2CH(CH2NH2); (II)].  II showed cellular activity including antiproliferation and downstream target modulation.  Selectivity profile is described.  A co-crystal of II with PKA is detd. and discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr13M2t7ZYPSrVg90H21EOLACvtfcHk0lihsWiQHxbPBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFersLg%253D&md5=b1ef161c712fc4c0cf6415b5caf407f5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.092%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DX.%2BD.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DRico%26aufirst%3DA.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BX.%26aulast%3DChu%26aufirst%3DD.%2BT.%26aulast%3DZhou%26aufirst%3DY.%2BS.%26aulast%3DDel%2BRosario%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DFang%26aufirst%3DE.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DJefferson%26aufirst%3DA.%2BB.%26atitle%3DDiscovery%2520of%25202-pyrimidyl-5-amidothiophenes%2520as%2520potent%2520inhibitors%2520for%2520AKT%253A%2520Synthesis%2520and%2520SAR%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4163%26epage%3D4168%26doi%3D10.1016%2Fj.bmcl.2006.05.092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huo, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. W.</span></span> <span> </span><span class="NLM_article-title">Assembly of 4-substituted 3-nitro-1,2,3,4-tetrahydropyridines via organocatalytic Michael addition</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1002/adsc.201100903</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1002%2Fadsc.201100903" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2012&pages=991-994&author=L.+L.+Huoauthor=A.+Q.+Maauthor=Y.+H.+Zhangauthor=D.+W.+Ma&title=Assembly+of+4-substituted+3-nitro-1%2C2%2C3%2C4-tetrahydropyridines+via+organocatalytic+Michael+addition&doi=10.1002%2Fadsc.201100903"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Assembly of 4-Substituted 3-Nitro-1,2,3,4-tetrahydropyridines via Organocatalytic Michael Addition</span></div><div class="casAuthors">Huo, Lele; Ma, Anqi; Zhang, Yihua; Ma, Dawei</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">991-994</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An organocatalytic Michael addn. of protected 2-amino-1-nitroethanes to α,β-unsatd. aldehydes followed by treatment with TFA afforded 4-substituted 3-nitro-1,2,3,4-tetrahydropyridines with good diastereoselectivity and excellent enantioselectivity.  Good yields were obsd. in the case of β-aryl-substituted α,β-unsatd. aldehydes as the substrates, while moderate yields were obtained when β-alkyl-substituted α,β-unsatd. aldehydes were used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjw3Plra58LVg90H21EOLACvtfcHk0libcVv15YhgVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGrt7w%253D&md5=5b7d4721dad948c135b09819da174ef6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fadsc.201100903&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.201100903%26sid%3Dliteratum%253Aachs%26aulast%3DHuo%26aufirst%3DL.%2BL.%26aulast%3DMa%26aufirst%3DA.%2BQ.%26aulast%3DZhang%26aufirst%3DY.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BW.%26atitle%3DAssembly%2520of%25204-substituted%25203-nitro-1%252C2%252C3%252C4-tetrahydropyridines%2520via%2520organocatalytic%2520Michael%2520addition%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2012%26volume%3D354%26spage%3D991%26epage%3D994%26doi%3D10.1002%2Fadsc.201100903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. F.</span></span> <span> </span><span class="NLM_article-title">DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">6944</span>– <span class="NLM_lpage">6958</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.18632%2Foncotarget.3128" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=25749514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A280%3ADC%252BC2MnitFGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=6944-6958&author=J.+Qinauthor=J.+Jiauthor=R.+Dengauthor=J.+Tangauthor=F.+Yangauthor=G.+K.+Fengauthor=W.+D.+Chenauthor=X.+Q.+Wuauthor=X.+J.+Qianauthor=K.+Dingauthor=X.+F.+Zhu&title=DC120%2C+a+novel+AKT+inhibitor%2C+preferentially+suppresses+nasopharyngeal+carcinoma+cancer+stem-like+cells+by+downregulating+Sox2&doi=10.18632%2Foncotarget.3128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2</span></div><div class="casAuthors">Qin Juan; Ji Jiao; Deng Rong; Tang Jun; Yang Fen; Feng Gong-Kan; Chen Wen-Dan; Wu Xiao-Qi; Qian Xiao-Jun; Zhu Xiao-Feng; Tang Jun; Ding Ke; Ding Ke</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6944-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Side population (SP) contains cancer stem-like cells (CSLCs).  In this study, we characterized SP cells from nasopharyngeal carcinoma (NPC) cell lines and found that SP cells had a higher self-renewal ability in vitro and greater tumorigenicity in vivo.  The AKT pathway was activated in NPC SP cells.  DC120, a 2-pyrimidyl-5-amidothiazole inhibitor of the ATP binding site of AKT, inhibited phosphorylation of FKHRL1 and GSK-3β.  DC120 inhibited SP fraction, the sphere-forming ability in vitro and growth of primary xenografts as well as secondary xenografts' tumor recurrence.  This inhibition was accompanied by reduced expression of stem-related gene Sox2 due to induction of p27 and miR-30a.  A combination of DC120 and CDDP more effectively inhibited NPC cells compared with monotherapy in vitro and in vivo.  Clinical evaluation of DC120 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS5Ma1donXoAmLFM_lbR1VmfW6udTcc2eZJDma1BRiolbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnitFGkuw%253D%253D&md5=121bde0f172b2be926daae6de66365a8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3128%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DG.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BD.%26aulast%3DWu%26aufirst%3DX.%2BQ.%26aulast%3DQian%26aufirst%3DX.%2BJ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DX.%2BF.%26atitle%3DDC120%252C%2520a%2520novel%2520AKT%2520inhibitor%252C%2520preferentially%2520suppresses%2520nasopharyngeal%2520carcinoma%2520cancer%2520stem-like%2520cells%2520by%2520downregulating%2520Sox2%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D6944%26epage%3D6958%26doi%3D10.18632%2Foncotarget.3128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crafter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricketts, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosulich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chresta, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0824-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=10.1158%2F1535-7163.MCT-11-0824-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=22294718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=873-887&author=B.+R.+Daviesauthor=H.+Greenwoodauthor=P.+Dudleyauthor=C.+Crafterauthor=D.+H.+Yuauthor=J.+C.+Zhangauthor=J.+Liauthor=B.+R.+Gaoauthor=Q.+S.+Jiauthor=J.+Maynardauthor=S.+A.+Rickettsauthor=D.+Crossauthor=S.+Cosulichauthor=C.+C.+Chrestaauthor=K.+Pageauthor=J.+Yatesauthor=C.+Laneauthor=R.+Watsonauthor=R.+Lukeauthor=D.+Ogilvieauthor=M.+Pass&title=Preclinical+pharmacology+of+AZD5363%2C+an+inhibitor+of+AKT%3A+pharmacodynamics%2C+antitumor+activity%2C+and+correlation+of+monotherapy+activity+with+genetic+background&doi=10.1158%2F1535-7163.MCT-11-0824-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background</span></div><div class="casAuthors">Davies, Barry R.; Greenwood, Hannah; Dudley, Phillippa; Crafter, Claire; Yu, De-Hua; Zhang, Jingchuan; Li, Jing; Gao, Beirong; Ji, Qunsheng; Maynard, Juliana; Ricketts, Sally-Ann; Cross, Darren; Cosulich, Sabina; Chresta, Christine C.; Page, Ken; Yates, James; Lane, Clare; Watson, Rebecca; Luke, Richard; Ogilvie, Donald; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">873-887</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">AKT is a key node in the most frequently deregulated signaling network in human cancer.  AZD5363, a novel pyrrolopyrimidine-derived compd., inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approx. 0.3 to 0.8 μmol/L.  AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematol. tumor cell lines with a potency of 3 μmol/L or less.  Cell lines derived from breast cancers showed the highest frequency of sensitivity.  There was a significant relationship between the presence of PIK3CA and/or PTEN mutations and sensitivity to AZD5363 and between RAS mutations and resistance.  Oral dosing of AZD5363 to nude mice caused dose- and time-dependent redn. of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 ∼ 0.1 μmol/L total plasma exposure), reversible increases in blood glucose concns., and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts.  Chronic oral dosing of AZD5363 caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab.  AZD5363 also significantly enhanced the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts.  It is concluded that AZD5363 is a potent inhibitor of AKT with pharmacodynamic activity in vivo, has potential to treat a range of solid and hematol. tumors as monotherapy or a combinatorial agent, and has potential for personalized medicine based on the genetic status of PIK3CA, PTEN, and RAS.  AZD5363 is currently in phase I clin. trials.  Mol Cancer Ther; 11(4); 873-87.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjG0wV4TyO57Vg90H21EOLACvtfcHk0libcVv15YhgVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xltl2ntbs%253D&md5=6ddcc67247fd07fd086baa03077983bd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0824-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0824-T%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DGreenwood%26aufirst%3DH.%26aulast%3DDudley%26aufirst%3DP.%26aulast%3DCrafter%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DB.%2BR.%26aulast%3DJi%26aufirst%3DQ.%2BS.%26aulast%3DMaynard%26aufirst%3DJ.%26aulast%3DRicketts%26aufirst%3DS.%2BA.%26aulast%3DCross%26aufirst%3DD.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DChresta%26aufirst%3DC.%2BC.%26aulast%3DPage%26aufirst%3DK.%26aulast%3DYates%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DWatson%26aufirst%3DR.%26aulast%3DLuke%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DD.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DPreclinical%2520pharmacology%2520of%2520AZD5363%252C%2520an%2520inhibitor%2520of%2520AKT%253A%2520pharmacodynamics%252C%2520antitumor%2520activity%252C%2520and%2520correlation%2520of%2520monotherapy%2520activity%2520with%2520genetic%2520background%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D873%26epage%3D887%26doi%3D10.1158%2F1535-7163.MCT-11-0824-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirtcliff, L. D.</span></span> <span> </span><span class="NLM_article-title">Syntheses and properties of 1,6 and 1,7 perylene diimides and tetracarboxylic dianhydrides</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4724</span>– <span class="NLM_lpage">4727</span>, <span class="refDoi"> DOI: 10.1021/ol2019407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol2019407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=4724-4727&author=N.+V.+Handaauthor=K.+D.+Mendozaauthor=L.+D.+Shirtcliff&title=Syntheses+and+properties+of+1%2C6+and+1%2C7+perylene+diimides+and+tetracarboxylic+dianhydrides&doi=10.1021%2Fol2019407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Syntheses and Properties of 1,6 and 1,7 Perylene Diimides and Tetracarboxylic Dianhydrides</span></div><div class="casAuthors">Handa, Nisha V.; Mendoza, Kayla D.; Shirtcliff, Laura D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4724-4727</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1,6 And 1,7 perylene diimides (PDIs) and perylene tetracarboxylic dianhydrides (PTCDs), e.g., I, were synthesized from the corresponding regioisomeric mixt. of 1,6/1,7-dibromo precursors, via Sonogashira cross-coupling with different alkynes,.  Both bulky tri-Ph propyne (TPP) groups and nonbulky hexyl groups allow for facile chromatog. sepn.  The optical properties of these compds. are discussed.  Neutral bay substituents hypsochromically shift both the absorption and emission through deformation from planarity of the perylene core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojeGhh4Q9jF7Vg90H21EOLACvtfcHk0lh6EYUtM_mUSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVSrtLvI&md5=b12fab3f848d16a8519b3505b9e5b73e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol2019407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol2019407%26sid%3Dliteratum%253Aachs%26aulast%3DHanda%26aufirst%3DN.%2BV.%26aulast%3DMendoza%26aufirst%3DK.%2BD.%26aulast%3DShirtcliff%26aufirst%3DL.%2BD.%26atitle%3DSyntheses%2520and%2520properties%2520of%25201%252C6%2520and%25201%252C7%2520perylene%2520diimides%2520and%2520tetracarboxylic%2520dianhydrides%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D4724%26epage%3D4727%26doi%3D10.1021%2Fol2019407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1','PDB','4GV1'); return false;">PDB: 4GV1</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i126"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00891">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43535"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00891">10.1021/acs.jmedchem.9b00891</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">The proposed binding mode of <b>GSK-795</b> with Akt protein (Figure S1); synthesis and chemical information of compound (3<i>R</i>,4<i>S</i>)-<b>A6</b> (Figure S2); the proposed binding mode of <b>GSK-795</b> with Akt protein (Figure S3); in vivo antitumor effect of compound <b>A12</b> (Figure S4); comparison of the selectivity profile between compound <b>E22</b> and <b>GSK-795</b> (Figure S5); synthetic route of acid fragments (Figure S6); analysis of the configurations (Figure S7); the effect of <b>A12</b> and <b>E22</b> on organ-to-brain weight ratio during 7 days repeated dose toxicity study (Table S1); inhibition rate of compound <b>E22</b> against different ion channels (Table S2); selectivity profile of compound <b>E22</b> (Table S3); compound information for the intermediates; and NMR spectra and HPLC results for the target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_002.csv">CSV</a>)</p></li><li><p class="inline">Binding model of Akt1 with <b>E22</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_001.pdf">jm9b00891_si_001.pdf (10.56 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_002.csv">jm9b00891_si_002.csv (7.47 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00891/suppl_file/jm9b00891_si_003.pdb">jm9b00891_si_003.pdb (430.27 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a> was used. The authors will release the atomic coordinates upon article publication for the models between compound <b>E22</b> with Akt1, which was built on <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4GV1">4GV1</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00891&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00891%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-15%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00891" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679936a0792d24c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
